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Most of the luxuries, and many of the so-called comforts of life, are not only not indispensable, but 
positive hindrances to the elevation of mankind. With respect to luxuries and comforts, the wisest 
have even lived a more simple and meagre life than the poor. 
 
(H.D. Thoreau) 
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ABBREVIATIONS 
 
2-DE   two-dimensional gel electrophoresis 
α-MEM  alpha-minimum essential medium 
anti-CCP  antibodies against citrulline containing proteins 
ACR    American College of Rheumatology 
ACPA   antibodies against citrullinated proteins 
AMC   anti-modified citrulline 
AS   akylosing spondylitis 
CAPS   3-(cyclohexylamino)-1-propanesulfonic acid 
CCL2   monocyte chemotactic protein-1 (MCP-1) 
CHAPS  3-[(3-cholamidopropyl)-dimethylammonio] propanesulfonate 
CD44   hyaluronan receptor 
Cp   ceruloplasmin 
Ct   cycle threshold 
DAF   decay accelerating factor 
DIGE   difference gel electrophoresis 
DTT   dithiothreitol 
DMARD  disease-modifying anti-rheumatic drug 
DMEM  Dulbecco’s modified eagle’s medium 
ESI   electrospray ionization 
FBS   fetal bovine serum 
FGF   fibroblast growing factor 
FLS   fibroblast-like synoviocytes  
HA   hyaluronan 
HIF   hypoxia inducible factor 
HLA   human leukocyte antigen 
HRE   hypoxia regulating element 
HC gp-39  human cartilage glycoprotein 39 
GAPDH  Glyceraldehyde-3-phosphate dehydrogenase 
ICAT   isotope-coded affinity tag 
IEF   isoelectric focussing 
Ig   immunoglobin 
IL   interleukin 
INF-β   interferon beta 
INT x mm   intensity x millimeter 
IPG   immobilized pH gradient 
LC   liquid chromatography 
MAP kinase  mitogen activated protein kinase 
MALDI  matrix assisted laser desorption ionization 
MLS   macrophage-like synoviocytes 
MMP   matrix metalloproteinase 
MnSOD  manganese superoxide dismutase 
MRP-8  migration inhibitory factor-related protein-8 = calgranulin A 
MS   mass spectrometry 
MSMS   tandem mass spectrometry 
MW   Molecular weight 
NF-κB   nuclear factor kappa B 
NK    natural killer 
NSAID  non-steroidal anti-inflammatory drug 
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OA   osteoarthritis 
OPG   osteoprotegerin 
PAD   peptidylarginine deiminase 
PDGF   platelet derived growth factor 
pI   isoelectric point 
pO2   partial oxygen pressure 
PsA   psoriatic arthritis 
PMF   peptide mass fingerprinting 
PTM   post-translational modifications 
Q   quadrupole  
RA   rheumatoid arthritis 
RANKL  receptor activator of NF-κB ligand  
ReA   reactive arthritis 
RFLF    rheumafactor latex fixation  
SCID   severe combined immunodeficient 
SDS-PAGE  sodium dodecylsulfate polyacrylamide gel electrophoresis 
SE   shared epitope 
SpA   spondyloarthropathy 
TNF-α   tumor necrosis factor alpha 
TM   tetrathiomolybdate 
TOF   time-of-flight 
TPI   triosephosphate isomerise 
U/µg   unit per microgram 
UDPGD  uridine diphosphoglucose dehydrogenase 
USpA   undifferentiated spondyloarthropathy 
VCAM-1  vascular cell adhesion molecule-1 
VEGF   vascular endothelial growth factor 
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ABSTRACT 
Rheumatoid arthritis (RA) and spondyloarthropathies (SpA) are two frequent forms of 
chronic arthritis. During these pathologies, similar joints can be affected; however, the clinical 
presentation of these inflammatory arthritides is very different. RA is characterized by 
symmetric polyarticular joint inflammation and destruction as well as by extra-articular 
manifestations such as rheumatoid nodules or vasculitis. The hallmark symptoms of SpA, on 
the contrary, are quite distinct. They include sacroiliitis, spondylitis, pauciarticular synovitis 
and enthesitis. Extra-articular manifestations such as uveitis or subclinical bowel 
inflammation may also occur in SpA. There are several entities that belong to the concept of 
SpA such as ankylosing spondylitis (AS), reactive arthritis (ReA), psoriatic arthritis (PsA) and 
undifferentiated SpA (USpA).  
Despite these different clinical presentations a major-shared feature between both diseases is 
the presence of synovitis, the chronic inflammation of the synovial tissue.   
This overview is intended to explain the process of synovitis. It guides the reader through the 
different characteristics of the normal synovium and gives a representation of the successive 
steps that this tissue undergoes upon inflammation. Additionally, a summary of the known 
histopathological synovial differences between RA and SpA will be discussed.       
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INTRODUCTION 
Arthritis actually means joint (~arthro) inflammation (~itis). When elderly people experience 
pain in the joints, they often refer to it as being arthritis. In reality, there are many different 
types of rheumatic diseases which are not only related to the joint, but which can also affect 
kidneys, lungs, eyes, the skin and the central nervous system, not only in elderly persons but 
in people of all ages. They can largely be divided into non-inflammatory and inflammatory 
pathologies. 
 
For a better understanding of the pathology of these two forms of arthritis, it is of interest to 
first take a good look at the organ that is most affected by arthritis; the joint.  
A joint, or articulation, is the place where two bones come together. There are three types of 
joints depending on the amount of movement that they allow; immovable joints or 
synarthroses, slightly movable joints or amphiarthroses and the freely movable joints or 
diarthroses. This last group is subject to arthritis and is also called synovial joints [1].  
 
THE SYNOVIAL JOINT 
The synovial joint can be seen as a capsule that covers the articulating surfaces (fig. 1). The 
end of each bone is made up of smooth articular cartilage making the movements of the joint 
as lithe as possible. The joint cavity is filled with an aqueous solution of hyaluronan (HA) 
which serves as a lubricant of the articular surfaces during movement. It also functions as a  
 
Figure 1: A simplified representation of the synovial joint (obtained from http://www.med.howard.edu; 
copyright © 2004 Pearson Education Inc. publishing as Benjamin Cummings).  
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carrier of nutrients to the chondrocytes or cartilage cells and transports waste products away 
from the cartilage. In pathological conditions, this synovial fluid is actually an ultra filtrate of 
plasma with the addition of locally synthesized HA. The regulation of the amount of synovial 
fluid in the joint cavity and its content is regulated by the synovial membrane [1].  
 
The synovial membrane can be identified macroscopically as a connective tissue layer lining 
the joint cavity [2]. Normal synovial tissue is composed of two distinct layers: a surface layer 
(intima or synovial lining) and an underlying layer (subintima) (fig. 2) [3, 4]. The intima, in 
direct contact with the intra-articular space, is 1 to 3 cell layers deep, loosely organized, does 
not contain any blood vessels and is not supported by a basement membrane. The subintima 
consists of a network of loosely organized connective tissue with cells and blood vessels [3].  
 
 
Figure 2: Schematic representation of a normal synovium. 
The intima contains specialized fibroblasts expressing vascular cell adhesion molecule-1 (VCAM-1), decay 
accelerating factor (DAF) and uridine diphosphoglucose dehydrogenase (UDPGD) (dark blue), and the 
specialized macrophages expressing FcγRIIIa (dark red). The deeper subintima contains relatively unspecialized 
counterparts (pale colors) (obtained from Edwards, J.C. [4]_© Current Science Ltd).  
 
 
The intima and subintima are populated with two cell types: cells that are similar to 
macrophages ( type A synoviocytes)  and fibroblast-like cells ( type B synoviocytes) [5, 6].  
 
Macrophage-like synoviocytes 
Macrophage-like synoviocytes (MLS) have been shown to originate from bone-marrow-
derived monocytes and they express a number of macrophage markers including CD68, CD14 
and CD45 [7]. Type A-synoviocytes can phagocytise cell debris and waste in the joint cavity 
and have an antigen-presenting role. They show non-specific esterase activity and express the 
immunoglobin receptor FCγRIIIa [7]. MLS are spherical in shape and densely covered with 
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filo- and lamellipodia; characteristics unique to macrophages, hence their name (fig. 3) [8]. 
MLS make up a minority of cells in the normal synovial intima, however, in diseased tissue 
the proportion of macrophages may rise up to 80% [9].  
 
 
Figure 3: Scanning electron microscopy of synovial villus in a healthy horse carpal joint. 
The round cells are identified as type A synoviocytes (x 430) (1). Higher magnification (x 3800) of the luminal 
surface at the villus tip (2). The MLS are indicated by (A), the arrow shows long microvilli extending from a B 
type cell (obtained from Shikichi M. et al. [8] ).   
 
Fibroblast-like synoviocytes 
The majority of native synoviocytes are fibroblast-like cells or FLS. FLS have a rather 
irregular dendritic shape. Through scanning electron microscopy, type B synoviocytes were 
visualized containing a round cell body and several long rod-shaped cytoplasmic branches 
along the surface of the synovial intima (fig. 4.1). These rod-shaped cytoplasmic ‘arms’ 
overlapped and crossed each other forming a network. FLS can also be directed apical 
towards the joint cavity (fig. 4.2). They penetrate the joint space like a kind of antenna 
covered with long microvilli (fig. 4.3) [8]. 
The function of intimal FLS can largely be divided into playing a role in joint homeostasis, on 
the one hand, and interaction with leukocytes, on the other hand [3]. Type B synoviocytes 
have a high activity of the enzyme Uridine Diphosphoglucose Dehydrogenase (UDPGD) 
producing and secreting extensive amounts of hyaluronan (HA) into the joint space [10]. HA 
plays an important role in lubricating the joint. Also lubricin and plasminogen activator are 
produced by FLS, contributing to the viscosity of the joint space and allowing normal 
movement by preventing fibrous adhesions in the joint, respectively [11].  
 
(1) (2) 
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Figure 4: Scanning electron microscopy of FLS in synovial villus in a healthy horse carpal joint. 
The type B cells have a dendritic shape and form a network along the luminal surface (x 3900) (1). FLS that 
extend vertically whose tips contain microvilli (x 2600) (2). An isolated type B-synoviocyte projecting towards 
the joint cavity (x 1800) (3) (obtained from Shikichi M. et al. [8] ).   
 
Synovial fibroblasts can interact with leukocytes through Vascular Cell Adhesion Molecule-1 
(VCAM-1) and Decay Accelerating Factor (DAF) [12, 13]. VCAM-1 interacts with α4β1 
integrin present on mononuclear leukocytes. Since polynuclear leukocytes do not express this 
molecule, granulocytes are not retained in the synovial intima and are released into the joint 
space traveling trough the synovial fluid [14].  
Expression of DAF is associated with the local macrophage expression of FCγRIIIa through 
its co-ligand CD97. However, its primary role is regulating a tissue response to the alternative 
complement pathway through degrading complement on the cell surface [13, 15].  
Several other connective tissue components like fibronectin, type IV and type VI collagen, 
laminin, chondroitin proteoglycans and fibrillin are also secreted by FLS [16]. They 
participate in the maintenance of the joint capsule.  
The fibroblasts in the sublining are less specialized, as they lack the expression of UDPGD, 
DAF or VCAM-I. However, upon synovial inflammation, type-B synoviocytes resident in the 
subintima start to obtain the specific characteristics of synovial lining fibroblasts.  
 
SYNOVITIS 
Synovitis or inflammation of the synovium, is believed to be the result of a combination of 
synovial hyperplasia, extensive angiogenesis, infiltration of cells from the circulation and a 
disturbance in apoptosis  (fig. 5) [2].  
In inflammatory arthritis, the phenotype of the synovial tissue changes into an activated, 
proliferative, invasive tissue. This uncontrolled process of tissue growth leads to narrowing of 
the joint space and subsequent increased efflux of synovial fluid, which results in swollen 
(1) (2) (3) 
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joints.  This tissue proliferation is accompanied by the production of certain destructive 
enzymes, eventually leading to cartilage and bone loss, especially in RA. As for SpA, the 
synovitis results in less joint destruction, it is characterized by bone formation in addition to 
bone erosions [17].  
 
 
Figure 5: Representation of normal synovial tissue (left) and synovitis (right) (obtained from 
http://www.rheumatoid-arthritis.net). 
 
 
Histological, synovitis is characterized by the thickening of the synovial lining, often called 
synovial hyperplasia, which can result in a cell depth of more than 8 cells [18]. This 
proliferation is probably the result of infiltration of circulating macrophages and monocytes 
and is also driven by local proliferation of synoviocytes by catabolic cytokines. The thickened 
lining cells are comprised, up to 80%, of CD68 positive macrophages [9, 18]. These 
macrophages produce Tumor Necrosis Factor-α (TNF-α), interleukin (IL)-1 and IL-6, which 
activate the FLS and stimulate them to proliferate in vitro [19] .  
Impairment of apoptosis of the type B synoviocytes also contributes to the thickening of the 
lining [20, 21]. Apoptosis, or programmed cell death, is tightly regulated and ensures the 
elimination of cells from tissue. A wide variety of so-called death signals exists, and a lower 
expression or deregulation of these signals leads to a reduction of apoptosis. Reduction of 
apoptosis can lead to the accumulation of cells and could, in part, play a role in the 
hyperplasia of the synovium. Especially, the Fas-mediated apoptosis pathway has been shown 
to be impaired in arthritis [22]. In addition, mutations in the p53 tumor suppressor gene [23] 
capsule
synovium
neutrophil
cartilage
synoviocytes
bone
osteoclast
fibroblast
macrophage
dendritic cell
T cell
plasma cell
B cell
extensive 
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hyperplastic
synovial lining
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and the higher expression in FLS of anti-apoptotic proteins like Bcl-2 [24] and sentrin-1 are 
responsible for impairement of apoptosis in the synovial tissue. Sentrin-1, also called SUMO-
1, is a small ubiquitin-like modifier that alters the binding of target molecules to subsequent 
molecules, instead of preparing them for degradation as ubiquitin does. In its specialized way, 
it ‘sumolates’ the correct form of Fas associated death domain and hereby interferes with Fas-
associated apoptosis in FLS [25]. Recently, synoviolin, an E3 ubiquitin ligase, has been found 
to be over expressed in RA synovium and this enzyme exerts both anti-appototic and pro-
proliferative characteristics. It is considered very important in the process leading to synovial 
hyperplasia as mice expressing lower amount of synoviolin, are free of synovial lining 
thickening due to enhanced apoptosis of synovial cells [26, 27]. 
 
The thickened synovium requires nutrients and adequate oxygenation and because of the 
synovial hyperplasia, the distance between the synovial lining cells and the blood vessels, 
present in the sublining, increases. These alterations in the microenvironment of the joint, lead 
to regional hypoxia, which itself is a strong trigger for angiogenesis, the formation of new 
blood vessels [28]. The principal regulator of gene expression in a hypoxic environment is 
Hypoxia Inducible Factor (HIF) [29]. This transcription factor is stabilized in hypoxic areas 
and binds to Hypoxic Regulating Elements (HRE) in the promoter region of certain genes, 
hereby regulating gene expression. In addition, pro-angiogenic factors are produced locally by 
the FLS and by the infiltrating macrophages. These include Vascular Endothelial Growth 
Factor (VEGF), Fibroblast Growing Factor (FGF), Platelet Derived Growth Factor (PDGF) 
and IL-8 [30, 31]. Angiogenesis can be visualized upon microscopic investigation of the 
synovial tissue and is observed as a fine network of vessels [32]. Vascularization does not 
only permit the supply of nutrients to the augmented cell mass, but it also promotes leukocyte 
infiltration and thereby stimulates the continuation of the synovial inflammation [31, 32].  
 
Inflamed synovial tissue is also characterized by the infiltration of leukocytes, mainly 
lymphocytes and monocytes. Infiltrating lymphocytes comprising mainly of CD4+ memory T 
cells, also small amounts of CD8+ T cells, NK cells and B cells are organized in three kinds of  
synovial infiltration patterns: diffuse; where there is a lack of organisation (~50% of synovia), 
perivascular; around the endothelial venules (~20%) and organized in lymphoid follicles with 
or without germinal centres (~20%) [33].   
Infiltration of macrophages is also observed in the process of synovitis [7, 34]. These CD68+ 
monocytes, produce increased amounts of pro-inflammatory cytokines like TNF-α and IL-1 
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[7] and there is a correlation of the quantity of macrophage infiltrates and the degree of joint 
damage [35]. Moreover, they are present in the synovium prior to clinical synovitis [36, 37].  
 
Although inflammatory cells play an important role in synovitis, the persistence of the 
inflammation and the destructive feature of the synovitis is largely attributed to FLS [38-40].  
Type B synoviocytes can produce a variety of pro-inflammatory cytokines, adhesion 
molecules and chemokines such as IL-6, INF-β, CCL2, IL-8, which attract and retain large 
numbers of leukocytes in the synovial tissue [41-43]. Studies indicate that the NF-κB 
transcription factor is of high importance in this so-called stromal cell contribution to the 
inflammation [44].  
Moreover, the pronounced role of FLS in the detrimental outcome of the synovitis was 
demonstrated when activated inflamed synovial tissue was implanted in Severe Combined 
Immunodeficient (SCID) mice. Within these implants, lymphocytes infiltrates disappeared, 
however, the synovial lining cells survived and their biological characteristics were 
maintained [45]. In the SCID mouse model, implanted activated fibroblasts were able to 
destroy cartilage and bone [46].  Studies have shown that Matrix Metalloproteinases (MMPs), 
which are secreted by FLS, are responsible for eroding the cartilage in the joint [47]. The 
expression of these zinc-dependent proteases is regulated by a variety of mechanisms 
including cell-cell interactions [48], upon stimulation by adhesion molecules and cytokines 
[49], MAP kinases have been reported to stimulate the secretion of MMPs [50] and the 
hyaluronan receptor (CD44) is apparently also implicated in the joint destruction by inducing 
the secretion of MMPs [51].  
Other studies also indicate that the chondrocytes, the cellular components of the cartilage, 
participate in the joint destructive process. They do not only respond to the catabolic 
cytokines released from the synoviocytes, but they contribute to the pathology by being a 
source of cytokines themselves [52, 53]. 
It has been speculated that synovial fibroblasts are mesenchymal stem cell look-a-likes. This 
could allow these cells to take on certain characteristics of other cell types that are of 
mesenchymal origin like osteoclasts, myocytes, chondroblasts and adipocytes, which are 
residents of the joint space [54]. This could in part explain the diversity of functional 
properties that these synoviocytes posses upon activation and this could contribute to their 
ability to proliferate themselves, activate and hold on to cell infiltrates and eventually 
transform into a devastating population of cells.    
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The different stages in synovitis are difficult to describe, because it is still largely unknown 
what the correct order of the different steps involved are. Also, the characterization of the 
different players taking part in the inflammatory process and especially who stimulates who 
and maybe more importantly when, is still not fully elucidated. Further studies will 
undoubtedly reveal more details of this complex interplay of cells leading to such a dramatic 
phenotypic change inside the joint tissue.  
 
NON-INFLAMMATORY JOINT DISORDERS 
Non-inflammatory rheumatic pathologies also known as osteoarthritis (OA), are often referred 
to as degenerative arthritis or degenerative joint disease, and are viewed as an age-related 
dynamic reaction pattern of a joint in response to insult or injury.  
The pathology is diverse and characterized by progressive destruction of the articular cartilage 
eventually affecting the entire joint. The most striking feature is loss of articular cartilage and 
changes in the adjacent bone [55]. These changes, consisting of bone growth at the joint 
margins, are called osteophytes and may be the result of an attempted repair process in the 
affected joint [56].  
Although severe injury can be sufficient to cause OA, there are many risk factors both 
systemic (age, sex, bone density, ….) and local (obesity, sport participation, muscle 
weakness…) that contribute to the severity of the pathology [57]. Osteoarthritis is the most 
common form of joint diseases worldwide e.g. OA of the knee occurs in 1% among people 
aged 25-34 (based on radiographic information) and mounts up to 80% in those aged 75 and 
above [58]. Since the prevalence of this degenerative joint disease increases with age, its 
occurrence will become even more dramatic in the future because of the aging population, 
with high socio-economic impact on our society. 
OA is not considered a classical inflammatory arthropathy, due to the absence of neutrophils 
in the synovial fluid and systemic manifestations of inflammation. The primary target in OA 
is the articular cartilage, in contrast with inflammatory joint disorder where the synovial tissue 
is primary involved. Studies indicate the participation of the chondrocytes, the cellular 
component of the articular cartilage, in the joint destructive process by the production of 
catabolic cytokines, like IL-1, and destructive enzymes like MMP’s [59].   
We included OA synovial tissue samples as non-inflammatory controls throughout this study.  
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INFLAMMATORY JOINT DISORDERS 
Rheumatoid Arthritis (RA) and Spondyloarthropathy (SpA) are two frequent forms of chronic 
inflammatory arthritis. The prevalence of both pathologies is similar. For RA, the prevalence 
worldwide is around 1-2%, as for SpA 1 up to 2.5% of the population worldwide is affected 
[60, 61]. Both inflammatory arthritides are multi-factorial diseases that occur in genetically 
predisposed persons. Although they have a different clinical presentation, they both are 
characterized by synovitis (fig. 6).  
 
Figure 6: Characteristics of the two frequent forms of inflammatory arthritis; RA and SpA. 
 
Rheumatoid arthritis 
Rheumatoid arthritis is a symmetric polyarticular inflammatory arthritis that affects the small 
diarthrodial joints. The primary site of inflammation is the synovial membrane. As described 
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above, this inflammation is accompanied by infiltration of lymphocytes that produce pro-
inflammatory mediators that attract other immune cells to the site. This process activates 
resident cells to proliferate. In addition, an excess of synovial fluid is produced which 
eventually results in a swollen, inflamed joint. Because of immunological disturbances in the 
joint, there is a perpetuation of the inflammation which results in the chronic nature of the 
joint inflammation in RA. Destructive enzymes are produced in the joint that lead to cartilage 
destruction. Activated synovial tissue transforms, invades and destroys the bone. Severe bone 
erosions can be seen radiographically and severe joint deformations can be the result of 
longstanding RA (fig. 7). 
 
(A) (B)
  
Figure 7: Joint erosions and deformations in RA. 
Erosion seen in X-ray, occur rapidly in the disease event (A), visible changes in joint architecture resulting in 
joint deformation with function loss associated with severe RA (B) (Obtained form John Hopkins arthritis center 
:http://www.hopkins-arthritis.som.jhmi.edu/; Clinical slide collection on the rheumatic diseases © 1991, 1995, 
1997). 
 
 
Symmetric joint swelling and inflammation are hallmarks in RA. In addition, extra-articular 
manifestations can occur of which the rheumatoid nodules are the most well known (fig. 6).    
The most common serological marker for RA is the presence of rheumatoid factor. This factor 
is an immunoglobin (Ig) M antibody response directed against the Fc portion of the IgG; 
forming complexes [62, 63]. However, this antibody is not very specific for RA (present in 
70-75% of patients with RA), and can be found in many inflammatory diseases and in healthy 
elderly individuals [64].   
  
 - - 21 - - 
 
Recently, antibodies directed against citrulline containing proteins (anti-CCP) have gained 
much attention [65, 66]. During citrullination of proteins, arginine residues are converted into 
citrulline residues (fig. 8). The enzyme responsible for this conversion is peptidylarginine 
deiminase (PAD). Anti-CCP antibodies are highly specific for RA and can be detected very 
early in the course of the disease, even before clinical onset [67, 68]. With a very sensitive 
assay called CCP2, anti-citrullinated protein antibodies can be detected in almost 80% of RA 
sera with a specificity of 98% [69-71]. Anti-CCP producing plasma cells have been shown in 
the inflamed synovial RA tissue [72] suggesting the presence of citrullinated proteins in the 
synovial membrane causing an antigen driven maturation of CCP-specific B cells at the site of 
inflammation.  
 
 
Figure 8: The citrullination process involves enzymatic conversion from arginine to citrulline. The enzyme that 
catalyzes this reaction is peptidylarginine deiminase (PAD). During the reaction, the arginine is attacked by the 
Cys residue of the enzyme establishing a tetrahedral adduct while ammonia is released. The adduct is then 
cleaved by the nucleophilic attack of a water molecule that regenerates the Cys residue and forms the keto-group  
(obtained from van György B. et al. [73]).  
 
Indeed, the presence of citrullinated proteins, like fibrinogen α and fibrinogen β, have been 
shown in the RA synovium [74]. However, these forms of fibrin are not specific for RA but 
are also observed in non-RA synovium [75]. Another citrullinated protein associated with RA 
is citrullinated vimentin, better known as the Sa-antigen. However, information of the 
presence of this form of vimentin in vivo in the synovial tissue is limited [76]. It is still largely 
unknown, what the exact role is of protein citrullination in arthritis, as PAD expression and 
citrullination of proteins are found in other tissue and pathologies [77, 78].  This process of 
arginine transformation could be a more universal characteristic of inflammation, although 
very little is known about the function of protein citrullination in general.  
Recently, there have been reports that show a link between protein citrullination and the 
genetic predisposition of RA patients.  
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The strongest genetic link with RA is its relationship with the specific human leukocyte 
(HLA)-DR genes. Already in the late seventies, Stastny found that 70% of white patients with 
RA, compared to 28% of patients with non-RA, expressed HLA-DR4 [79]. HLA-DR4 genes 
are part of the MHC class II molecules that contain the shared epitope (SE). This SE is a 
conserved amino acid motif (QK/RAAA) found within the third variable region of the DRβ 
chains of DRB1*0101, DRB1*0404 and DRB1*0401 [80]. This SE hypothesis postulates that 
the SE motif is directly involved in the pathogenesis of RA by allowing the presentation of an 
arthritogenic peptide to T cells [81]. It has been shown that the peptide-MHC interaction of 
peptides containing citrulline in stead of arginine is dramatically increased and leads to the 
activation of CD4+ T cells in HLA-DRB1*0401 transgenic mice [82]. A recent study of van 
der Helm-van Mil A. H. et al. showed that SE alleles are primarily associated with the 
presence of anti-CCP antibodies [83]. These recent findings indicate that SE alleles are not 
associated with RA as such, but rather with a distinct phenotype of the disease, namely the 
anti-CCP-positive RA. Moreover, it suggests that the SE alleles act as a classic immune 
response gene for the development of anti-CCP antibodies.  
 
Spondyloarthropathy 
SpA reflects a group of interrelated and overlapping chronic inflammatory diseases including 
ankylosing spondylitis (AS), reactive arthritis (ReA), psoriatic arthritis (PsA), arthritis 
associated with inflammatory bowel disease, and undifferentiated SpA (USpA).  
SpA is characterized as a chronic inflammatory rheumatoid factor negative arthritis of the 
spinal and peripheral joints (fig. 9). The observed synovitis is pauciarticular and is frequently 
associated with inflammation of the entheses. Hallmarks of these types of chronic arthritis are 
that the destructive properties are simultaneously combined with the formation of new bone. 
Some groups have therefore termed these types of disorders as an example of destructive and 
remodeling arthritis. Extra-articular manifestations are observed and include inflammation of 
gut, skin, and the eye (fig. 7).  
The diseases are not associated with rheumatoid factor, but they show a strong association 
with HLA-B27, an allele of the major histocompatibility complex class I [84, 85]. Misfolding 
of HLA-B27 molecules, homodimerisation of the heavy chains could lead to a pro-
inflammatory unfolded protein response [86, 87]. Also, the activation of T-lymphocytes by 
presenting bacterial peptides or self-derived peptides could, in part, play a role in the 
inflammatory nature of SpA. In addition, peptides derived from HLA-B27 itself can be 
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recognized by CD4+ T cells [88]. The true nature of the underlying mechanism of HLA-B27 
susceptibility is not fully understood. The link with HLA-B27 is not absolute, as there in no 
association of HLA-B27 in African patients with SpA [89], indicating that other genes may 
also contribute to the disease susceptibility.  
 
(A) (B)  
Figure 9: The radiographic hallmark of SpA is the presence of erosions of the sacroiliac joint (A). In patients 
with advanced and severe SpA, the entire spine becomes fused into a single structure termed the bamboo spine 
(B) (obtained from UCLA Rheumatology department: http://www.cdaarthritis.com/; Craig W. Wiesenhutter 
©2005). 
 
 
HLA-B27 transgenic rats do not develop SpA in germ-free conditions, which indicate the 
importance for bacterial infections [90]. Indeed, bacterial strains that infect the gut or the 
urogenital tract, especially in ReA, can play a role in triggering inflammation. Also, there are 
indications that the increased intestinal permeability of patients with SpA could lead to the 
starting or continuing events of chronic inflammation [91, 92].  
 
Synovial histopathology  
The study of the synovium is important in understanding the nature of inflammatory synovial 
diseases. Histological studies have thus far provided insight into the pathofysiology of chronic 
joint inflammations. The introduction of needle arthroscopy provided a tool with which both 
visualization and sampling of the synovium became possible. Previous studies concentrated 
largely on the histological description of RA synovitis. However, as it became clear that the 
prevalence of SpA could be as high as, or even higher than RA [60], the investigation of SpA 
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synovium was stimulated. This was partly due to the use of needle arthroscopy which is a safe 
and well-tolerated technique.  
As previously indicated, SpA consists of an interrelated group of inflammatory pathologies. It 
is difficult to say if there are specific differences in synovial histopathology in SpA subtypes 
since they were never systematically compared. As the synovial heterogeneity observed in 
SpA was found to be independent between SpA phenotypes [93], the section below will not 
discriminate between the different subtypes.   
 
A first major characteristic of synovitis is the hyperplasia of the synovial lining. There is a 
significant difference in lining-layer thickness between RA and SpA synovitis. SpA is 
characterized by a lower score in maximum and mean lining thickness measured semi-
quantitatively [93, 94]. This difference in hyperplasia could be related to higher infiltration of 
immune regulatory cells as it has been reported that infiltration of lymphocytes and especially 
lymphoid aggregation appears to be more prominent in RA than SpA. There is an increase in 
CD3+, CD4+ and CD20+ T cells in RA although lymphoid aggregates are only seen in about 
10% of the SpA synovia [94, 95]. Although the number of CD68+ macrophages is similar 
between the synovitis of the two forms of inflammatory arthritis, a specific subset of CD163+ 
macrophages is increased in SpA [93-96]. This scavenger receptor has the unique function of 
internalizing the haemoglobin/haptoglobin complex upon rupture of red blood cells. This 
prevents oxidative stress caused by the free heme group.  The CD163 receptor, thereby, is 
considered to play a role in an anti-inflammatory response [97].  
Angiogenesis, the formation of new blood vessels has also been indicated as an important 
feature in the process of synovitis. Apparently, the vascularity is increased in SpA as opposed 
to RA [93, 95, 98] and the vascular morphology seems to be related to the form of 
inflammatory arthritis; straight vessels are predominantly seen in RA, whereas tortuous 
patterns are observed in SpA. These data were confirmed independently in a larger patient 
cohort containing 100 cases [99].  
The proliferative vascularised inflamed synovial tissue in RA eventually transforms into an 
invasive tissue destroying cartilage and bone by production of matrix metalloproteinases 
(MMPs). Although the detrimental nature of synovitis is more pronounced in RA, there is no 
difference in MMPs staining pattern of diseased RA and SpA synovial tissue [100]. Also, 
similar expression of the tissue inhibitors of MMPs was found. The authors suggested that the 
destructive progression in SpA and RA was probably not related to the MMP system [100]. In 
addition to enzymatic destruction of cartilage, the role of osteoclast formation in destruction 
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of the bone matrix has gained interest [101, 102]. The primary mediator of osteoclast 
formation is the receptor activator of NF-κB ligand or RANKL and is present both in SpA 
and RA synovial tissue, although there is on average a lower expression of RANKL in the 
SpA synovial tissue in comparison to RA [103]. This down regulation in SpA could be 
explained by the fact that the osteoprotegerin (OPG) which blocks the interaction between 
RANK and RANKL is significantly more active in SpA than in RA synovium [104]. The 
authors concluded that a deficiency in OPG could have a role in the pathogenesis of bone 
erosion which characterizes RA.  
It is of interest to notice that there has only been one histopathology study on healthy normal 
synovium. This study indicated the presence of macrophages and T lymphocytes; T helper 
and T suppressor/cytotoxic cells in the normal synovium and HLA-DR+ cells were 
confirmed. The major difference in contrast to diseased synovium is the absence of B 
lymphocytes [105]. These findings, however, need to be confirmed by other investigators.  
Besides the differences indicated above, there are currently only two specific 
immunohistochemical features that discriminate between RA and SpA. The presence of 
intracellular citrullinated proteins has been specifically associated with RA [71, 93, 94, 106]. 
Also the presence of HLA-DR4-positive cells presenting human cartilage glycoprotein 39 
(HC gp-39) was found to be highly specific for RA [94, 107, 108].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 - - 26 - - 
 
REFERENCES 
[1.] Harris, E., Rheumatoid arthritis, W.B. Saunders Company, Philadelphia 1997. 
[2.] Tarner, I. H., Harle, P., Muller-Ladner, U., Gay, R. E., et al., Best Pract Res Clin Rheumatol 2005, 19, 19-
35. 
[3.] Firestein, G. S., Rheumatoid synovitis and pannus, Mosby, London 1997, pp. 13.11 - 13.15. 
[4.] Edwards, J. C., Arthritis Res 2000, 2, 344-347. 
[5.] Wilkinson, L. S., Pitsillides, A. A., Worrall, J. G. and Edwards, J. C., Arthritis Rheum 1992, 35, 1179-1184. 
[6.] Barland, P., Novikoff, A. B. and Hamerman, D., J Cell Biol 1962, 14, 207-220. 
[7.] Athanasou, N. A., Ann Rheum Dis 1995, 54, 392-394. 
[8.] Shikichi, M., Kitamura, H. P., Yanase, H., Konno, A., et al., Arch Histol Cytol 1999, 62, 219-229. 
[9.] Edwards, J. C., Structure of synovial lining, Chapman & Hall, London 1987, pp. 17-40. 
[10.] Yielding, K. L., Tomkins, G. M. and Bunim, J. J., Science 1957, 125, 1300. 
[11.] Brommer, E. J., Dooijewaard, G., Dijkmans, B. A. and Breedveld, F. C., Ann Rheum Dis 1992, 51, 965-
968. 
[12.] Rice, G. E., Munro, J. M., Corless, C. and Bevilacqua, M. P., Am J Pathol 1991, 138, 385-393. 
[13.] Medof, M. E., Walter, E. I., Rutgers, J. L., Knowles, D. M., et al., J Exp Med 1987, 165, 848-864. 
[14.] Muller-Ladner, U., Gay, R. E. and Gay, S., Structure and function of synoviocytes, Lippincott-Williams and 
wilkins, Philidelphis 2001, pp. 243-251. 
[15.] Hamann, J., Wishaupt, J. O., van Lier, R. A., Smeets, T. J., et al., Arthritis Rheum 1999, 42, 650-658. 
[16.] Iwanaga, T., Shikichi, M., Kitamura, H., Yanase, H., et al., Arch Histol Cytol 2000, 63, 17-31. 
[17.] Baeten, D. and De Keyser, F., Curr Mol Med 2004, 4, 1-12. 
[18.] Youssef, P. P., Kraan, M., Breedveld, F., Bresnihan, B., et al., Arthritis Rheum 1998, 41, 663-669. 
[19.] Tak, P. P. and Bresnihan, B., Arthritis Rheum 2000, 43, 2619-2633. 
[20.] Nishioka, K., Hasunuma, T., Kato, T., Sumida, T., et al., Arthritis Rheum 1998, 41, 1-9. 
[21.] Baier, A., Meineckel, I., Gay, S. and Pap, T., Curr Opin Rheumatol 2003, 15, 274-279. 
[22.] Peng, S. L., Rheumatology (Oxford) 2006, 45, 26-30. 
[23.] Sun, Y. and Cheung, H. S., Semin Arthritis Rheum 2002, 31, 299-310. 
[24.] Perlman, H., Georganas, C., Pagliari, L. J., Koch, A. E., et al., J Immunol 2000, 164, 5227-5235. 
[25.] Pap, T., Cinski, A., Baier, A., Gay, S., et al., Joint Bone Spine 2003, 70, 477-479. 
[26.] Amano, T., Yamasaki, S., Yagishita, N., Tsuchimochi, K., et al., Genes Dev 2003, 17, 2436-2449. 
[27.] Yamasaki, S., Yagishita, N., Tsuchimochi, K., Nishioka, K., et al., Arthritis Res Ther 2005, 7, 181-186. 
[28.] FitzGerald, O. and Bresnihan, B., Ann Rheum Dis 1995, 54, 511-515. 
[29.] Wang, G. L. and Semenza, G. L., J Biol Chem 1993, 268, 21513-21518. 
[30.] Paleolog, E. M., Br J Rheumatol 1996, 35, 917-919. 
[31.] Taylor, P. C. and Sivakumar, B., Curr Opin Rheumatol 2005, 17, 293-298. 
[32.] Hirohata, S. and Sakakibara, J., Lancet 1999, 353, 1331. 
[33.] Takemura, S., Braun, A., Crowson, C., Kurtin, P. J., et al., J Immunol 2001, 167, 1072-1080. 
[34.] Sack, U., Stiehl, P. and Geiler, G., Rheumatol Int 1994, 13, 181-186. 
[35.] Yanni, G., Whelan, A., Feighery, C. and Bresnihan, B., Ann Rheum Dis 1994, 53, 39-44. 
[36.] Pando, J. A., Duray, P., Yarboro, C., Gourley, M. F., et al., J Rheumatol 2000, 27, 1848-1854. 
  
 - - 27 - - 
 
[37.] Soden, M., Rooney, M., Cullen, A., Whelan, A., et al., Br J Rheumatol 1989, 28, 287-292. 
[38.] Pap, T., Meinecke, I., Muller-Ladner, U. and Gay, S., Ann Rheum Dis 2005, 64 Suppl 4, iv52-54. 
[39.] Mor, A., Abramson, S. B. and Pillinger, M. H., Clin Immunol 2005, 115, 118-128. 
[40.] Burman, A., Haworth, O., Bradfield, P., Parsonage, G., et al., Joint Bone Spine 2005, 72, 10-16. 
[41.] Bombara, M. P., Webb, D. L., Conrad, P., Marlor, C. W., et al., J Leukoc Biol 1993, 54, 399-406. 
[42.] Smith, R. S., Smith, T. J., Blieden, T. M. and Phipps, R. P., Am J Pathol 1997, 151, 317-322. 
[43.] Georganas, C., Liu, H., Perlman, H., Hoffmann, A., et al., J Immunol 2000, 165, 7199-7206. 
[44.] Bondeson, J., Brennan, F., Foxwell, B. and Feldmann, M., J Rheumatol 2000, 27, 2078-2089. 
[45.] Geiler, T., Kriegsmann, J., Keyszer, G. M., Gay, R. E., et al., Arthritis Rheum 1994, 37, 1664-1671. 
[46.] Pap, T., Nawrath, M., Heinrich, J., Bosse, M., et al., Arthritis Rheum 2004, 50, 2794-2802. 
[47.] Pap, T., Claus, A., Ohtsu, S., Hummel, K. M., et al., Arthritis Res Ther 2003, 5, R163-173. 
[48.] Wernicke, D., Schulze-Westhoff, C., Brauer, R., Petrow, P., et al., Arthritis Rheum 2002, 46, 64-74. 
[49.] Dayer, J. M. and Burger, D., Eur Cytokine Netw 1994, 5, 563-571. 
[50.] Han, Z., Boyle, D. L., Chang, L., Bennett, B., et al., J Clin Invest 2001, 108, 73-81. 
[51.] Tolboom, T. C., Huidekoper, A. L., Kramer, I. M., Pieterman, E., et al., Clin Exp Rheumatol 2004, 22, 158-
164. 
[52.] Goldring, S. R. and Goldring, M. B., Clin Orthop Relat Res 2004, S27-36. 
[53.] Tetlow, L. C., Adlam, D. J. and Woolley, D. E., Arthritis Rheum 2001, 44, 585-594. 
[54.] De Bari, C., Dell'Accio, F., Tylzanowski, P. and Luyten, F. P., Arthritis Rheum 2001, 44, 1928-1942. 
[55.] Schouten, J. S., van den Ouweland, F. A. and Valkenburg, H. A., Ann Rheum Dis 1992, 51, 932-937. 
[56.] Dieppe, P., Osteoarthritis Cartilage 1999, 7, 325-326. 
[57.] Felson, D. T., Lawrence, R. C., Dieppe, P. A., Hirsch, R., et al., Ann Intern Med 2000, 133, 635-646. 
[58.] Arden, N. and Nevitt, M. C., Best Pract Res Clin Rheumatol 2006, 20, 3-25. 
[59.] Goldring, M. B., Best Pract Res Clin Rheumatol 2006, 20, 1003-1025. 
[60.] Khan, M. A., Ann Intern Med 2002, 136, 896-907. 
[61.] Smith, J. B. and Haynes, M. K., Ann Intern Med 2002, 136, 908-922. 
[62.] Masi, A. T., Maldonado-Cocco, J. A., Kaplan, S. B., Feigenbaum, S. L., et al., Semin Arthritis Rheum 
1976, 4, 299-326. 
[63.] Neumann, E., Barnum, S. R., Tarner, I. H., Echols, J., et al., Arthritis Rheum 2002, 46, 934-945. 
[64.] Lisse, J. R., Postgrad Med 1993, 94, 133-134, 139. 
[65.] Schellekens, G. A., de Jong, B. A., van den Hoogen, F. H., van de Putte, L. B., et al., J Clin Invest 1998, 
101, 273-281. 
[66.] Yamada, R., Autoimmun Rev 2005, 4, 201-206. 
[67.] Nielen, M. M., van Schaardenburg, D., Reesink, H. W., van de Stadt, R. J., et al., Arthritis Rheum 2004, 50, 
380-386. 
[68.] Rantapaa-Dahlqvist, S., de Jong, B. A., Berglin, E., Hallmans, G., et al., Arthritis Rheum 2003, 48, 2741-
2749. 
[69.] van Boekel, M. A., Vossenaar, E. R., van den Hoogen, F. H. and van Venrooij, W. J., Arthritis Res 2002, 4, 
87-93. 
[70.] Bizzaro, N., Mazzanti, G., Tonutti, E., Villalta, D., et al., Clin Chem 2001, 47, 1089-1093. 
  
 - - 28 - - 
 
[71.] Zendman, A. J., van Venrooij, W. J. and Pruijn, G. J., Rheumatology (Oxford) 2006, 45, 20-25. 
[72.] Masson-Bessiere, C., Sebbag, M., Durieux, J. J., Nogueira, L., et al., Clin Exp Immunol 2000, 119, 544-
552. 
[73.] Gyorgy, B., Toth, E., Tarcsa, E., Falus, A., et al., Int J Biochem Cell Biol 2006, 38, 1662-1677. 
[74.] Masson-Bessiere, C., Sebbag, M., Girbal-Neuhauser, E., Nogueira, L., et al., J Immunol 2001, 166, 4177-
4184. 
[75.] Chapuy-Regaud, S., Sebbag, M., Baeten, D., Clavel, C., et al., J Immunol 2005, 174, 5057-5064. 
[76.] Vossenaar, E. R., Despres, N., Lapointe, E., van der Heijden, A., et al., Arthritis Res Ther 2004, 6, R142-
150. 
[77.] Chang, X. and Han, J., Mol Carcinog 2005. 
[78.] Ishigami, A., Ohsawa, T., Hiratsuka, M., Taguchi, H., et al., J Neurosci Res 2005, 80, 120-128. 
[79.] Stastny, P., N Engl J Med 1978, 298, 869-871. 
[80.] Nepom, G. T., Adv Immunol 1998, 68, 315-332. 
[81.] Gregersen, P. K., Silver, J. and Winchester, R. J., Arthritis Rheum 1987, 30, 1205-1213. 
[82.] Hill, J. A., Southwood, S., Sette, A., Jevnikar, A. M., et al., J Immunol 2003, 171, 538-541. 
[83.] van der Helm-van Mil, A. H., Verpoort, K. N., Breedveld, F. C., Huizinga, T. W., et al., Arthritis Rheum 
2006, 54, 1117-1121. 
[84.] Brewerton, D. A., Hart, F. D., Nicholls, A., Caffrey, M., et al., Lancet 1973, 1, 904-907. 
[85.] Khan, M. A., Curr Opin Rheumatol 1995, 7, 263-269. 
[86.] Bird, L. A., Peh, C. A., Kollnberger, S., Elliott, T., et al., Eur J Immunol 2003, 33, 748-759. 
[87.] Dangoria, N. S., DeLay, M. L., Kingsbury, D. J., Mear, J. P., et al., J Biol Chem 2002, 277, 23459-23468. 
[88.] Boyle, L. H., Goodall, J. C., Opat, S. S. and Gaston, J. S., J Immunol 2001, 167, 2619-2624. 
[89.] Reveille, J. D., Ball, E. J. and Khan, M. A., Curr Opin Rheumatol 2001, 13, 265-272. 
[90.] Taurog, J. D., Maika, S. D., Satumtira, N., Dorris, M. L., et al., Immunol Rev 1999, 169, 209-223. 
[91.] De Vos, M., Mielants, H., Cuvelier, C., Elewaut, A., et al., Gastroenterology 1996, 110, 1696-1703. 
[92.] Martinez-Gonzalez, O., Cantero-Hinojosa, J., Paule-Sastre, P., Gomez-Magan, J. C., et al., Br J Rheumatol 
1994, 33, 644-647. 
[93.] Baeten, D., Kruithof, E., De Rycke, L., Boots, A. M., et al., Arthritis Res Ther 2005, 7, R359-369. 
[94.] Kruithof, E., Baeten, D., De Rycke, L., Vandooren, B., et al., Arthritis Res Ther 2005, 7, R569-580. 
[95.] Baeten, D., Demetter, P., Cuvelier, C., Van Den Bosch, F., et al., Ann Rheum Dis 2000, 59, 945-953. 
[96.] Baeten, D., Moller, H. J., Delanghe, J., Veys, E. M., et al., Arthritis Rheum 2004, 50, 1611-1623. 
[97.] Moestrup, S. K. and Moller, H. J., Ann Med 2004, 36, 347-354. 
[98.] Reece, R. J., Canete, J. D., Parsons, W. J., Emery, P., et al., Arthritis Rheum 1999, 42, 1481-1484. 
[99.] Canete, J. D., Rodriguez, J. R., Salvador, G., Gomez-Centeno, A., et al., Semin Arthritis Rheum 2003, 32, 
378-387. 
[100.] Vandooren, B., Kruithof, E., Yu, D. T., Rihl, M., et al., Arthritis Rheum 2004, 50, 2942-2953. 
[101.] Takayanagi, H., Iizuka, H., Juji, T., Nakagawa, T., et al., Arthritis Rheum 2000, 43, 259-269. 
[102.] Haynes, D. R., Crotti, T. N., Loric, M., Bain, G. I., et al., Rheumatology (Oxford) 2001, 40, 623-630. 
[103.] Crotti, T. N., Smith, M. D., Weedon, H., Ahern, M. J., et al., Ann Rheum Dis 2002, 61, 1047-1054. 
[104.] Haynes, D. R., Barg, E., Crotti, T. N., Holding, C., et al., Rheumatology (Oxford) 2003, 42, 123-134. 
  
 - - 29 - - 
 
[105.] Singh, J. A., Arayssi, T., Duray, P. and Schumacher, H. R., Ann Rheum Dis 2004, 63, 785-790. 
[106.] Baeten, D., Peene, I., Union, A., Meheus, L., et al., Arthritis Rheum 2001, 44, 2255-2262. 
[107.] Baeten, D., Steenbakkers, P. G., Rijnders, A. M., Boots, A. M., et al., Arthritis Rheum 2004, 50, 444-451. 
[108.] Steenbakkers, P. G., Baeten, D., Rovers, E., Veys, E. M., et al., J Immunol 2003, 170, 5719-5727. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 - - 30 - - 
 
 
 
 
 
 
 
 
 
 
 
  
 - - 31 - - 
 
 
 
General  
introduction 
 
Part II:  
Proteomics and its use in the field of 
rheumatology 
 
Kelly Tilleman1 
Dieter Deforce1 
Dirk Elewaut2  
 
 
 
 
 
 
 
 
1 Laboratory for Pharmaceutical Biotechnology, Ghent University, Ghent, Belgium 
2 Department of Rheumatology, University Hospital Ghent, Ghent, Belgium 
 
Rheumatology 2005, 44, 1217-1226 as ‘Rheumatology: a close encounter with proteomics’ 
 
  
 - - 32 - - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 - - 33 - - 
 
ABSTRACT 
Proteomics is a fast growing discipline in biomedicine that can be defined as the large-scale 
characterization of the entire protein complement of a cell, tissue or organism. Because 
protein levels and function may be critically dependent upon posttranscriptional mechanisms 
(e.g. posttranslational modifications) there has been significant interest in directly examining 
protein structure and function. It is now clear that proteomics studies may unmask previously 
unknown functions of proteins or protein interactions. However, proteomics in the field of 
rheumatology is still in its infancy.  
This review guides the reader through the consecutive steps of a proteomics study and 
provides an outline of the applications in the field of rheumatology which may range from 
proteome analyses of biological fluids of rheumatic diseases to identify possible new 
diagnostic tools towards more pathophysiological studies on target tissues such as synovial 
tissue or articular cartilage. 
Proteomics has great potential in the field of rheumatology and will no doubt have a great 
significant impact on our molecular understanding of these complex diseases.  
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INTRODUCTION 
 
1. Definition of proteomics 
The term ‘proteome’ was first coined by Marc Wilkins, an Australian postdoctoral fellow and 
was originally defined as the complete protein complement expressed by a genome [1].  This 
definition, however, does not take into account that the proteome is highly dynamic and that 
protein expression is influenced by environmental conditions of the cell, tissue or organism. 
Therefore, the definition of a proteome should specify that it is the protein complement of a 
given cell at a specified time, including the set of all protein isoforms and protein 
modifications [2]. Proteomics is then defined as the large-scale characterization of the entire 
protein complement of a cell, tissue or organism.  
 
2. From genomics to proteomics 
The Human Genome Initiative provided us with a blueprint of the human genome [3]. By 
studying the genome, it became clear that the behaviour of genome products is difficult to 
predict from the gene sequence alone. This realization has led to a variety of new large-scale 
disciplines analyzing down stream of the genome sequence. The introduction of these new 
techniques came along with a variety of ‘omics’-terminologies (fig. 1).  
First of all, genes are transcribed into mRNA. Since cells use alternative splicing, there is no 
one-to-one relationship between the genome sequence and the transcript [2]. Determining the 
level of mRNA in cells or tissues and the relationship between these levels in different 
conditions (e.g. diseased versus healthy) is the main goal of functional genomics also called 
‘transcriptomics’.    
Transcripts are further translated into proteins, which are considered to be the main carriers of 
biological activity. One gene, can lead to different mRNA molecules due to alternative 
splicing. These mRNA species are further translated into proteins. These proteins can become 
fully active by adding post-translational modifications (PTM) or by interaction with other 
proteins. Due to all these processes, one gene can result in many different protein isoforms. 
Protein function is highly dynamic and influenced by environmental factors. It not only 
depends on the amino acid sequence, but also on PTM, degradation and/or 
compartmentalization of proteins in protein complexes. Proteomics aims at determining 
protein expression levels, but also protein structure, modifications, localization and interaction 
with other proteins.  
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Proteomics is one area among the various ‘omics’ disciplines, which also includes new 
disciplines such as metabolomics. Thus, a total integration of all these areas, called systems 
biology, will lead to a comprehensive understanding of cellular biology.  
For evident reasons, we will only further discuss proteomics and its applications in the field of 
rheumatology.  
 
 
 
Figure 1: Overview of the currently available disciplines for large-scale analyses of genes, transcripts, proteins 
and metabolites. 
 
 3. Types of proteomics 
Roughly, there are three types of proteomics: expression proteomics, structural proteomics 
and functional proteomics. 
Expression proteomics seeks to identify all the protein species present in a proteome of a cell, 
tissue or organism at a certain time. Structural proteomics, by contrast, aims at identifying the 
molecular structure, i.e. the amino acid sequence of the protein entities involved in a given 
DNA 
RNA 
mRNA 
Protein 
Transcription 
Processing 
Translation 
PTM  
Processing 
Interaction
Genomics 
Functional  
genomics 
Proteomics 
Metabolites etabolomi 
Metabolomics 
  
 - - 37 - - 
 
process and to relate this information to the database of identified genes [4]. De Hoog C.L. et 
al. defined it as a comprehensive coverage of a single protein or domain structure [2]. Finally, 
functional proteomics describes the changes in protein abundance and modification during 
differentiation, proliferation and signalling of cells, both in qualitative and quantitative terms. 
It also includes studies of co-ordinated expression of proteins, as well as elucidation of the 
sequence of regulatory events during all stages that a cell or an organism undergoes during its 
entire life span [4].  
 
PROTEOMIC APPROACHES 
 
1. Classic approach: gel-based proteomics 
a) Two-dimensional gel electrophoresis 
Two-dimensional gel electrophoresis (2-DE), the prototype of the classic proteomics has been 
around since the mid 1970s [5] [6], but has undergone major technological improvements 
over the past decade. Especially, in terms of reproducibility, handling, resolution, separation 
of extremely basic or acidic proteins and data analysis [7].   
2-DE is a high resolution method for separating proteins in two dimensions; according to their 
isoelectric point (pI) in the first dimension and according to their size (molecular weight) in 
the second dimension. Firstly, proteins are separated by isoelectric focussing (IEF). Therefore, 
proteins are brought into a small gel strip that contains an immobilized pH gradient (IPG). 
This gel strip is applied on a plastic backing for easier handling and is further referred to as 
the IPG strip. When an electric field is applied over this IPG strip, the proteins migrate along 
the pH gradient in the strip until they reach the pH at which their overall charge is neutral; the 
isoelectric point (pI) of the protein. The result of this separation is a gel strip containing 
discrete protein bands at the pH position of their pI. This IPG strip is then applied onto a 
polyacrylamide gel. An electric current drives the focussed proteins out of the strip into the 
gel and separates the proteins according to their size. (for reviews on 2-DE and sample 
preparation see [7-9]).  
One of the greatest strengths of 2-DE is its ability to resolve proteins differing in a single 
charge and consequently, in vivo modifications of proteins can be visualized. Multiple protein 
isoforms can be analyzed, by determining factors as solubilization conditions and pH range of 
the IPG strip. Currently, a wide range of pH gradients are available on the market, varying in 
different pH gradients [9, 10]. 
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  b) 2-D gel visualization 
In order to visualize the separated proteins, 2-D gels can be stained with a variety of different 
stains. Detection methods in 2-DE can be divided in two large groups: general protein 
staining and specific detection of PTM. A limited overview of the most commonly used 
detection methods will shortly be discussed.  
Coomassie Blue staining is probably the most widely used general protein stain. Major 
advantages are its low cost, ease of use and its compatibility with identification by mass 
spectrometry. Because of its limited sensitivity (10ng per protein spot), Coomassie Blue is 
mostly used for detection of proteins in preparative gels from which spots are cut to be 
identified (see section 2.2 ‘Mass spectrometry and protein identification). Although silver 
stains are more sensitive (0.5-1ng per protein spot), they have a very small linear range and 
are time-consuming because of the numerous steps involved in the protocol. Moreover, they 
are less compatible with mass spectrometry based identification of gel separated proteins. 
Radio-active labelling is a very sensitive method of protein visualization; however it’s 
hazardous and expensive. It is only applied for very specific analyses like protein synthesis 
(35S) or protein phosphorylation (32P). To date, fluorescent dyes like Sypro Ruby or Tangerin 
dyes are becoming more and more the standard for general protein staining. They are sensitive 
(1ng per protein spot), have a large linear range (over three orders of magnitude), are 
extremely easy to use and are compatible with mass spectrometry. Fluorescent dyes can also 
be used to label protein complexes prior to 2-DE. This so-called ‘difference gel 
electrophoresis’ or ‘DIGE’ approach is gaining interest. The method allows to fluorescently 
label (with cyanine dyes Cy2, Cy3, Cy4) as many as 3 different complex protein populations 
prior to mixing them together and running them on the same 2-D gel [11].  
As the role of post-translational modifications became more prominent, specific detection 
methods of protein modifications were developed in which specifically glycoproteins, 
phosphoproteins and other modified proteins can be visualized in the gel. For detailed 
information on detection in proteomic analysis we refer to [12]. 
  c) 2-D gel data analysis 
Although, 2-D gel data analysis is a complex and laborious work, state-of-the art software 
programs have made this process easier and more straightforward. After acquiring 2-D 
images, protein spots have to be detected. Such a protein spot has three characteristics: the x 
and y-axis of the spot represented by the pI of the protein and its molecular mass, respectively 
and the z-axis which is a measure for the intensity of the spot and is demonstrative for the 
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amount of protein present in the spot. A spot on a 2-D gel can therefore correspond to a single 
protein, an isoform of a protein or a modified protein.   
 
 
 
 
Figure 2: In-gel digest of differentially expressed proteins. Spots of interest are excised from the gel and digested 
by site-specific proteases. The resulting peptides are eluted from the gel, desalted, concentrated and analyzed by 
mass spectrometry. 
 
 
In order to compare spots across several gels, spots have to be matched to each other. This is 
generally done by highlighting spots that are clearly present in all the gels as marker points. 
Using these markers, other spots present in the gels are matched to one another. Exploring 
differences in spot intensity or tracking protein spots that appear or disappear on gels derived 
from experimental and control conditions is the main goal of functional proteomics.   
Spots of interest are further processed and identified by mass spectrometry (MS) (fig. 2). 
Briefly, protein spots are cut from the gels and digested by using a sequence-specific protease 
(e.g. trypsin, chymotrypsin, Arg-C, Asp-N). The resulting mixture of peptides is desalted and 
analyzed by MS. 
 
2. Mass spectrometry 
Mass spectrometry (MS) is an analytical technique that measures an intrinsic property of a 
molecule, its mass, with very high sensitivity. Although this technique dates back to the early 
days of the last century, it’s only in the beginning of the 1980s with the development of new 
ionization techniques that mass spectrometry has found its applications in biological sciences. 
Mass spectrometers require charged gaseous ions and this was initially achieved by heating 
the sample. Since high temperatures are detrimental for proteins and peptides, this method 
could not be applied to vaporize these large biomolecules. Therefore, soft ionization methods 
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had to be developed in order to analyze biomolecules by MS. Almost simultaneously two soft 
ionization methods were developed: matrix assisted laser desorption ionization (MALDI) [13] 
and electrospray ionization (ESI) [14]. (For extended reading on analysis of proteins and 
peptides by mass spectrometry see review [15]).  
Although both proteins and peptides can be analyzed, we only further discuss peptide analysis 
by MS since it is the way to identify proteins derived from different proteomic approaches.   
 
 Ionization  
a) MALDI 
MALDI is a soft ionization technique that uses matrix material in order to get the peptides 
into the gaseous phase. Protonated peptides are co-precipitated with matrix material on a 
metal surface and air dried. The resulting dried spots are irradiated by laser pulses, usually 
from small nitrogen lasers. The matrix contains small organic molecules with absorbance at 
the wavelength of the laser (e.g. α-cyano-4-hydroxycinnamic acid or dihydrobenzoic acid).  
The exact nature of the ionization process in MALDI is largely unknown. During ionization 
and desorption, matrix molecules pass energy absorbed from the laser light to the charged 
peptides which are dispersed into gaseous phase (Fig. 3). Ionized peptides are further 
analyzed in the mass spectrometer.  
 
 
 
Figure 3: The MALDI ionization process. Charged peptides are co-precipitated with matrix molecules on a 
MALDI target plate and are irradiated by laser pulses. The gaseous charged peptides are further analyzed by 
mass spectrometry. 
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b) ESI 
In contrast with MALDI where ionization takes places from a dried sample, ESI ionizes the 
peptides from solution. The liquid sample flows through a micro capillary tube into the mass 
analyzer. A high electrical potential is applied between the capillary and the inlet of the mass 
spectrometer. The result is a mist of small highly charged droplets which evaporate rapidly, 
either by field desorption or solvent evaporation. The ionized peptides are consequently 
released into to the gaseous phase and further analyzed by MS [16] (Fig. 4).  
 
 
 
 
Figure 4: The ESI ionization process. Charged peptides in solution are brought into a capillary on which a high 
electrical voltage is applied. Charged droplets are evaporated and gaseous ionized peptides are released into the 
mass spectrometer. 
 
There are several ways in which the sample can be delivered to this micro capillary tube. The 
simplest method is to load each sample in an individual capillary. Although cross-
contamination is avoided, the method is slow and tedious. As an alternative approach, ESI 
sources can be coupled to liquid chromatography (LC) systems. The benefit of this on-line 
coupling is that the sample clean-up, concentration and analysis becomes semi-automated. 
 
2.2 Mass analyzers and protein identification 
a) Mass analyzers 
Every mass spectrometer consists of 3 basic elements: an ionization source, one or more mass 
analyzers and a detector. The names of the mass spectrometers are simply a compilation of 
their ionization source and the mass analyzer. There is a wide range of different types of mass 
spectrometers, commonly divided in two groups: single MS machines, when only one mass 
analyzer is present and tandem MS or MSMS machines, if more mass analyzers are present.  
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The most commonly used single MS analyzers are Time-Of-Flight (TOF), Quadrupole (Q) 
and iontrap. The most generally used MSMS analyzers are Q-TOF and TOF-TOF.  
The list of mass analyzers cited above is far from complete, however they can be viewed as 
those most routinely used in protein identification. (for extended reading on mass analyzers 
we refer to specific sections of [15, 17])  
The great difference between single MS and MSMS analyzers is that the latter can not only 
separate the ions according to their mass, but they are able to select and fragment ions. The 
benefit of this will become evident in the next section. 
b) Identification of proteins by peptide mass fingerprinting 
When ions are passed into a mass spectrometer, they are separated according to their mass.  
This analysis results in a “mass fingerprint” of the peptides present in the mixture. These 
peptides are the result of the cleavage of a particular protein using a sequence-specific 
protease such as trypsin. The set of masses obtained by the mass spectrometer is compared to 
the theoretically expected tryptic peptide masses for each protein present in a certain database 
(Fig. 5).  
There are numerous databases on the World Wide Web which are publicly accessible. The 
ExPASy biological server (http://www.expasy.org) has an extensive collection of proteomics 
tools and links to other sites for identification of proteins by peptide mass fingerprints (PMF) 
like mascot, PepSea, PeptideSearch and many more.  
These search engines will subsequently rank the positively identified proteins according to the 
number of peptide matches. Positively identified proteins identified by PMF have, on average, 
minimum peptide coverage of 20%. Identification of proteins by PMF is often the result of 
MALDI-TOF analysis.  
c) Identification by tandem mass spectrometry 
Mass spectrometers can not only determine the mass of the peptide, but also its amino acid 
sequence which is typical for MSMS mass analyzers. A particular peptide is selected out of a 
mixture of peptides in the first mass analyzer and is subsequently dissociated by collision with 
an inert gas, such as nitrogen or argon in a ‘collision’ cell. During these energetic collisions of 
the selected peptide and the collision gas, bonds are broken along the peptide backbone. In 
most applications, this leads to so called b and y ions, which indicate fragmentation at the 
amide bond with charge retention on the N or C terminus, respectively [18]. The resulting 
fragments are analyzed by the second mass analyzer, producing a tandem mass spectrum also 
called fragmentation spectrum or MSMS spectrum. Each peptide fragment in a series differs 
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from its neighbour by only one amino acid. It is therefore possible to determine the amino 
acid sequence by considering the mass difference between the neighbouring peaks in a series 
[18]. The experimental MSMS spectrum is matched against a calculated spectrum for all 
peptides in the database (e.g. Mascot, SEQUEST).  
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VIMENTIN_HUMAN  
Figure 5: MALDI peptide map and identification of a protein. A spot was excised from a 2-D gel and in-gel 
digested with trypsin. 10% of the peptide solution was applied on a MALDI target plate in combination with 
1mg/ml α-cyano matrix material. The samples were acquired on a MALDI-Q-TOF (Waters, Milford, USA). The 
peptide mass fingerprint was identified as vimentin_human. A total of 34 peptides were derived from vimentin 
and are indicated by a squared asterix. Matched peptides are highlighted and indicate protein coverage of 59.6%. 
Please note that the sequence of several identified peptides can overlap.  
 
 
A score is calculated which reflects the quality of the match between the experimental 
spectrum and the theoretical one (fig.6).  
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Figure 6: LC/MSMS analysis of a mixture of peptides derived from a protein spot. The remainder of the peptide 
solution of the sample analyzed by MALDI-Q-TOF (fig. 5), was loaded onto a nanoLC column and eluted with a 
gradient of acetonitrile and 0.1% formic acid. The nanoLC system was online coupled to an ESI-Q-TOF (Water, 
Milford, USA) and spectra were acquired of only doubly charged peptides over a mass range from 500Da to 
1000Da every 1 sec. The resulting chromatogram is displayed in which the total ion current (TIC) is plotted 
against the retention time of the eluting peptides (A). The chromatogram of the ion with m/z= 770.54 is replotted 
and this is called a single ion current chromatogram (SIC) (B). Several other peptides co-eluted with ion m/z= 
770.54 at time 25 min. and are displayed in a single mass spectrum (C). When the ion current (IC) of certain ions 
reaches a predefined IC threshold, the mass spectrometer selects these ions for fragmentation. This figure shows 
the subsequent fragmentations spectrum of peptide m/z= 770.54 (D). This MSMS spectrum reveals the amino 
acid sequence of the peptide and is used to identify which protein the peptide is derived from (E). The protein 
was identified as vimentin_human by the mascot search engine.  
 
 
Since tandem mass spectra data contain information on the sequence of the peptides, these 
searches are generally more specific and discriminating than peptide mass fingerprints.  
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  d) Identification by sequence-tag analysis 
It is not necessary to obtain a complete amino acid sequence of a peptide in order to be able to 
identify the protein. A short sequence tag is often sufficient to identify the corresponding 
protein from which the peptide(s) was (were) derived. A small stretch of amino acids can be 
combined with the start mass and the end mass of the series, which specifies the exact 
location of the sequence in the peptide and the known cleavage specificity of the enzyme. 
Such a peptide sequence will then retrieve from the database (e.g. MS-Tag, mascot, dbEST) 
one or a few sequences whose theoretical fragmentation pattern is matched against the 
experimental one.  
Tandem mass spectrometry and sequence-tag analysis are routinely obtained by ESI-Q-TOF, 
MALDI-Q-TOF or MALDI-TOF-TOF mass spectrometers.  
 
3. Alternative approach: gel-free proteomics 
2-DE is still widely used as separation and quantitative analysis of complex protein mixtures. 
It is by far the best technique to visualize and analyze PTM of proteins; however, the 
technique also has its limitations. These limitations include the low-throughput of samples, 
problems in detecting low abundant, extremely basic and acidic proteins and proteins with 
very high or very low molecular weights. Because of these restrictions, several groups 
explored alternative separation techniques for proteins using MS [19-26]. Many of these 
alternative separation techniques rely on the ability of tandem mass spectrometers to collect 
sequence information from a specific peptide even if several other peptides, derived from 
other proteins, are in the sample at the same time. In order to be able to perform quantitative 
analysis, stable isotope labelling of the samples is used. This is achieved in different ways: 
proteins can be labeled metabolically by culturing cells in media that are enriched (e.g. 
containing 15N salts or 13C-labeled amino acids) or by enzymatic digestion of proteins in 18O 
containing water [19, 26]. Proteins can also be labeled at specific sites with an isotopically 
encoded reagent. One of the best known examples of this technique is called ICAT (isotope-
coded affinity tag).  This  method stably labels peptides of  two populations of proteins using 
reactive probes that differ in isotope composition [24]. Proteins from the experimental 
mixture are labeled with either the heavy reagent composed of eight deuterium atoms (d8- 
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Figure 7: Differential gel-free proteomics by ICAT labelling of the samples. Proteins are extracted from two 
different populations or cell states and are labeled on cysteine residues with either the light (d0_ICAT) reagent or 
the heavy (d8_ICAT) reagent. Next, the samples are mixed together and digested with a protease e.g. trypsin. 
Peptides that were labeled with the ICAT reagents are isolated by affinity chromatography because of the biotin 
tag present in the reagent. After purification, the peptides are analyzed by MS and the peak ratios of the 
differently labelled peptides, which differ by 8 Da, are quantified. Identification of the peptides is done by 
sequencing the peptides by MSMS. 
  
ICAT) or the light reagent composed of eight hydrogen atoms (d0-ICAT) and then mixed 
together. The mixed proteins are digested by a site-specific protease e.g. trypsin. ICAT-
labeled peptides are isolated from the complex mixture utilizing the biotin tag present in the 
ICAT reagent. Selected peptides are further separated and analyzed by liquid chromatography 
on-line coupled to electrospray tandem mass spectrometry (LC-ESI/MSMS). Mass 
spectrometry is used to reveal the ratio of the isotopic molecular weight peaks that differ by 8 
Da, and this gives a measure of the relative amount of each protein present in the original 
samples [20, 21] (fig. 7). Other gel-free proteomic approaches are chip-based techniques 
based on different technologies [27, 28]. 
It is important to notice that both gel-based and gel-free proteomic approaches have there 
strengths and drawbacks. It is therefore crucial to find out which method is best suited for 
achieving the goals that were set out.  
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PRESENT STATUS OF PROTEOME RESEARCH IN THE FIELD OF 
RHEUMATOLOGY 
 
Searching the NCBI database, mid-march 2005, using keywords like <arthritis> and 
<proteomics> revealed 22 hits. For comparison; using the keyword <cancer> in combination 
with <proteomics> revealed 758 hits. Notwithstanding the fact that the amount of reports is 
rather small, the content is extremely interesting, and the methods vary from the classic 2-DE 
approach to gel-free isotopic labelling of samples.    
Proteomic papers in the field of rheumatology can largely be divided in three groups: protein 
target identification by differential screening of biological fluids, biomarker search in 
rheumatic tissues and proteomic surveillance of autoantigens. 
 
1. Protein discovery by differential screening of biological fluids 
The comparison of protein patterns in body fluids of diseased and healthy individuals has the 
potential to identify new diagnostic tools and could subsequently lead to new disease specific 
therapies. Analysis of serum and synovial fluids is of great importance in the diagnosis of 
rheumatic diseases but also in monitoring a patient’s response to certain medication. Currently 
available biomarkers are related to the degree of inflammation, but lack straightforward 
correlation with disease severity or do not change dramatically in response to treatment [29]. 
Moreover, it is known that the joint damage may progress in spite of decreased inflammatory 
activity and erosions may develop in patients who have few clinical signs of inflammation 
[30, 31]. In addition, there is a need for serum biomarkers in other rheumatic pathologies such 
as spondyloarthropathy (SpA).   
Large-scale analysis of synovial fluid and serum provides information on disease specific 
differences due to local processes in the inflamed joint, compared to systemic disease 
symptoms. Several discriminating acute-phase proteins have been identified in serum, plasma 
and synovial fluid of different rheumatic pathologies using classic proteomic approaches [32-
36].  Serum amyloid A protein is present in synovial fluid and plasma of RA patients, but is 
undetectable in plasma or synovial fluid of osteoarthritis (OA) patients. This acute-phase 
protein has a crucial role in the very early organization of host-defence, but could have a 
destructive effect in chronic inflammation [33]. Certain fibrinogen and the calgranulin protein 
isoforms show diseases associated expression and processing in biological fluid matrices of 
RA and OA patients [33, 36].   
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Although the classic proteome approach is able to identify new discriminating targets, it is not 
applicable for fast screening. Several groups have therefore attempted to directly analyze 
pathologic fluids by mass spectrometry [30, 37, 38]. Liao H. et al. identified at least 33 
possible protein biomarkers in synovial fluid of RA patients by applying a semi-quantitative 
gel-free proteomics approach using internal 13C labeled peptide standards [30]. Besides 
members of the S100 proteins, other proteins like osteopontin (plays a role in attachment and 
invasion of synovial fibroblasts [39]), cyclophilin (proinflammatory mediator in arthritis [40], 
cathepsin B and many others were highly increased in synovial fluid of RA patients with 
erosions [30]. These newly identified proteins need further validation in larger patient cohorts, 
to evaluate their specificity and sensitivity. 
  
Large-scale proteomic analysis of biological fluids has great potential, however, one must 
realize that these samples constitute of highly abundant proteins (e.g. albumin, IgG’s). These 
proteins are detrimental for the detection of other species in the sample. A good sample clean-
up, or efficient enrichment techniques are therefore pivotal for the investigation of proteins 
present in smaller concentrations.   
 
  2. Biomarker discovery in rheumatic tissue samples 
Potentially interesting samples are not only synovial fluid and serum but may also include 
analysis of joint components such as synovial tissue and cartilage. The molecular 
understanding of the process leading to joint destruction is not complete yet. Therefore, large-
scale proteome and genome analysis of joint tissue could reveal important information about 
mechanisms leading to joint damage. 
 
Joint destruction in non-inflammatory arthritis or OA is characterized by degradation of 
articular cartilage. It is thought that this is due to an imbalance between anabolism and 
catabolism of the extracellular matrix. Therefore, several groups have been studying the 
regulation of the protein synthesis and protein secretion by cartilage using proteomic 
approaches [41, 42].  
Proteome analysis of the phenotype of articular cartilage in OA and normal patients could be 
of great help in understanding the endogenous control mechanisms of matrix turnover in 
cartilage. Moreover, this information could be of help in tissue engineering during stem cell 
differentiation. 
  
 - - 50 - - 
 
 Joint destruction in inflammatory arthritis is very different from OA and is initiated by 
chronic inflammation of the synovial tissue. To unravel the molecular and cellular mechanism 
of chronic synovitis, synovial proteomes of RA and OA patients have been investigated. The 
group of Thiessen HJ, has used a multi-Western blot PowerblotTM (BD Biosciences), for 
differential protein screening of synovium obtained from OA and RA patients [43]. This 
commercially available method offers the possibility to analyze over 700 protein species 
simultaneously. Some differentially expressed proteins were further validated in a larger 
patient cohort, namely Stat 1, p47phox and MnSOD which were up regulated in RA and 
cathepsin D which showed a lower expression in RA in comparison to OA. All of these 
proteins are related to inflammation, cytokine induced activation or have been described in 
tissue damage and joint destruction in arthritic joints [43].  
Chronic synovitis is not only a characteristic of RA, but also of SpA. These two frequent 
forms of inflammatory arthritis have a different clinical outcome, but have some shared 
features such as chronic synovitis. Our group analyzed the synovial proteome of RA, SpA and 
OA patients and came to the conclusion that the synovial proteome of RA patients consists of 
a unique protein expression pattern in contrast to the synovial proteome of SpA patients [44]. 
We identified several proteins related to either RA or SpA inflammation amongst them MRP-
8 (calgranulin A), a well known biomarker for inflammatory arthritis. MRP-8 was highly up 
regulated in the inflammatory arthritides in comparison with OA patients, in which this 
protein spot was completely absent from the 2-D images [44] (Chapter 1). 
Proteome studies of fibroblast-like cells, derived from the synovium of patients with 
inflammatory arthritis can aid in resolving the mechanism(s) behind the synovial hyperplasia 
and the associated tissue damage [45]. Likewise, tissue derived from inflamed joints of 
animals can also be helpful in gaining access to the complex pathology of joint inflammation 
[46]. 
 
3. Proteomic surveillance of autoimmunity 
The majority of rheumatic diseases are characterized by autoimmune processes. Identification 
of autoantigens playing a role in these complex pathologies is extremely important. Also, the 
presence of autoantibodies in otherwise healthy individuals may perhaps predict the 
development of autoimmune disease. Furthermore, the appearance of certain autoantibodies 
might predict the clinical course of a patient with established disease [47].  
Using 2-DE to separate tissue proteins, autoantibodies against these proteins can be detected 
with serum or synovial fluid of patients by Western Blot. This technique has already been 
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used in rheumatic pathologies in the late 80s [48, 49], and is currently widely applied. A 
recent example of this technology is described by Xiang Y. et al. [50], in which they 
investigated autoantigens present in chondrocytes in both RA and OA patients. 
Triosephosphate isomerase (TPI) was identified as an OA specific autoantigen. The 
autoantibodies recognized multiple epitopes on TPI and titres were both high in serum and 
synovial fluid [50].  
Also alpha-enolase, a well known autoantigen, has been investigated by proteomics in several 
autoimmune diseases [51, 52]. Autoantibodies against glycolytic proteins like glucose-6-
phosphate isomerase [53] and Aldolase A [54] have been identified in RA sera. Moreover, 
dysregulation of glucose metabolism could play a role in the hyperplasia of synoviocytes in 
RA. Autoantibodies against these proteins might be implicated in the pathology of RA.   
Not only the discovery of new autoantigens, but also analysis of specific post-translational 
modifications of these autoantigens, has great potential in proteomic applications in rheumatic 
pathologies. Immunoreactive spots can clearly be identified using 2-DE. These spots can 
represent a specific isoform of a protein or particular modification of a protein. Some of these 
PTM, particularly citrullination of certain proteins, elicit autoimmune reactivity in RA [55, 
56]. Other post-translational modifications which may play a key role in the acquisition of 
autoantigenicity in rheumatic pathologies may be unmasked by proteomics [57]. 
 
 
A LOOK TOWARDS THE FUTURE 
Proteomics is a technique with great promise in the field of rheumatology. Since both tissue 
and body fluids can easily be obtained from patients suffering from rheumatic pathologies, the 
in vivo situation can readily be examined.  
There is no doubt that fast screening methods like array-based protein chips and quantitative 
mass spectrometry will become very important in the future. Using these high-throughput 
techniques, the potential application for diagnosing or to monitor prognostic markers of 
patients with rheumatic diseases, is almost unlimited.  
There is, however, still a need for classic proteomic approaches. As the role of post-
translational modifications will increase in the future, 2-DE could play a part in elucidating 
specific protein modifications.  
Synovial tissue proteomics could help us understand the complex nature of rheumatic 
pathologies. Techniques like laser-capture micro dissection in combination with 2-DE and 
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mass spectrometry allow in situ analyses [58]. Specific cell types can be isolated and the 
diseases associated proteins subsequently determined.  
As biomarkers, protein interactions and signalling pathways become apparent during 
proteome analyses, disease mechanisms may be unravelled that eventually could open new 
avenues for drug targets in the field op rheumatology.  
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Inflammatory arthritides include different forms of joint inflammation which lead to joint 
deformations, loss of joints, and disability. These pathologies have a tremendous socio-
economic impact, not only on the patient, but on society as a whole.  
We distinguish two frequent forms of chronic inflammatory arthritis; RA as an aggressively 
eroding joint disease and SpA as a less erosive disease with extensive remodelling and repair 
processes. As described in the general introduction, there are clearly distinct clinical and 
pathological features that are specific for the different forms of arthritis. However, RA and 
SpA have one characteristic in common; synovitis, the chronic inflammation of the synovial 
tissue.  
The synovial membrane, more specific its inflammation, has been investigated from an 
immunological point of view. Numerous reports indicate that similar immune cells and 
cytokines play a role in both pathologies. Therefore it is possible that certain molecular 
differences between RA and SpA synovitis are responsible for the differences in clinical 
outcome. The knowledge of the molecular pathophysiology of chronic arthritis and synovitis 
is still far from complete, especially in SpA. In part this is due to the fact that the prevalence 
of SpA was thought to be rather low. It is only recently, that the interest in this related group 
of inflammatory arthritides has grown, since it is now known that the prevalence of SpA is of 
the same magnitude as RA. Several research groups are including SpA in their studies 
whereas before, the emphasis was exclusively on RA and OA. 
 
The primary aim of this project was to learn more about the molecular nature of synovitis in 
chronic inflammatory arthritides. Especially the expression of proteins in the inflamed 
synovial tissue was investigated. This was accomplished by using a traditional proteomics 
approach. 2-DE patterns of synovial tissue extracts of RA, SpA and OA patients were 
analyzed and differentially expressed proteins were identified by mass spectrometry (chapter 
1). 
 
Looking at the synovial proteome of inflammatory arthritides, we observed different isoforms 
of vimentin. Citrullinated vimentin is known as the Sa-antigen in RA; however, citrullinated 
vimentin has not been identified in protein extracts of inflamed synovial tissue. We therefore 
further characterized these different isoforms of vimentin and investigated the presence of 
antibodies against processed citrullinated forms of vimentin in RA and SpA (chapter 2). 
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Differential proteome analysis also revealed differentially expressed proteins of which their 
expression is hypoxia-induced. It is known that the RA joint is hypoxic. Since both RA and 
SpA are characterized by synovitis, it is plausible that the environmental condition in the RA 
and SpA joint are alike. Angiogenesis, which can be observed in RA and SpA inflamed 
synovial tissue, is triggered by hypoxia. Moreover, there is a significant higher vascularity in 
SpA than in RA. We investigated whether this dissimilarity could be the result of a different 
molecular response to the hypoxic environment. We therefore analyzed the stabilisation of 
HIF, the transcription factor responsible for the gene expression under hypoxia, in RA and 
SpA FLS. In addition, the possibility of hypoxia induced expression of VEGF and 
Ceruloplasmin by FLS, two proteins involved in angiogenesis, were examined (chapter 3). 
 
The majority of rheumatic diseases are characterized by autoimmunity. Identification of 
autoantigens playing a role in these pathologies is important. The study presented in chapter 4 
was conducted in order to register the spectrum of synovial autoantigens that induce an 
autoimmune humoral response. 2-D immunoblotting with RA and control patients’ sera to an 
RA synovial protein extract was performed, followed by identification by mass spectrometry 
(chapter 4).   
 
 
In summary, this thesis describes a close encounter of rheumatology and proteomics. The 
latter was the central technique during this research project. Because of its global approach, 
results of proteome analyses are often descriptive. It is therefore a good starting point to learn 
about the molecular pathophysiology of a certain diseased tissue, in our case, the synovial 
tissue. In addition, by using a classic proteomics approach and thereby using 2-DE as protein 
separation technique, we clearly show that it is possible to visualize PTM, like citrullination, 
which are important in rheumatic pathologies.   
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ABSTRACT 
We investigated the cytosolic proteome of inflamed synovial tissue by hierarchical clustering 
analysis and validated the feasibility of this proteome analysis by identifying proteins that 
were differentially expressed between rheumatoid arthritis (RA), spondyloarthropathy (SpA) 
and osteoarthritis (OA). 
Synovial biopsy samples were obtained from 18 patients undergoing needle arthroscopy for 
knee synovitis associated with RA (n=6) and SpA (n=6), and for joint effusion of the knee 
associated with OA (n=6). Cytosolic proteins were extracted from the tissue and subjected to 
two-dimensional gel electrophoresis. Protein expression patterns were statistically analyzed 
and used for hierarchical cluster analysis. Proteins of interest were independently identified by 
MALDI and ESI mass spectrometry. 
Hierarchical cluster analysis of the complete match set, containing 640 spots, remarkably 
segregated SpA from RA and OA. Next, we used a subset of spots that were statistically 
differentially expressed (p<0.01), between RA and SpA, SpA and OA or RA and OA, in both 
a Student T-test and Mann Whitney U test. The dendrograms revealed distinct clustering of 
RA versus SpA and RA versus OA.  
Spots that were differentially expressed between the groups were identified by tandem mass 
spectrometry. Fructose bisphosphate aldolase A and alpha-enolase showed higher expression 
levels in SpA than in OA (p<0.01). Calgranulin A (MRP8) was markedly upregulated in RA 
and SpA patients in comparison with OA patients where this spot was below detection limit.  
The analysis of the cytosolic proteome of synovial tissue is a useful approach to identify 
disease-associated proteins in chronic inflammatory arthritis.  
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INTRODUCTION 
Rheumatoid arthritis (RA) and spondyloarthropathies (SpA) are two frequent forms of 
chronic arthritis with an important morbidity and socio-economic impact in our society. 
Although similar joints can be affected in both diseases, their clinical presentation is different. 
RA is characterized by symmetric polyarticular joint inflammation and destruction as well as 
by extra-articular manifestations such as rheumatoid nodules or vasculitis. The hallmark 
symptoms of SpA, by contrast, are quite distinct. They include sacroiliitis, spondylitis, 
pauciarticular synovitis and enthesitis. Extra-articular manifestations such as uveitis or 
subclinical bowel inflammation may also occur in SpA. There are several entities that belong 
to the concept of SpA such as ankylosing spondylitis (AS), reactive arthritis (ReA), psoriatic 
arthritis (PsA) and undifferentiated SpA (USpA) [1,2]. Despite these different clinical 
presentations a major-shared feature between both diseases is the presence of synovitis. Joint 
effusion may also occur in patients suffering from osteoarthritis (OA). However, this occurs 
as a secondary symptom induced by biomechanical stress on cartilage and subchondral bone, 
in contrast to inflammatory joint diseases such as RA and SpA where primary inflammation 
occurs within the synovial membrane. 
In both RA and SpA, the synovial membrane of affected joints undergoes several profound 
changes in synovial architecture with thickening of the synovial lining layer, 
neovascularization and lymphocyte infiltration [3-5]. Besides differences in general 
histological characteristics between RA and SpA (lining thickness, vascularization, and 
cellular infiltration) [6], two specific immunohistochemical features that recently have been 
described, discriminate RA from SpA. The presence of intracellular citrullinated proteins has 
been specifically associated with RA [7]. Also, synovial immunohistochemical staining for a 
combination epitope of complexes of the RA associated autoantigen epitope, HC gp-39 263-
275, and the RA associated DRB1*0401 HLA class II molecule was found to be restricted to 
HLA-DRB1*0401 positive RA patients [8]. 
Despite intensive investigations into the nature of chronic synovitis, the molecular differences 
of RA versus SpA synovial inflammation are poorly understood. While several groups have 
therefore initiated gene expression profile studies using cDNA microarrays in order to 
identify disease relevant genes and proteins, it became apparent that these techniques have 
several limitations. There are situations where RNA expression does not match protein 
expression and function [9], for example in the event that mRNA encodes for 2 or more 
alternative splice variants of a given protein with distinctive functions [10].  Furthermore, 
several regulatory elements exist such as 3’ mRNA AU-rich elements that regulate translation 
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of mRNA into protein [11-13]. Finally, many posttranslational modifications by enzymes 
such as kinases or proteinases regulate protein function. One of the best examples is the 
cascade of phosphorylation events upon crosslinking of T cell receptors. Proteomics refers to 
the large-scale study of protein expression and function in a tissue or organism [14]. Several 
different technologies exist to study the proteome of autoimmune diseases [15] and it is clear 
that this area of investigation is still immature. While proteomics has become increasingly 
popular in several areas of research particularly in oncology [16-19], no detailed analysis of 
the human proteome in chronically inflamed synovium exists to date.  
Therefore, the aim of this study was to use and compare protein expression profiles of 
cytosolic proteins in inflamed synovial tissue from RA, SpA and OA. The data presented here 
indicate that a differential screening approach of the synovial cytosolic proteome by 2-DE is a 
feasible approach that may be useful to identify proteins implied in the pathogenesis of RA 
and SpA.  
 
PATIENTS AND METHODS 
 Patients 
Synovial biopsy samples were obtained from 18 patients undergoing needle arthroscopy of 
the knee for diagnostic work-up or for therapeutic reasons. Six patients with RA fulfilling the 
American College of Rheumatology  (ACR) criteria [20], 6 patients with SpA fulfilling the 
European Spondyloarthropathy Study Group criteria [21] and 6 patients with osteoarthritis 
(OA) fulfilling the ACR criteria [22] were included in this study. All patients undergoing 
needle arthroscopy had active synovitis (RA and SpA) or joint effusion (OA) of the knee.  
Preferably, patients did not receive DMARD at the time of tissue sampling. However, some 
patients received DMARD in the past but were not treated with DMARD at the time of or up 
to one month before tissue sampling. Reasons for discontinuation of previous DMARD were 
intolerance and non-compliance. Disease duration at the moment of tissue sampling varied 
from one month to more than 10 years. No significant differences existed in disease duration 
between the various groups studied.  
The clinical characteristics of these patients are summarized in table 1. Within the SpA group, 
the precise clinical entities are indicated as well.  
The study was conducted after approval by the local ethics committee. Written informed 
consent was obtained from all participating patients. 
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Table 1: Clinical data on the patients with RA, OA and SpA.* 
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RA 25 70 M - - 5 8.9 77 10240 >1600 1 
RA 9 51 F + - 9 2.2 41 160 143 10 
RA 17 65 M + - 19 10.7 87 1280 >1600 5 
RA 5 74 M + - 14 3.6 42 20480 >1600 3 
RA 36 62 M + - 7 9.6 56 0 2 0.3 
RA 29 29 F + - 8 3.3 45 160 1600 0.3 
OA 20 54 M + - 2 0.1 3 0 2 0.1 
OA 47 76 F + - 0 0.2 9 0 3 0.2 
OA 64 62 F - - 1 1.4 25 0 3 6 
OA 7 73 F - - 1 0.5 13 0 2 4 
OA 19 60 M + - 0 0.2 3 0 1 35 
OA 58 89 M - - 1 ND ND ND 1 20 
USpA 55 45 F + - 1 0.9 18 0 3 0.3 
USpA 23 21 M + - 4 4.2 39 0 5 0.1 
USpA 27 48 M - +(a) 1 2.6 42 0 4 20 
AS 41 59 M + - 2 4.0 30 0 4 25 
USpA 50 57 M + - 2 0.6 4 ND 3 10 
USpA 60 48 M - +(b) 1 1.7 8 0 0 2 
 
*Except where mentioned otherwise: M = male; F = female; (+) = receiving; (-) = not receiving; NSAID’s = 
nonsteroidal antiinflammatory drugs; DMARD’s = disease-modifying antirheumatic drugs where (a) = 
Sulfasalazine, (b) = Imuran (Azathioprine). Treatment characteristics were determined at the time of tissue 
sampling. Patients were chosen preferably DMARD negative at the time of tissue sampling;  RA = rheumatoid 
arthritis; SpA = spondyloarthropathy; OA = osteoarthritis; USpA = undifferentiated spondyloarthropathy; AS = 
ankylosis spondylitis; ND = no data available; SJC = swollen joint count; CRP = C-reactive protein; ESR = 
erythrocyte sedimentation rate; RFLF = rheumafactor latex fixation; anti-CCP = antibody against cyclic 
citrullinated protein determined by ELISA (Immunoscan RA, mark 2, Euro-diagnostica AB (Arnhem, The 
Netherlands)) with a cut-off of 25 U/ml; the disease duration displayed was determined at the time of tissue 
sampling.  
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Synovial biopsies 
Synovial biopsy samples were obtained by needle arthroscopy [23]. Briefly, needle 
arthroscopy of the knee was performed under local anesthesia, using a 2.7mm Hopkins 
rodlens telescope (Storz, Tuttlingen, Germany). The joint cavity was carefully inspected and 
synovial membrane biopsy samples (8-10 specimens/patient) were obtained using a 2.7mm 
biopsy forceps (Storz, Tuttlingen, Germany). The biopsy samples were immediately snap 
frozen in liquid nitrogen and stored in liquid nitrogen until further analysis. In addition, 8 
biopsy samples from each patient were stored in formaldehyde and embedded en bloc in 
paraffin. Sections (5 µm) were cut and stained with hematoxylin and eosin for histological 
analysis. 
 
Histological assessment 
Stained sections were coded and analyzed by 2 independent observers who were blinded to 
the patient’s clinical data. A validated semiquantitative scoring system for synovial tissue was 
used [4, 6, 24]. The analysis included all areas of the biopsy samples and a global 
semiquantitive score was given for each parameter (0-3 scale where 0=lowest expression and 
3=highest). In cases of discordant scores, which differed by a maximum of 1 point, the mean 
of the 2 scores was used. 
Histological evaluation of the paraffin sections included the mean synovial lining layer 
thickness (0 = 1-2 cell layers, 1 = 3-4 cell layers, 2 = 5-6 cell layers, and 3 = ≥ 7 cell layers), 
degree of vascularity of the sublining layer, degree of infiltration of the sublining layer, 
number of plasma cells and neutrophils, and number of lymphoid aggregates. Comparison of 
histological semi-quantitative scores was performed using the non-parametric Mann-Whitney 
U test. P values less than 0.05 were considered to be statistically significant. 
 
 Protein extraction 
The protein content of the pooled synovial biopsy samples was extracted using the ReadyPrep 
Sequential Extraction Kit from Biorad (Hercules, CA, USA) according to the manufacturer’s 
instructions. A cocktail of phosphatase inhibitors containing cantharidin, bromotetramisole, 
microcystin LR, sodium orthovanadate, sodium molybdate, sodium tartrate and imidazole 
(Sigma, Steinheim, Germany) was added to each sample. Additional to endonucleases 
(Sigma, Steinheim, Germany), protease inhibitors for a broad range of serine, cysteine and 
metalloproteases, as well as calpain (Roche diagnostics, Mannheim, Germany) were also 
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added to each sample. Before protein extraction, synovial biopsy samples were transferred to 
an eppendorf and homogenized during 2 minutes using a Turrax homogenizer (Ika-Werke, 
Stanfer, Germany) in buffer I of the ReadyPrep Sequential Extraction kit (Biorad, Hercules, 
CA, USA) containing 40mM Trisbase. Protein concentrations were measured using the 
Coomassie Protean Reagent assay from Pierce (Rockford, USA) according to the guidelines 
provided by the manufacturer. 
 
 Two-dimensional gel electrophoresis 
Fifty µg of total protein extract was precipitated with cold acetone overnight at –20°C. After 
centrifugation at 20000g for 5 minutes, the pellet was airdried. 2-DE was performed 
according to Görg A. et al. [25] with minor adjustments. Briefly, 50µg of the soluble protein 
extract of the synovial biopsy pool of each patient was dissolved in 360µl of rehydration 
buffer solution containing 7M urea, 2M thiourea, 4% CHAPS, 20mM DTT and 0.2% Carrier 
Ampholyte solution (Amersham Biosciences, Uppsala, Sweden). Once the pellet was 
completely dissolved, each sample was incorporated in a linear immobilized pH gradient strip 
(IPG) with a pH gradient of 3 up to 10 and rehydrated overnight [26]. After in-gel 
rehydration, the strips were iso-electrically focused on the Protean IEF cell (Biorad, Hercules, 
CA, USA) at 18°C, using 250V for 30 min (linear ramping), 500V for 1h (linear ramping), 1 
kV for 1h (linear ramping), 3kV for 1h (linear ramping), rapid ramping to 10 kV in 3h and 
steady state at 10 kV for 45 kVh. After iso-electric focusing, the strips were equilibrated in 
two steps by gently shaking for 15 minutes in a solution containing TrisHCl buffer (50mM, 
pH 8.8), 6M urea, 20% v/w glycerol, 2% SDS. DTT (1.5% v/w) was added to the first, and 
4% iodoacetamide to the second step. After equilibration, the IPG strips were placed on a 
polyacrylamide gel (12% T; 2.6% C) and run in sets of 6 gels in the vertical Protean II xi 
Multi Cell (Biorad, Hercules, CA, USA) at 16mA/gel for 30 minutes and 32mA/gel for 
approximately 4 hours and 30 minutes at 10°C. The gels were stained with Sypro Ruby 
(Biorad, Hercules, CA, USA) for 1 hour, according to manufacturer’s guidelines. 
 
Gel scanning and image analysis 
2-D gels stained with Sypro Ruby were scanned and digitized by the ProXpress Imager from 
Perkin Elmer (Wellesley, MA, USA) using top illumination, maximum scanning area and a 
resolution of 100µm. Image exposure was set to 15 seconds. A yellow flatfield was used to 
correct the data for uneven illumination. 
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Digitized images were analyzed with PDQuest 2D-analysis Software v7.1 (Biorad, Hercules, 
CA, USA). Spots were detected by using the spot detection wizard. Background was removed 
by applying the floater background subtraction and horizontal and vertical streaks were also 
removed from the gels in this step. All gels were matched to each other creating a match set 
standard image containing the match information of all the gels. 
 
Data analysis and statistical analysis 
In order to compare protein expression levels across the 18 gels, the gels were corrected for 
small pipetting errors or minor staining differences. This was realized by normalizing the 
protein expression data of each gel for its total density in the gel image. Statistical analysis of 
the data was done according to Aliya A. A. et al. [27] and Tan F. L. et al. [28] by using SPSS 
v.11.5 software (SPSS inc., Chicago, Illinois, USA). Tests for normality and equal variances 
were performed in order to examine whether the data qualified for parametric (Student T-test) 
or non-parametric statistical tests (Mann Whitney U test). The majority of our data was not 
normally distributed (Shapiro-Wilk p<0.05) with equal variances (equal variance test, 
p>0.05). However, some protein expression levels showed a normal distribution (Shapiro-
Wilk p>0.05) (data not shown). Therefore, data that were significantly different in both Mann 
Whitney U test (p<0.01) and Student T-test (p<0.01, after Log-transformation) were used as 
variables to perform hierarchical cluster analysis. The between-group linkage method and the 
Pearson correlation similarity measure were utilized for clustering analysis and the result of 
the cluster analysis was displayed in a dendrogram.  
 
Protein identification by mass spectrometry 
In-gel digestion with trypsin 
Spots of interest were excised, from semi-preparative 2-D gels containing 200µg protein 
material, and digested with modified sequence grade trypsin (Porcine) (Promega, Madison 
WI, USA). Briefly, spots were cut into small pieces of +/- 1mm3 and washed with 400µl 
50%ACN/50mM NH4HCO3 for 15 minutes. After the buffer was removed, the gel pieces 
were dehydrated by adding 100µl of 100% ACN and rehydrated in 15µl 25mM NH4HCO3 
containing 10ng/µl sequence grade modified trypsin (Promega, Madison WI, USA) for 30 
minutes on ice. In-gel digestion with trypsin was continued over night at 37°C. Peptides were 
extracted in 60%ACN/5%TFA, completely dried and resuspended in 10µl 0.1% TFA.  
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Identification by Maldi Q-Tof 
A peptide solution of 1.5µl was mixed 1:1 with matrix solution (2mg/ml recrystilized α-
cyano-4-hydroxycinnamic acid (CHCA) in 50% ACN/50% 0.1%TFA) and 1µl was spotted 
onto the Maldi target plate. On-target desalting was performed by adding 4µl of Milli-Q 
purified water to each spot. The data were acquired on Maldi Q-Tof (Waters, Milford, USA) 
using Data Dependent Analysis software. Processing and database searching of the data 
against the Swiss-prot database was performed by ProteinLynx Global Server v2.0 software 
(PLGS) (Waters, Milford, USA). 
Identification by ESI mass spectrometry 
The remaining peptide solution (8.5µl) was injected on a on-line RP-HPLC system using 
column switching (LC Packings, Sunnyvale, CA, USA) coupled to a Q-Tof I mass 
spectrometer (Waters, Milford, USA) fitted with an orthogonal Z-spray [29]. The data were 
acquired using the Automatic Function Switching software. Fragmentation spectra, resulting 
from tandem mass spectrometry were searched against the mascot search engine 
(http://www.matrixscience.com).  
 
Real-time RT-PCR 
TRIzol (Life Technologies, Paisley, U.K.) was added to synovial biopsy samples of OA 
(n=10), RA (n=9) and SpA (n=10) patients. The total RNA was extracted using the RNeasy 
Mini Kit (QIAGEN, Valencia, CA) according to the manufacturer’s instructions. Before 
reverse transcription, digestion of DNA was performed using the RNase-Free DNase Set 
(QIAGEN). cDNA was synthesized with oligo(dT) as primer using the Superscript II kit (Life 
Technologies). Primers for the housekeeping enzymes GAPDH and cyclophylin A were 
designed using the Primer Express software (Applied Biosystems, Foster City, CA). For 
GAPDH, primers were TCC TCT GAC TTC AAC AGC GAC A (sense) and GTG GTC GTT 
GAG GGC AAT G (antisense). For cyclophylin A, primers were AAG CAT GTG GTG TTT 
GGC AA (sense) and CCA TTC CTG GAC CCA AAG C (antisense). Amplification of 
cDNA with housekeeping enzymes primer pairs was monitored using the SYBRGreen I 
chemistry. Assays on Demand (Applied Biosystems, Foster City, CA) were used for the 
amplification of Calgranulin A (Hs000374264_g1). Amplification and on-line detection of 
PCR products were carried out with optical 96-well plates (Applied Biosystems, Foster City, 
CA) in the ABI PRISM 7000 Sequence Detection System (Applied Biosystems, Foster City, 
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CA). mRNA expression levels were calculated according to Vandesompele J. et al . [30]. 
Statistical analysis was performed using Student T-test.  
 
RESULTS 
Protein extraction of synovial biopsy tissue and 2-DE 
Extraction of the cytosolic proteome from synovial biopsy tissue (wet weight: 41,001 ± 
21,84mg) yielded an average cytosolic protein concentration of 1116,43 ± 468,93µg/ml x 
1ml. The cytosolic proteome of synovial biopsy tissue of 18 patients was analyzed. A total 
amount of 50µg of cytosolic proteins was subjected to 2-DE using IPG strips pH 3-10. 
 
 
Figure 1: Match set standard of the cytosolic proteome of synovial tissue in RA, OA and SpA.  
Spots that were identified are indicated by their corresponding spot number.  
 
Gels were visualized, scanned and digitized as described in the section patients and methods. 
A data set of 18 gels was analyzed. Six gels originated from RA patients, 6 gels from patients 
with SpA and 6 gels were obtained from OA patients. Spot detection and matching of these 
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gels was done using the automated detection and matching dialog in PDQuest v.7.1 (Biorad, 
Hercules, CA, USA). After manual editing, a match set was created. In a match set, the 
protein spots from different gels are matched to each other and are included in a synthetic 
image, called a match set standard. This match set standard is originally based on a real raw 
data gel and this gel is arbitrarily chosen. It is preferably the gel with the most spots and the 
least streaking on it, which in our case was the gel of patient SPA55. Although the standard is 
based on a real raw data gel, it was extended to a complete artificial composite image 
containing all the matched information of the gels in the analysis. Spots that were matched to 
at least two other members of the match set, but were absent from the initial standard, were 
also added to the match set standard. This artificial composite image contains all the 
information the software needs to analyze the gels quantitatively, qualitatively or statistically. 
A total of 640 spots were present in the artificial composite image (Fig.1). The way, in which 
the match set standard is chosen, extended and transformed to a complete artificial image, 
implies that the initial selection of another gel as match set standard eventually leads to the 
same results. 
 
Analysis of protein expression levels by hierarchical clustering analysis 
We evaluated whether the expression levels of all the spots matched in this 2-D analysis could 
be used for hierarchical cluster analysis. A total of 640 spots were separated by 2-DE and 
matched between the gels. This entire match set was used for clustering analysis. The 
resulting dendrogram is displayed in figure 2.  
 
  
Figure 2: Hierarchical cluster analysis of entire match set using 640 variables.  
The dendrogram revealed a complete segregation of SpA from RA and OA. 
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All patients diagnosed with SpA clustered together. According to the clustering, patient 
SPA60 is less related to the rest of the SpA patients, but still joins the cluster early. Clustering 
was also observed between patient RA25 and RA17, both RA patients and less strongly 
between patient OA58 and OA64, both OA patients. Also patients OA47 and OA20, patients 
both diagnosed with OA, clustered together. 
Thus, hierarchical clustering on the entire match set remarkably segregated the SpA as a 
group from the patients diagnosed with RA or OA. However, no distinctive clustering was 
seen between OA and RA as a group. 
If an unselected data set of spots does not result in accurate clustering, the use of a defined 
subset of differentially expressed proteins between the groups could improve the clustering of 
these groups [27]. Therefore, we next evaluated the use of statistically differentially expressed 
protein expression levels for hierarchical cluster analysis. We analyzed our match set 
statistically, using both a parametric (Student T-test after Log-transformation, p<0.01) and a 
non-parametric test (Mann Whitney U test, p<0.01) for statistical analysis of our data since 
our data set was comprised of both normally and not normally distributed data. In addition, by 
requiring significance for both tests, this approach minimizes the likelihood of false positives 
[27,28]. Using this statistical approach 24, 16 and 5 spots were significantly (p<0.01) 
differentially expressed between RA and SpA, SpA and OA, and RA and OA, respectively. A 
flowchart demonstrating the experimental and statistical approach is displayed in figure 3. 
In order to explore the possibility to segregate between RA and OA, the 5 spots that were 
statistically differentially expressed (p<0.01) between both diseases were used as variables for 
hierarchical cluster analysis. The dendrogram represented in figure 4(a) showed 6 very closely 
related RA patients segregating from the 6 OA patients that were divided in two sub clusters. 
Subsequently, we investigated whether using the spots that were differentially expressed 
between SpA and RA (n=24) as variables would allow to obtain improved clustering features 
upon hierarchic cluster analysis. Interestingly, this analysis revealed complete segregation 
between RA and SpA. The resulting dendrogram represented in figure 4(b) displayed two 
major branches (a) and (b). Branch (a) clusters 6 closely related RA patients, whereas branch 
(b) combines 3 related SpA patients with 3 SpA patients that are more distant. 
Likewise, statistical analysis between SpA and OA revealed 16 spots to be expressed 
differentially. Hierarchical cluster analysis of these expression levels resulted in almost a 
complete segregation between SpA and OA (data not shown). 
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Figure 3: Flowchart of experimental and statistical design. Five, 16 and 24 spots are the subsets of differentially 
expressed proteins in the cytosolic synovial tissue proteome between OA and RA, OA and SpA and RA and 
SpA, respectively, which were further subjected to hierarchical cluster analysis. Some of these spots were 
selected for identification by mass spectrometry.  These subset of selected spots were obtained by determining 
protein spots that significantly differed in both the non-parametric Mann Whitney U test and the parametric 
Student T-test (after Log transformation) (p<0.01). 
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 (a) 
 
 
(b) 
 
 
Figure 4: Hierarchical cluster analysis on a subset of protein expression levels that are statistically differentially 
expressed (both in Mann Whitney U test and Student T-test, after Log-transformation, p<0.01) between two 
groups studied. 
(a) Hierarchical cluster analysis of protein spots which are significantly differentially expressed between RA 
and OA (n= 5 spots). The dendrogram separated into two clusters segregating 6 closely related RA patients 
from 6 OA patients.  
(b) The dendrogram of the hierarchical cluster analysis of protein expression levels statistically differently 
expressed between RA and SpA (n=24 spots), revealed complete segregation of RA from SpA 
 
 
 
Histological evaluation and protein expression pattern 
While the above mentioned results indicated that cytosolic protein profiles from RA synovial 
tissue could be segregated from OA and SpA, it remained possible that these differences 
could be attributed to differences in the synovial microarchitecture. To examine this, we 
performed a histological assessment with hematoxylin-eosin staining of synovial tissue using 
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semiquantitative scoring methods as described earlier. All RA and SpA patients suffered from 
active synovitis for which they underwent needle arthroscopy. 
As previously described, synovial tissue of both patient groups showed increased thickness of 
the synovial lining layer and infiltration of inflammatory cells. Whereas in large patient 
cohorts some significant differences were observed in synovial tissue from RA versus SpA 
patients in routine histological assessment (6) by hematoxylin-eosin staining, no statistical 
significant differences were observed in the presently studied patient cohort (data not shown). 
Nevertheless, marked differences in protein expression patterns were observed as described 
above. These findings clearly indicate that the observed differences in protein expression in 
this group of patients can not be solely attributed to changes in synovial histology. As a non-
inflammatory control, a group of OA patients suffering from joint effusion in the knee was 
also included. No signs of inflammation could be observed in OA synovial tissue. This 
resulted in some significant differences between RA and SpA synovial tissue in this patient 
cohort (data not shown). 
 
Identification of differentially expressed proteins 
We identified proteins that were related to either RA or SpA inflammation in the synovial 
tissue. Spots that fulfilled this criterion were spots that were statistically differentially 
expressed either between RA and OA or SpA and OA. In addition the spots should show a 
higher expression level in the inflammatory arthritis in comparison to OA. Five spots were 
statistically different between RA and OA (fig. 3). However, only one spot (6006) showed a 
higher expression level (>10-fold) in RA than in OA. In the group of spots that were 
statistically differentially expressed between SpA and OA (n=16), 15 spots were 
overexpressed in SpA in comparison to OA.  
In summary, 16 spots of which 1 spot was related to RA inflammation and 15 spots were 
related to SpA inflammation, were subjected to tandem mass spectrometry. We 
unambiguously identified 10 proteins as these were the most abundantly expressed and 
yielded the most peptides for protein identification by ESI and MALDI mass spectrometry 
(table 2 – fig. 1). 
We investigated whether these proteins were previously described being related to 
inflammation in general or inflammatory rheumatoid diseases, like RA and SpA. Literature 
searches revealed several papers in which these proteins were related to inflammation. The 
references are indicated in table 2.  
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Table 2: Identification of spots of which the protein expression level is statistically significantly different 
between RA and OA or SpA and OA*. 
 
 
spots upregulated in RA in comparison with OA      
    Maldi Maldi ESI 
SSP Identification OA av RA av MS MSMS MSMS
6006 Calgranulin A[33-39] 0,46 (0/6) 860,96 (6/6) 12 1 1 
       
spots upregulated in SpA in comparison with OA      
    Maldi Maldi ESI 
SSP Identification OA av SPA av MS MSMS MSMS
2614 Vimentin[45-47] 0,46 (0/6) 506,88 (6/6) 49 0 26 
4601 Protein disulfide isomerase A3 prec. 0,46 (0/6) 151,78 (5/6) 18 1 3 
6312 Triosephosphate isomerase[48,49] 0,46 (0/6) 549,36 (5/6) 12 1 4 
6610 Alpha-enolase[41] 133,61(1/6) 1253,38 (6/6) 10 2 2 
6616 Glutamate dehydrogenase 1 0,46 (0/6) 248,08 (4/6) 25 0 1 
9506 Fructose bisphosphate aldolase A[40, 42-44] 86,78 (1/6) 1072,21 (5/6) 12 1 1 
2805 Endoplasmin precursor[50-54] 0,46 (0/6) 526,95 (6/6) 39 1 5 
3820 Ceruloplasmin[55,56] 0,46 (0/6) 118,05 (5/6) 18 0 1 
6503 Creatine kinase M chain[57-58] 0,46 (0/6) 499,55 (6/6) 24 2 2 
 
*‘SSP’ shows the number of the spot on fig.1; ‘av’ is the average expression level of the protein spot in OA or 
SpA; The number of patients in which a particular spot was detected is shown between brackets; ‘Maldi MS’ 
indicates the number of peptides used to identify the protein by peptide mass fingerprinting; ‘Maldi MSMS’ 
describes the number of amino acid sequences obtained from Maldi-Q-TOF used for identification;  ‘ESI 
MSMS’ refers to the amount of amino acid sequences obtained from ESI-Q-TOF used for independent 
identification of the proteins by Mascot database searching; the references displayed between brackets next to 
the identification of the protein show papers found in the literature describing a role for the identified protein in 
inflammation or more specific in inflammatory arthritis like RA or SpA.  
 
 
 Real-time RT-PCR 
To further establish de significance of the protein expression level profiles of calgranulin A, 
better known as MRP-8, a real-time RT-PCR experiment was conducted on a separate cohort 
of 29 patients (see section patients and methods). Results showed statistically higher mRNA 
expression level of MRP-8 in inflamed synovial tissue of RA (average mRNA expression of 
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MRP-8 (normalized to the geometric means of 2 household genes; GAPDH and 
CyclophilinA) in RA patients ± SD = 1,04 ± 0,99) in comparison with mRNA expression 
levels of MRP-8 in OA patients (0,31 ± 0,29) on p=0.04 using Student T-test. The average 
mRNA expression level of MRP-8 normalized to the geometric means of GAPDH and 
Cyclophilin A in SpA patients is  0,37 ± 0,39 (fig.5).  
These data are in line with the protein expression profiles of MRP-8 and indicate local 
synthesis of MRP-8 in inflamed synovial tissue.  
 
 
 
Figure 5: Gene expression of MRP8 in synovium of RA, OA and SpA patients. 
Gene expression levels are normalized with GAPDH and Cyclophilin A. (°) represents the gene expression of 
MRP8 in the individual patients. (-) shows  the average gene expression of MRP8 in the group. Gene expression 
levels of MRP8 in RA and OA patients showed a significant difference on p<0.05. 
 
 
 
DISCUSSION 
Proteomics has become increasingly popular to identify disease-associated proteins in a 
variety of human diseases, particularly in the study of human cancers [31, 32]. The 
identification of proteins with distinct expression in a diseased state may improve our 
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understanding of the pathogenesis of a given disease and may potentially result in the 
identification of novel therapeutic targets.  
We performed a differential screening of the synovial protein expression of cytosolic proteins 
between RA, SpA and OA. High resolution 2-DE in combination with Sypro Ruby staining 
was used to separate, quantify and analyze the cytosolic proteome of the synovium obtained 
from synovial biopsy tissue of 18 patients, divided in 3 groups of 6 patients diagnosed with 
RA, SpA and OA respectively. Quantification of protein spots using Sypro Ruby was 
preferred over silver staining. Although it is as sensitive as silver staining, it is much more 
reliable to use for quantification given its large linear range of staining [33]. Silver staining by 
contrast is impeded by rapid saturation of the spots. 
Utilizing synovial tissue biopsies for proteomics enabled us to examine the primary site of 
inflammation and to select a patient cohort of clinically good defined patient samples. In fact, 
all RA and SpA patients had clinical signs of synovitis, and the majority of them did not 
receive DMARD’s (Table 1). We incorporated routine histological assessment to exclude 
potential differences attributed to alterations in synovial microarchitecture. 
In a first approach, we used the complete match set of 640 spots to perform a hierarchical 
cluster analysis on all patient samples (Fig 2). Interestingly, all the patients of the SpA group 
clustered together, despite the presence of both USpA and AS in the patient group. This could 
indicate that the nature of inflammation is quite homogenous in SpA. In this initial approach, 
no clear segregation was observed between RA and OA. Therefore, we explored whether 
using a subset of differentially expressed proteins as variables for hierarchical cluster analysis 
would improve the obtained clustering features. We therefore analyzed our data set 
statistically (Fig. 3) and used spots that were significantly differentially expressed (p<0.01) 
between two groups studied as variables for cluster analysis, as previously described by Aliya 
A.A. et al. [27].  
Five spots were significantly differentially expressed between RA and OA. The resulting 
dendrogram of the hierarchical clustering of the protein expression levels of these proteins 
revealed complete differentiation between RA and OA (fig. 4(a)). Likewise, using the 24 
spots that were statistically different between RA and SpA, complete segregation between 
these two inflammatory arthritides was accomplished (fig. 4(b)). This approach was also 
applied to the 16 spots that were different between OA and SpA. Hierarchical cluster analysis 
of these protein expression levels resulted in a dendrogram that almost completely 
differentiated between the two groups studied (dendrogram not shown). 
  
 - - 79 - - 
 
The obtained distinct clusters between RA and SpA do not necessarily imply that the use of 2-
DE on synovial tissue extracts would be suitable for diagnostic purposes, which would require 
validation in a separate patient cohort. This however, was beyond the scope of the present 
study. Rather, the data indicate that this approach is useful to identify proteins implicated in 
the pathogenesis of chronic inflammatory rheumatic diseases such as RA and SpA.  
Next, we identified proteins that were related to RA or SpA inflammation. These proteins, 
which were statistically differentially expressed between RA and OA or SpA and OA and 
demonstrated an up regulated expression level in inflammatory arthritides (table 2 – fig. 1), 
were subjected to identification by tandem mass spectrometry. Several of these proteins have 
clearly been implicated in chronic arthritis such as calgranulin A, fructose bisphosphate 
aldolase A and alpha-enolase.  
Calgranulin A also known as myeloid related protein-8 or MRP-8, was found to be higher 
expressed in all RA patients and in 3 SpA patients. By contrast, this spot (6006) was below 
the detection limit in the OA group. The expression of this protein is specific for cells of 
myeloid origin, namely granulocytes, monocytes and macrophages. It is known that in 
chronic inflammation, the infiltrating macrophages express MRP-8 [34]. Moreover, MRP-8 is 
specifically released during the interaction of monocytes with inflammatory activated 
endothelium, probably at the site of inflammation [35]. MRP-8 levels are found increased in 
serum, synovial fluid and synovium of PsA, RA and SpA patients [36]. A detailed study on 
MRP8 expression between RA and SpA was conducted by De Rycke L. et al. [37], in which 
they revealed a local presence of MRP8 in the synovial sub lining layer of mononuclear cells 
in both RA and SpA patients. Calgranulin A was also identified as ‘biomarker’ in a cyphergen 
experiment using synovial fluid of RA and OA patients [38]. In addition, a microarray 
analysis of peripheral blood mononuclear cells of SpA, RA, PsA  and OA patients shows that 
MRP-8 is higher expressed in SpA, RA and PsA patients in comparison with OA patients 
[39]. Real-time RT-PCR analysis of synovial tissue of 29 patients showed a statistically 
higher expression of MRP-8 in RA patients in comparison with OA patients on p=0.04. These 
mRNA expression profiles were in line with the observed protein expression profiles of MRP-
8 in inflamed synovial tissue and indicate a local synthesis of this protein.  
Alpha-enolase (6610) and fructose bisphosphate aldolase A (muscle type) (spot 9506) are two 
enzymes playing a major role in the glycolysis. Antibodies against these two proteins have 
been found in the sera of especially RA patients [40, 41]. Upregulation of aldolase A has been 
described in proliferating cells [42], which may suggest that higher expression of this protein 
in patients with inflammatory arthritides could be related to the proliferating synovial lining. 
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Aldolase A binds to actin-containing filaments of the cytoskeleton, more specifically to F-
actin [43] and could play a role in the structure of the cytoplasm. It may even contribute to 
metabolic regulation and cell motility. Interestingly, F-actin plays an important role in joint 
fibroblasts determining the normal synovial microvascular resistance to fluid filtration. F-
actin disruption has been described as a potential factor in the link between inflammatory 
mediators and the formation of arthritic joint effusions [45]. The expression of aldolase A is 
regulated by TNF-α in vitro and it is known that microbial infections or tissue invasion can 
induce in the host a systemic inflammatory response that is frequently associated with 
increased glucose metabolism [46].  
Vimentin (2614), a major structural component of the intermediate filaments in many cell 
types, is found highly expressed in fibroblasts and it is stated that there is some expression in 
T and B lymphocytes [Swissprot].  It is shown that vimentin plays an important role in vital 
mechanism and biological functions such as cell contractility, migration and proliferation 
[45]. Vimentin is also a growth related gene and is often expressed when epithelial cells are 
stimulated to proliferate by serum or growth factors. In cancer, vimentin expression is 
associated with dedifferentiated malignant phenotype, increased motility and invasive ability, 
drug resistance and poor clinical prognosis [46]. It could be possible that a higher expression 
of vimentin contributes to the invasive character of the synvovial pannus like tissue in 
inflammatory arthritides. 
Ceruloplasmin (3820), a copper-binding glycoprotein is higher expressed in synovial tissue of 
SpA patients in comparison with OA patients. This protein has been shown to be up regulated 
in serum and synovial fluids of patients with inflammatory arthritides [47]. The higher 
expression of ceruloplasmin in synovial tissue could be the result of active diffusion of 
ceruloplasmin from serum and synovial fluid into the synovial tissue. It is known that the 
synovial permeability in the knee joint of patients with inflammatory arthritis if significantly 
higher than in patients suffering of OA [48]. In contrast, ceruloplasmin mRNA expression has 
been found in invasive tumor tissue and has been discussed playing a role or being associated 
with tumor invasion and metastasis [49]. Moreover, the expression of ceruloplasmin is 
regulated by the pro-inflammatory IL1-β in rat glioma cells [50]. Although, there is no data 
on mRNA expression of ceruloplasmin in synovial tissue, it could be that this protein plays a 
larger role in invasiveness of synovial tissue in joint of inflammatory arthritides than is 
currently known. 
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In conclusion, the results of this study indicate that the use of expression levels of proteins 
derived from 2-DE is a useful approach to investigate the inflammation behind different 
complex rheumatic pathologies. The cytosolic synovial proteome of SpA as opposed to RA 
patients consists of a unique set of proteins with a defined expression pattern for each form of 
chronic synovitis.  
Altogether, this proteomics analysis may significantly increase our understanding of the 
molecular biology of inflammation of these diseases.  
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ABSTRACT 
The presence of autoantibodies in the sera of patients diagnosed with inflammatory arthritis, 
like rheumatoid arthritis (RA), reflects the humoral autoimmune processes occurring during 
this pathology. Many autoantibodies directed against a variety of autoantigens have been 
described in RA, amongst them the Sa antigen. Although this antigen has been elucidated as 
citrullinated vimentin, there is an apparent lack of information on these modified forms in 
synovial tissue. 
In this present report we investigated the characteristics of citrullinated vimentin isoforms in 
cytosolic protein extracts obtained form inflamed synovial tissue. On two-dimensional gel 
electrophoresis of cytosolic synovial tissue extracts, vimentin was visualized as a specific 
cluster of spots. Interestingly, our results indicate that these isoforms are probably the result 
of caspase cleavage. In addition, these cleaved forms of vimentin were found to be 
citrullinated in synovial cytosolic protein extracts of RA patients, contrary to SpA where the 
presence of citrullinated vimentin appeared to be limited. Furthermore, the presence of 
autoantibodies against these citrullinated processed forms of vimentin was found to be highly 
specific for RA patients.  
These findings indicate a novel concept in the development of autoantibodies in RA by which 
humoral autoimmunity is targeted against caspase cleaved and citrullinated fragments of an 
intermediate filament in synovial tissue, in a highly disease specific manner.  
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INTRODUCTION 
Rheumatoid arthritis (RA) and Spondyloarthropathies (SpA) are two frequent forms of 
inflammatory arthritis which are both characterized by synovitis, the chronic inflammation of 
the synovial membrane. As a result, synovial hyperplasia, neovascularisation and the 
infiltration of lymphocytes and macrophages eventually leads to the transformation of the 
synovial membrane into an invasive and destructive tissue, called the pannus [1]. Although 
there are some differences in synovial histopathology between RA and SpA [2], the molecular 
differences between RA and SpA synovial inflammation remain poorly understood.  
The presence of autoantibodies in the sera of patients diagnosed with inflammatory arthritis 
reflects the humoral autoimmune processes occurring during these pathologies. Many 
autoantibodies directed against a variety of autoantigens have been described [3], amongst 
them the Sa antigen (named after the patients’ name who began with ‘Sa’ where specific 
autoimmunity was described using this patients’ serum) [4]. Although, Vossenaar E.R. et al. 
showed that anti-Sa antibodies targeted citrullinated epitopes of vimentin [5], information on 
in vivo citrullinated vimentin, in particular, in synovial tissue extracts is scarce.  
Vimentin, an intermediate filament which is abundantly expressed in synovial fibroblasts [6], 
has long been thought to solely play a role in the stability of the cytoplasmic architecture [7]. 
It is now known, that vimentin is a highly dynamic protein whose assembly and disassembly 
is regulated by phosphorylation [8, 9]. In addition, its function stretches far beyond being part 
of the cytoskeleton. This was elucidated by Eckes B. et al. who observed impaired wound 
healing in vimentin-/- mice by a failure of mesenchymal contraction [10].  
More recently, studies indicate a possible role for vimentin in inflammation, since fragments 
of this protein can be secreted by activated macrophages during inflammation [11]. Secretion 
of vimentin was induced by TNF-α and this extracellular vimentin seemed necessary for 
efficient killing of bacteria [11]. Cell surface expression of vimentin peptides has also been 
observed by neutrophils undergoing spontaneous apoptosis [12]. The possible consequence of 
secreting or presenting vimentin or fragments of this protein is the development of auto-
antibodies against this intermediate filament. Indeed, the presence of anti-vimentin 
autoantibodies in autoimmune diseases like RA has been demonstrated. Citrullinated vimentin 
has been identified to be the Sa antigen in RA [5]. Although the presence of citrullinated 
vimentin has been reported in monocytes, macrophages and synovial fluid mononuclear cells 
[13], there are no reports that indicate that the antigen itself is present in protein extracts of 
synovial tissue. 
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In the present study, we further explore the characteristics of vimentin isoforms in 2-D images 
of inflamed synovial tissue. Our data show that the isoforms could be the result of caspase-3 
cleavage of vimentin. In addition, evidence is shown for the presence of citrullinated vimentin 
fragments in cytosolic protein extracts obtained from synovial tissue biopsy samples derived 
from patients with inflammatory arthritis. Finally, development of autoantibodies against 
these modified vimentin fragments was found to be highly specific for RA.   
 
 
PATIENTS AND METHODS 
Patients 
Synovial tissue biopsy samples were obtained from patients undergoing needle arthroscopy of 
the knee [14] for diagnostic work-up or for therapeutic reasons. Patients with RA fulfilling the 
American College of Rheumatology  (ACR) criteria [15], patients with SpA fulfilling the 
European Spondyloarthropathy Study Group criteria [16] and patients with knee osteoarthritis 
(OA) fulfilling the ACR criteria [17] were included in this study. All patients undergoing 
needle arthroscopy had active synovitis (RA and SpA) or joint effusions (OA) of the knee.  
Serum samples were collected from 6 RA and 6 SpA patients.  
The clinical characteristics of these patients are summarized in table 1. The study was 
conducted after approval by the local ethics committee. Written informed consent was 
obtained from all participating patients. Detailed information on the samples used in each of 
the experiments is given in table I.  
 
Protein extraction 
The cytosolic proteins (hereafter also referred to as the soluble proteins) were extracted from 
the synovial tissue samples using the ReadyPrep Sequential Extraction Kit from Biorad 
(Hercules, CA, USA) according to the manufacturer’s instructions. A cocktail of phosphatase 
inhibitors containing cantharidin, bromotetramisole, microcystin LR, sodium orthovanadate, 
sodium molybdate, sodium tartrate and imidazole (Sigma, Steinheim, Germany) was added to 
each sample. Endonucleases (Sigma, Steinheim, Germany), protease inhibitors for a broad 
range of serine, cysteine and metalloproteases, as well as calpain (Roche diagnostics, 
Mannheim, Germany) were also added to each sample. Before protein extraction, synovial 
biopsy samples were transferred to an Eppendorf tube and homogenized during 2 minutes 
  
 - - 91 - - 
 
using a Turrax homogenizer (Ika-Werke, Stanfer, Germany) in buffer I of the ReadyPrep 
Sequential Extraction kit (Biorad, Hercules, CA, USA) containing 40mM Trisbase. Protein 
concentrations were measured using the Coomassie Protean Reagent assay from Pierce 
(Rockford, USA) according to the instructions provided by the manufacturer. 
 
Table I: Clinical data on synovial biopsy samples and serum samples. 
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Synovium           
RA966 23/9/53 F + + (a) +(d) 1 0.2 5 960 24 
RA969 31/12/59 F + - +(d) 5 ND 31 608 18 
RA947 27/11/34 F + - +(e) 1 3.2 65 1600 25 
RA882 21/2/68 M + + (a) +(d) 5 4.7 90 328 4 
RA658 4/9/31 F + + (a) +(e) 4 ND ND ND 12 
RA130 28/1/51 M + - - 11 16.4 71 1775 3 
RA208 29/3/46 M + - - 3 0.8 16 2 1 
RA234 11/7/24 F + + - 3 0.1 4 2 6 
RA262 21/2/35 M + + - 1 4.9 39 1600 15 
RA482 22/4/64 F + - - 0 3.2 46 828 0.3 
RA571 18/9/37 F + + - 2 1.6 38 101 6 
SpA524 27/12/46 M + +(b) - 1 9.9 21 2 10 
SpA350 4/2/51 F + +(b) - 3 5.2 69 1 0.17 
SpA511 7/2/32 M - - - 3 6 40 2 5 
SpA713 28/7/52 F + - - 3 0.1 7 1 4.5 
SpA142 4/1/46 F + - - 2 0.3 7 1 9 
SpA673 26/6/81 F + + - 2 0.5 6 1 3 
SpA720 14/8/77 M + - - 1 0.2 2 2 0.58 
SpA958 19/1/88 F + - - 4 1.9 18 1 0.17 
SpA1085 17/2/83 M + - - 1 11 103 ND 0.06 
OA162 16/3/57 M - - - 1 0.3 2 3 15 
OA315 14/5/55 F + - - 2 0.3 14 ND 15 
OA377 21/1/32 F + - - 1 0.4 33 2 0.17 
OA768 14/6/33 F + - - 2 1.9 37 2 7 
OA19 19/9/43 M + - - 0 0.2 3 1 35 
OA58 8/9/14 M - - - 1 ND ND 1 20 
OA7 2/10/30 F - - - 1 0.5 13 2 4 
OA1 26/9/41 F - - - 1 1.4 25 3 6 
Sera           
RA812(*) 29/9/34 F + + (a) - 2 3.2 31 484 9 
RA709(*) 2/12/51 M + + (a) +(e) 8 0.1 1 687 13 
RA597(*) 4/9/31 F + + (a) +(e) 3 4.3 ND 1600 12 
RA562(*) 17/3/52 F + + (a) - 12 1.3 33 871 19 
RA53328(§) 6/8/1959 F _ - +(f) 0 0.4 3 10 11 
RA70105(§) 2/6/1966 F + + (a) - 0 1 13 2 6 
RA74579(§) 8/7/1944 M + +(c) - 0 0.8 15 >1600 8 
RA55625(§) 7/5/1935 M + + (a) - 2 0.9 17 706 4 
RA75378(§) 8/9/1947 F + + (a) - 0 2 39 312 8 
RA69841(§) 24/1/1938 M + +(b) - 0 1.5 34 1600 12 
SpA59200(§) 11/2/1967 M - - +(e) 0 ND ND 11 24 
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SpA67965(§) 28/5/1982 M - +(b) - 0 0 1 19 8 
SpA53861(§) 24/8/1949 M + - - 3 1.1 20 11 5 
SpA66508(§) 14/4/1955 M + - - 1 0.1 2 1 4 
SpA78973(§) 20/7/1970 F + - - 0 0.2 15 2 13 
SpA80598(§) 19/3/1987 M + - - 1 0.4 10 2 3 
SpA27(*) 11/10/55 M + +(b) - 1 2.6 42 ND 22 
SpA182(*) 20/2/37 M + - +(g) 4 0.1 1 ND 3 
SpA194(*) 27/3/58 F + - - 1 0.4 7 ND 14 
SpA111(*) 13/4/79 F + - +(g) 0 0.6 22 ND 6 
Except where mentioned otherwise: M = male; F = female; (+) = receiving; (-) = not receiving; (ND) = no data 
available; NSAID’s = nonsteroidal antiinflammatory drugs; DMARD’s = disease-modifying antirheumatic drugs 
where (a)= methotrexate and (b)= sulfasalazine,  (c)= D-penicilamine,; Biologicals = biological modifiers where 
(d) = Adalimumab, (e)= Infliximab, (f)= Leflunomide ,(g)= etanercept. Patients RA709 and RA562 also received 
corticosteroids (prednisolon). Treatment characteristics were determined at the time of tissue sampling; RA = 
rheumatoid arthritis, OA = osteoarthritis, USPA = undifferentiated spondyloarthropathy, PsA = psoriatic 
arthritis, AS = ankylosis spondylitis, SLE = systemic lupus erythematosus; ND = no data available; SJC = 
swollen joint count; CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; anti-CCP = antibody 
against cyclic citrullinated peptides determined by ELISA (Immunoscan RA, mark 2, Euro-diagnostica AB 
(Arnhem, The Netherlands) according to the manufacturer’s instructions with a cut-off value of 25U/ml; the 
disease duration displayed was determined at the time of tissue sampling. Synovium samples of the same 
pathology were either pooled together or used separately for gel electrophoresis; serum samples indicated by (*) 
and (§) were used for 1-D or 2-D immunoblotting experiments as specifically indicated in the text.  
 
 
Gel electrophoresis 
1-dimensional gel electrophoresis 
10µg of protein extract was diluted with sample buffer containing 0.5M TrisHCl (pH 6.8), 
10% glycerol, 2% SDS, 5% β-mercaptoethanol and incubated at 95°C for 5 minutes. The 
samples were subsequently subjected to SDS-PAGE (10%, Laemmli) at 150V for 30min 
followed by 200V for 1hour. For visualization of citrullinated proteins 50µg of soluble protein 
extract was loaded on the SDS-PAGE. 1-D gels were further prepared for Western Blotting.  
2-Dimensional gel electrophoresis 
For 2-D analysis, 50µg of soluble synovial protein extract was precipitated with cold acetone 
overnight at –20°C. After centrifugation at 20000xg for 5 minutes, the pellet was air dried. 2-
DE was performed as described before (IPG 3-10 (17cm) + 12% SDS-PAGE (Laemmli)) 
[18]. The gels were stained with Sypro Ruby (Molecular probes, Eugene, OR, USA) and 
analyzed by PD Quest software (Biorad, Hercules, CA, USA). 
For 2-D immunoblotting experiments, 40µg soluble protein extract was prepared as described 
above and incorporated in a lineair IPG pH4-7 (11cm) strip (Biorad, Hercules, CA, USA) and 
rehydrated overnight. After in-gel rehydration, the strips were iso-electrically focused on the 
Protean IEF cell (Biorad, Hercules, CA, USA) at 18°C, using 100V for 30 min (linear 
ramping), 250V for 30 min (linear ramping), 500V for 1h (linear ramping), 1 kV for 1h (linear 
ramping), rapid ramping to 8kV in 2h and steady state at 8 kV for 25 kVh. After iso-electric 
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focussing, the IPG strips were equilibrated as described before [18], and placed on a Laemmli 
10% (29:1) resolving polyacrylamide gel and run in sets of two at 150V for 30 minutes 
followed by 60 minutes at 200V.  
 
Western Blotting 
Protein transfer onto nitrocellulose membranes (Biorad, Hercules, CA, USA), was performed 
by tank blotting using the Trans-Blot Cell (Biorad, Hercules, CA, USA) at 50V for 3h. Prior 
to tank blotting, both the polyacrylamide gels and nitrocellulose membranes were incubated in 
1x CAPS (pH=11) for at least 15 minutes. 
Ponceau S visualization of the membranes was conducted to check the blotting efficiency, and 
to verify if the 2-DE was done successfully. Blocking was performed for 1 hour, using 
PBS/0.3% Tween-20 and followed by probing the membrane with patient sera (1/100 in 
PBS/0.3% Tween-20) overnight. Immune reactive spots were detected using HRP labelled 
goat anti-human IgG (Pierce, Rockford, IL, USA) (1/5000 in PBS/0.3%Tween-20) and 
visualized by enhanced chemiluminescent (ECL) using the Supersignal West Dura Extended 
Duration Substrate from Pierce (Rockford, IL, USA). Blots were stripped using the Restore 
Western Blot Stripping Buffer (Pierce, Rockford, IL, USA) at 37°C for 30 min and 
reincubated with blocking buffer for 1h. Sufficient stripping was confirmed by reprobing the 
membrane with secondary antibody and subsequent detection by ECL.  
Vimentin was visualized using mouse anti-human vimentin anti-body diluted 1/400 in 
PBS/0.3% Tween-20 (overnight incubation) (Clone V9, Sigma, St. Louis, MI, USA). The 
vimentin cluster was visualized by ECL following incubation with HRP labelled rabbit anti-
mouse IgG (Pierce, Rockford, IL, USA) (1/1000 dilution in PBS/0.3% Tween-20) for 1h.  
For the detection of citrullinated proteins, blots were first stripped as described above and 
subsequently chemically modified prior to immunostaining using the anti-modified citrulline 
(AMC) detection kit (Upstate, Charlottesville, VA, USA) as indicated by the manufacturer’s 
instructions.  
Protein patterns were scanned and digitized using the VersaDoc Imaging System (Biorad, 
Hercules, CA, USA) and band detection analysis was performed using Quantity One Analysis 
Software (Biorad, Hercules, CA, USA). Bands were represented as Gaussian models where 
the Gaussian model trace, representing the area under the profile curve calculated in pixel 
intensity x millimetres (INT x mm), was used to quantify the bands.  
For all Western Blot experiments, negative controls were included in which the nitrocellulose 
membranes were incubated solely with the secondary antibody. In addition, to determine 
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disease specific autoantibody reactivity, blots were incubated with a pool of serum obtained 
from 4 healthy individuals.  
 
Protein identification by mass spectrometry 
Spots of interest were excised from the gel and digested with modified sequence grade trypsin 
(Porcine) (Promega, Madison WI, USA) and analyzed on a Q-TOF Ultima mass spectrometer 
(Waters, Milford, USA)  using MALDI or ESI as previously described [18]. Processing and 
database searching of the data against the Swiss-prot database was performed by ProteinLynx 
Global Server v2.2.5 software (PLGS) (Waters, Milford, USA) or manually using MASCOT 
search engine (http://www.matrixscience.com). 
 
In vitro caspase-3 cleavage of vimentin 
Human recombinant vimentin (Progen Biotechnik GmbH, Heidelberg, Germany) was cleaved 
by human recombinant caspase-3 (Chemicon International Inc., Temecula, CA, USA) 
overnight at 37°C at 1U/1µg vimentin.  
 
 
RESULTS 
Processed vimentin is observed as a specific pattern on 2-D images of soluble 
inflammatory synovial tissue protein extracts 
Analysis of the soluble synovial tissue proteome of inflammatory arthritides revealed a rather 
specific pattern on the acidic side of the 2-D gel image. This figure consisted of different 
forms of the protein vimentin and this was confirmed by mass spectrometry (table II - fig. 1). 
We focussed on two vimentin protein isoform spots, further referred to as VIM_1 and VIM_2 
and indicated on figure 1. Detailed examination of the mass spectrometric data revealed a 
clear difference between the higher MW form VIM_1 and VIM_2, which was found at a 
lower MW. For the identification by ESI-Q-TOF of VIM_2, no peptides were retrieved within 
the first 100 amino acids of the protein sequence (fig. 2A) in contrast with the identification of 
VIM_1 (fig. 2B). 
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Figure 1: Raw 2-D image of the cytosolic proteome of synovial tissue obtained from a knee biopsy sample of a 
patient diagnosed with SpA.  
The vimentin cluster is organized in a specific figure on the 2-D image of the synovial tissue soluble protein 
extract. Spots that were analyzed by mass spectrometry are indicated from (a) to (i). The green spots represent 
VIM_1 and VIM_2.   
 
 
In addition, MALDI-Q-TOF identification of these isoforms confirmed this data. The peptide 
mass fingerprint (PMF) responsible for the identification of VIM_1 showed peptides derived 
from the first 100 amino acids with high ion count intensity (>50% of total ion count), 
contrary to the PMF for VIM_2, where these peptides had very low ion count intensity (<20% 
of total ion count) or were absent from the mass spectrum in multiple analyses (data not 
shown).  
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Table II: Identification of processed vimentin isoforms obtained soluble synovial tissue extracts analyzed by 2-D 
gel electrophoresis. 
 
Spot (fig.1) Name Peptide sequence matches 
by ESI-Q-tof 
 
Sequence coverage 
(%) by Maldi-Q-
tof 
a VIME_human (K)VELQELNDR(F) 
(R)EEAENTLQSFR(Q) 
(R)EYQDLLNVK(M) 
(R)ISLPLPNFSSLNLR(E) 
21.1% 
b VIME_human (K)ILLAELEQLK(G) - 
c VIME_human (K)VELQELNDR(F) 
(K)MALDIEIATYR(K) 
14.6% 
d VIME_human (K)FADLSEAANR(N) 
(K)VELQELNDR(F)  
(R)EYQDLLNVK(M) 
(K)ILLAELEQLK(G) 
(R)ISLPLPNFSSLNLR(E 
(R)SLYASSPGGVYATR(S) 
(R)EEAENTLQSFR(Q) 
38.5% 
e VIME_human (K)VELQELNDR(F) 
(K)ILLAELEQLK(G) 
(R)QVDQLTNDK(A) 
(R)EEAENTLQSFR(Q) 
(R)QDVDNASLAR(L) 
(R)ISLPLPNFSSLNLR(E) 
(K)FADLSEAANR(N) 
(R)EYQDLLNVK(M) 
(K)MALDIEIATYR(K) 
(R)KVESLQEEIAFLK(K) 
 
- 
f VIME_human (K)VELQELNDR(F) 
(R)EEAENTLQSFR(Q) 
(K)ILLAELEQLK(G) 
(R)QDVDNASLAR(L) 
(R)ISLPLPNFSSLNLR(E) 
(K)FADLSEAANR(N) 
(R)EYQDLLNVK(M) 
(K)MALDIEIATYR(K) 
(K)VESLQEEIAFLK(K) 
- 
g VIME_human (K)VELQELNDR(F)  
(R)EEAENTLQSFR(Q) 
(R)EYQDLLNVK(M) 
(K)MALDIEIATYR(K) 
(R)ISLPLPNFSSLNLR(E) 
16.3% 
h VIME_human (K)VELQELNDR(F)  
(K)ILLAELEQLK(G) 
(R)QVDQLTNDK(A) 
(R)EEAENTLQSFR(Q) 
(R)QDVDNASLAR(L) 
52.04% 
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(R)ISLPLPNFSSLNLR(E) 
(K)FADLSEAANR(N) 
(R)EYQDLLNVK(M) 
(K)MALDIEIATYR(K) 
(R)KVESLQEEIAFLK(K) 
i VIME_human (K)MALDIEIATYR(K) 
(R)EYQDLLNVK(M) 
(R)DNLAEDIMR(L) 
- 
‘Spot’ resembles the letter indicated on figure 1; ‘Name’ indicates the protein name of vimentin described in the 
protein identification format of the Swiss-Prot database (http://www.expasy.org/); Peptides identified by ESI 
tandem mass spectrometry and protein coverage obtained by peptide mass fingerprinting are shown; protein 
spots that were not analyzed by maldi are indicated as ‘-‘.  
 
 
 
 
Vimentin has a defined structure consisting of a head, starting from the second amino acid up 
to amino acid 95, a body containing the coils 1A, 1B and coil 2 and a tail (amino acid 408-
466) (fig. 2C) [19]. The mass spectrometric data clearly showed that the N-terminal head 
(comprising of the first 95 amino acids) of vimentin form VIM_2 was absent (fig.2A).  
We reasoned that this may reflect protein processing. It is known that vimentin is a substrate 
for caspase cleavage [20]. Indeed, caspase-3 can cleave vimentin at amino acid 85, cleaving 
the head from the body of the protein resulting in a cleaved form of vimentin with theoretical 
MW=44.5kDa and pI= 4.75. This form would appear +/- 9kD lower than the native form 
which has a MW of 53.5kDa and would shift towards the acidic side on a 2-D gel as the 
native form has a pI of 5.06. When comparing these theoretical characteristics with the 
experimental data obtained from the 2-D gel (table III, fig. 1), in addition to the mass 
spectrometric data, we can assume that VIM_2 is a caspase-3 cleaved form of vimentin. 
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(C) (obtained from Fujita J. et al.)
Coil 1A
(96-131)
Coil 1B
(154-245)
Coil 2
(269-407)
N C
Head
(2-95)
Tail
(408-466)
(A)
VIM_2
(B)
VIM_1
 
Figure 2: Mass spectrometric identification of the high and low MW form of vimentin.  
For the low MW form of vimentin (VIM_2), there were no peptides identified that were present in the first 100 
amino acids of the protein sequence (A). Identification of the high MW form (VIM_1) indicates presence of 
peptides derived from the N-terminal head of the protein, represented by the first 100 amino acids of the protein 
(B). The data shown are obtained from ESI-Q-TOF MSMS analysis and are processed by ProteinLynxServer 
v2.2.5 (waters, Milford, USA). The protein work pad obtained from MALDI MS analysis showed the same 
results (not shown). Representation of the structure of vimentin describing its head, body and tail is shown (C).  
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Table III: Theoretical and experimental 2-D characteristics of vimentin isoforms 
 Full length (Vim_1) Cleaved (Vim_2) Δ(VIM_1 – VIM_2) 
pIth (pH) 5.06 4.75 0.31 
MWth (Da) 53520.19 44534.56 8985.63 
pIexp (pH) 5.00 4.63 0.37 
MWexp (Da) 57300 49300 8000 
  
‘pIth’ and ‘MWth’= the theoretical isoelectric point and molecular weight calculated from the amino acid 
sequence of the full length protein as indicated in the Swissprot database; ‘pIexp’ and ‘MWexp’= the experimental 
isoelectric point and molecular weight obtained from the position on the 2-D gel; ‘Δ(VIM_1 – VIM_2)’ = difference in 
characteristics between VIM_1 and VIM_2. 
 
 
In vitro caspase-3 cleavage of vimentin 
In order to confirm these data, in vitro cleavage of vimentin with caspase-3 was analyzed by 
1-DE and 2-DE. Vimentin cleavage by caspase-3 gives raise to a fragment at approximately 
48kDa on SDS-PAGE [20]. Therefore, 1-DE analysis was performed in order to verify the 
caspase-3 cleavage. This indeed showed the appearance of a vimentin isoform at MW=48kDa 
(fig. 3B (P)). 
The 2-D image showed several cleavage products. However, they did not show a dramatic 
shift towards the acidic pI of the IPG strip (data not shown). Nevertheless, the fragments were 
located at the correct MW, at approximately 48kDa. An explanation could be that the in vivo 
cleavage forms of vimentin bear an additional modification, making these products more 
acidic. Citrullination, a modification that changes an arginine to citrulline, is known to shift 
proteins towards a more acidic pI [21]. This possibility was explored by anti-modified 
citrulline (AMC) staining of the soluble synovial proteome. 
 
Citrullinated vimentin in soluble protein extracts of inflammatory arthritides 
Pooled synovial tissue extract of 4 RA patients (658 – 882 – 966 – 947) and 4 SpA patients 
(713 – 524 – 511 – 350) was analyzed by 2-DE. The proteins were transferred to 
nitrocellulose membranes and the vimentin cluster was first visualized. Protein citrullination 
was subsequently analyzed by AMC staining. 
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Figure 3:  Detection of processed citrullinated vimentin in soluble synovial proteins in RA, SpA and OA 
40µg of a pool of soluble synovial tissue protein extract was subjected to 2-DE (IPG 4-7, 10% SDS-PAGE) and 
transferred to nitrocellulose membrane. The vimentin cluster was first visualized in RA and SpA (panel A, left) 
after which the blot was stripped and citrullinated proteins were detected in RA and SpA using the AMC staining 
(panel A, right).  
Individual patient protein extracts were analyzed by western blot on which vimentin (panel B) and citrullinated 
proteins were detected (panel C). In vitro capase-3 cleavage of vimentin was run as a positive control for the 
appearance of the 48kDa fragment (panel B, (P)).  
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The vimentin cluster was nicely visualized in both RA and SpA (fig. 3, panel A, left). We 
observed citrullination of vimentin fragments in both RA and SpA (fig. 3, panel A, right). 
However, the citrullinated vimentin fragments in RA appeared at a MW lower than 50kDa, 
whereas in SpA, no citrullinated vimentin fragments were seen below 50kDa.  
This experiment was extended in order to verify patient variability. Therefore, cytosolic 
protein extracts of RA, SpA and OA patients were subjected separately to SDS-PAGE 
followed by Western Blotting. The vimentin fragments were visualized in all pathologies (fig. 
3, panel B). Processed isoforms of vimentin were present in all pathologies. Strong AMC 
staining (Gaussion Model Trace of most intense band > 1000 INT x mm) was observed in 
50% of the RA patients, weak detection in soluble protein extracts of SpA patients (Gaussion 
Model Trace of most intense band >300 INT x mm) and none in OA patients (Gaussion 
Model Trace of most intense band <100 INT x mm) (fig. 3, panel C).  
 
Autoantibody reactivity of in vivo synovial citrullinated vimentin fragments 
Citrullinated vimentin has been described as a potential autoantigen in RA; therefore 
autoantibody reactivity was examined by immunoblotting.  
In a first experiment, we analyzed individual protein extracts on SDS-PAGE and incubated 
the blots with a pool of RA sera and SpA sera. A strong autoantibody reactivity against 
numerous cleavage forms of vimentin was observed in RA patients (fig. 4, panel A). The 
proteins that reacted with the serum were found at MW<50kDa. In SpA patients, the only 
immune reactive bands appear around 52kDa, which were artefacts since they were also 
found on blots incubated only with the secondary antibody (fig. 4, panel A (BL)).  
Next, we analyzed the potential patient variability in autoantibody reactivity. Therefore, 
incubations with individual serum samples (table 1 ‘§’) were analyzed on 2-D blots containing 
a pool of soluble synovial protein extracts of RA (969 – 882 – 966 – 947). In order to verify 
the autoantibody reactivity to the exact forms of cleaved vimentin, the blots were landmarked 
with narrow lines. After serum incubation, the nitrocellulose membranes were stripped and 
reprobed with anti-human vimentin in order to visualize the vimentin cluster.  Using the 
landmarks, exact positioning of the autoimmune spots within the vimentin cluster was 
possible.  These spots were indicated by ‘+’ on the image. For easy interpretation of the data, 
the position of the vimentin cluster is indicated on each blot displaying the autoimmune 
reactivity of the patient’s sera (fig. 4, panel B).  
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Figure 4: Presence of autoantibodies against vimentin in inflammatory arthritides. 
(Panel A) Soluble synovial tissue extracts of individual patients diagnosed with RA or SpA were run on SDS-
PAGE and transferred to nitrocellulose membranes. The blots were probed with a pool of RA and SpA sera, 
respectively. A strong positive reaction with cleaved synovial vimentin forms was observed in RA patients, in 
contrast with SpA sera, where immune reactivity was extremely weak. The immune reactive band at 52kD was 
IgG as indicated by the negative control strip (BL), only incubated with secondary antibody  
(Panel B) Soluble synovial tissue extracts of a pool of RA patients was subjected to 2-D immunoblotting. In 
order to verify that the autoantibody reactivity was against vimentin, the blots were stripped and vimentin was 
detected. Immune reactive spots indicated by (+) correlated to vimentin isoforms subsequently detected on the 
same membranes. To facilitate the interpretation, the position of the vimentin cluster is indicated on the blots in 
colour. Reactivity of healthy sera is indicated in blue and should be regarded as non-disease specific. CCP(-) sera 
showed no reactivity for vimentin in contrast with CCP(+) RA sera in which strong positive detection of 
vimentin isoforms was observed. In SpA patients, autoantibody reactivity against cleaved products of vimentin 
was rather weak to absent. Figures are representative for sera of the same pathology as can be verified in the 
supplementary data of figure 4.  
 
As a control for disease specific autoantibody reactivity, blots were incubated with a serum 
pool obtained from 4 healthy individuals, in which minor immune reactivity against the high 
MW forms of vimentin was observed (fig. 4, panel B). This reactivity was considered not 
disease specific and is indicated in blue on the blots.  
When the 2-D blots were incubated with individual RA patient serum, we observed a different 
immune reactive pattern in serum derived from RA CPP- patients in comparison to RA CCP+ 
patients. In contrast to RA CCP- patients (0/3 patients showed autoantibody reactivity against 
vimentin), there was a distinct reactivity of RA CCP+ sera against processed forms of synovial 
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vimentin (3/3 showed positive autoantibody reactivity). When blots were probed with 
individual SpA serum, only the serum of 1 SpA patient was considered as positive 
autoantibody reactivity against vimentin fragments, since the blots probed with serum of other 
patients were negative or the signal was only slightly above the background noise level.  
The data shown in figure 4 (panel B) are representative for each group. All 2-D 
immunoblotting results can be viewed as supplementary data for figure 4. 
 
Figure 4:  Supplementary data. 
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DISCUSSION 
Processed forms of vimentin are citrullinated in RA and are accompanied with the 
development of autoantibodies in RA patients. Although it is known that citrullinated 
vimentin is an autoantigen in RA (previously known as the Sa-antigen) [5], the present report 
indicates a novel concept in the development of humoral autoimmunereactivity in RA since 
only processed fragments of soluble vimentin were found to be citrullinated.  
Vimentin is known to be processed by caspases during the event of apoptosis [20]. Within 2h 
of apoptosis induction, when the majority of the cells are still viable, a 48kDa fragment of 
vimentin appears as the result of a caspase-3 like cleavage releasing the N-terminal head of 
the protein [20]. In our study, the low MW isoform of vimentin appeared at approximately 
48kDa. In addition, careful interpretation of the mass spectrometric data revealed the absence 
of peptides which originated from the head of the protein (amino acids 1-85). We therefore 
concluded that this processed form of vimentin could be derived from caspase-3 cleavage.  
When in vitro caspase-3 cleavage of vimentin was performed and subjected to 2-DE, we 
observed multiple cleavage fragments. However, we could not observe any fragments shifting 
towards the acidic pI. As this was in contrast with the in vivo situation, where fragments of 
vimentin were observed shifting towards the acidic side of the IPG strip, we investigated the 
presence of citrullinated residues in these fragments by AMC staining. Vimentin fragments 
appeared to be citrullinated in cytosolic synovial protein extracts of RA patients.  In SpA, 
AMC staining was weak and no significant presence of citrullinated proteins was found in 
soluble protein extracts of synovial tissue obtained from OA patients. 
Upon in vitro citrullination, vimentin is irreversibly disassembled resulting in an 
accumulation of soluble vimentin oligomers [22]. This could explain in part the lack of 
previous observations of citrullinated vimentin in synovial protein extracts as most extracts 
described in literature are ureum-DTT extracts as described by Masson-Bessière C. et al. [23]. 
These ureum-DTT extracts are enriched in deiminated fibrin, the most well known deiminated 
protein in synovial tissue [23].  
It has been indicated that citrullination of proteins is not specific for RA, but inherent to 
chronic inflammation of the synovial tissue. Deiminated fibrin has been reported to be present 
in synovial protein extracts of other arthritides [24]. Our study showed the presence of 
citrullinated vimentin in soluble protein extracts obtained from the synovial tissue of RA 
patients, in contrary to SpA where the presence of citrullinated vimentin appeared to be very 
limited.  
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The reason why proteins are deiminated is not entirely known, although there are reports that 
indicate a possible role in apoptosis [25-27]. It has been shown that vimentin is selectively 
and rapidly citrullinated in macrophages undergoing apoptosis [27].  In addition, activated 
macrophages secrete fragments of vimentin [11]. Also neutrophils undergoing spontaneous 
apoptosis express fragments of the C-terminal tail of vimentin on their surface [28]. Whether 
these fragments are citrullinated has not been determined yet. It is possible that citrullination 
of vimentin is the only way towards a direct and irreversible disassembly of vimentin 
filaments resulting in cytoskeleton disruption leading to cell shrinkage in the process of 
apoptosis [20]. Therefore, citrullination of vimentin could be an early event in the processing 
of the protein. Disassembly of the intermediate filament by citrullination could be necessary 
for further processing of the protein by caspases or other proteases. However, the exact 
sequence of events is not known.  
Not only the presence of processed citrullinated vimentin is shown in inflammatory arthritis, 
we also show the specific autoantibody reactivity in RA against these fragments. Indeed, RA 
CCP+ sera reacted strongly with low MW citrullinated vimentin isoforms, whereas in RA 
CCP- and SpA, this reactivity was absent or extremely weak. Antibodies against citrullinated 
proteins (ACPA) are highly specific for RA [29]. The presence of ACPA is significantly 
related to HLA-DR shared epitope (SE) [30]. This is explained by the fact that MHC with SE 
has a high affinity for negatively charged or uncharged polar amino acids while positively 
charged amino acids inhibit peptide binding [31]. Therefore, when arginine is deiminated, the 
positive charge is converted to a polar but uncharged residue increasing the affinity in the 
binding pocket. This was shown by Hill J. A. et al., where conversion of an arginine into 
citrulline in the N-terminal head of vimentin increased peptide affinity and resulted in CD4+ 
T cell activation in HLA-DR4-IE transgenic mice [32].  
 
In conclusion, we reported on processed vimentin isoforms in the cytosolic proteome of 
inflammatory arthritides. Our data suggest that these isoforms are probably the result of 
caspase cleavages. In addition, these cleaved forms of vimentin are citrullinated in soluble 
protein extracts of synovial tissue obtained form RA, in comparison to SpA patients, where 
there is little presence of citrullinated vimentin in soluble protein extracts.  Furthermore, the 
presence of autoantibodies against these citrullinated fragments is highly specific for RA 
patients.  
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ABSTRACT 
A hypoxic microenvironment is created in the joints affected by inflammatory arthritis. In 
response to the higher metabolic demand of the proliferating tissue, angiogenesis is triggered. 
The key regulator of angiogenesis is vascular endothelial growthfactor (VEGF) and in order 
to function properly, VEGF needs copper as cofactor. The majority of circulating copper is 
bound to Ceruloplasmin (Cp), a well known plasma protein secreted by the liver. Both VEGF 
and Cp are under the transcriptional control of hypoxia induced factor-1 (HIF-1) in hypoxic 
conditions.  
In this study we investigated the hypoxia induced gene and protein expression of Cp and 
VEGF in RA and SpA fibroblast-like synoviocytes (FLS).  
Hypoxia induced secretion of VEGF was observed in both RA and SpA FLS. Secreted levels 
of VEGF after 8h of hypoxia, were higher in SpA than in RA.  
Our data showed that Cp can be locally produced by both RA and SpA FLS and there is a 
trend towards a higher hypoxia-induced gene expression of Cp in SpA compared to RA.   
These finding suggest that the tissue response of FLS upon hypoxia is different in RA in 
comparison to SpA. It is conceivable that these differences account for the reported higher 
vascularity in SpA synovium.  
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INTRODUCTION 
Synovitis, the chronic inflammation of the synovial tissue, is commonly considered as the 
initial change in the joints of patients with inflammatory arthritis. Synovitis is characterized 
by massive synovial proliferation and subintimal infiltration of inflammatory cells, which 
along with angiogenesis (the formation of new blood vessels) results in a very aggressive 
tissue called pannus [1, 2].  
The oxygen supply to the synovium becomes impaired when the synovial lining starts to 
proliferate. The high metabolic state of the tissue and the fact that the cells become more 
distant from the closest blood vessel, compounds to the hypoxic state [3]. Early reports in the 
seventies, describe the arthritic joint as being hypoxic. Indeed, synovial fluid samples from 
patients with rheumatoid arthritis (RA) were hypoxic and acidotic, with low glucose and high 
lactate concentrations which indicated the presence of an anaerobic metabolism in the 
synovial tissue [4-6]. In these early reports the mean synovial fluid pO2 in RA knee joints was 
reported to be as low as 27mm Hg compared to 43mm Hg in osteoarthritis (OA) and 63mm 
Hg in traumatic effusions in healthy control individuals. The group of Taylor P. recorded 
mean intra-articular pO2 values of 13mm Hg in mice with collagen-induced arthritis and 
similar levels in patients with RA [7].  
At such low oxygen levels, the hypoxia-inducible-factor-1 (HIF-1) starts to take control over 
the transcription rate of over 70 genes [8]. At oxygen concentrations below 5%, cellular levels 
of HIF-1α rise exponentially to a maximum of 0.5% O2. In this situation HIF-1α is no longer 
targeted for degradation, and starts to accumulate. Subsequently, it translocates to the nucleus 
where it binds to HIF-1β and forms the HIF-1 complex [9] . This complex binds the hypoxia-
regulating elements in the promoter region of several genes, hereby stimulating the cell to 
adapt to its new environmental conditions. The presence of HIF-1 has been indicated in the 
synovial lining of synovial tissue sections of RA and OA biopsy samples in comparison to 
healthy controls [10, 11].  
 
In order to sustain its homeostasis in a hypoxic atmosphere, the cell starts to produce 
angiogenic factors. A key factor in this process is vascular endothelial growth factor (VEGF). 
VEGF, known to be regulated by HIF-1 [12], can be detected in synovial fluids of patients 
diagnosed with RA and SpA [13, 14] and the local production of VEGF by RA synoviocytes 
in hypoxic conditions has been reported [15]. 
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Angiogenic factors, like VEGF, need cofactors in order to function properly [16]. Such a 
cofactor is copper [17]. In healthy individuals, 95% of total circulating copper is bound to 
ceruloplasmin (Cp), an abundant plasma alpha-2-glycoprotein which has been reported to be 
elevated in the serum of RA patients [18]. Although Cp is synthesized primarily in the liver, 
other cell types like monocytes, astrocytes and sertoli cells can express the protein [19]. 
Because of its ability to change its function in response to a change in substrate, localization 
or differential expression, Cp has been described as a moonlighting protein [20]. Cp is 
responsible for the transport of copper, plays a role in controlling iron homeostasis, and is a 
circulating anti-oxidant [21]. Its transcription is regulated by HIF-1 under hypoxia [22]. 
Reports on Cp in inflammatory arthritis are limited. However, tetrathiomolybdate (TM), a 
copper-lowering agent, which has been evaluated extensively in the treatment of Wilson’s 
disease [23], can also attenuate angiogenesis and tumor growth in animal models  [24]. A 
recent report by Omoto A. et al. showed that TM has a strong protective effect against the 
progression of adjuvant-induced arthritis in rats [25]. These data indicate a possible important 
role for Cp in arthritis.  
  
It is known that the RA joint is hypoxic. Since RA and SpA are both characterized by 
synovitis, it is plausible that the environmental condition in the SpA joint is similar and 
therefore also hypoxic; however there are no studies that have explored this yet. Likewise, 
reports on the effect of hypoxia on FLS explants from SpA patients are lacking.   
Neovascularization is a known consequence observed in tissues under hypoxic conditions. It 
has been reported that the inflamed synovial membrane in the SpA joint is more vasulated 
than in the RA joint [26]. Therefore, it could be possible that the tissue response to the 
hypoxic environment in the joint is different in SpA compared to RA.  
 
In order to explore this we investigated the induction of protein expression of VEGF and Cp, 
two proteins involved in angiogenesis and transcriptionally activated under hypoxia via HIF-
1α, in RA and SpA. Hypoxia induced expression of Cp appeared higher in SpA FLS than in 
RA FLS.  These results also show that Cp can be locally expressed by FLS. In addition, we 
observed hypoxia activated secretion of VEGF by RA and SpA FLS. The VEGF secretion 
was shown to be higher in SpA FLS compared to RA FLS. Our results indicate a possible 
difference in tissue respons in RA and SpA upon hypoxia.  
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MATERIAL AND METHODS 
Isolation and culture of synovial fibroblast 
Synovial tissue was obtained from 6 patients with RA, 6 patients with SpA and 5 patients 
with OA at the time of needle arthroscopy of the knee. RA patients were diagnosed according 
to the criteria prescribed by the American College of Rheumatology (ACR) [27],  patients 
with SpA fulfilled the European Spondyloarthropathy Study Group criteria [28] and patients 
with OA fulfilled the ACR criteria for the classification of OA [29]. All patients undergoing 
needle arthroscopy had active synovitis (RA and SpA) or joint effusion (OA) of the knee. 
The study was conducted after approval by the local ethics committee. Written informed 
consent was obtained from all participating patients. 
Tissue was immediately processed for synovial fibroblast culture according to Muller-Ladner 
U. et al. [30]. Briefly, Synovial tissue was digested with dispase (1.5mg/ml) in alpha 
Minimum Essential Medium (αMEM) (both from Gibco, Burlington, Ontario, Canada) twice 
1 hour at 37°C. Cells were collected, centrifuged at 1000rpm for 15 minutes and resuspended 
in DMEM containing 10% fetal bovine serum (FBS), 1% L-glutamine and 1% 
penicilline/streptomycine (all obtained from Gibco, Burlington, Ontario, Canada) and cultured 
at 37°C and 7%CO2 (this was regarded as passage 1). Cells were stored in liquid nitrogen 
upon passage 4 (P4). 
For hypoxia experiments, fibroblasts (P4) were brought in suspension in 6-well polystyrene 
plates with coverslips at a concentration of 5 x 104cells/well for immunohistochemistry or 
without coverslips at a concentration of 3 x 105cells/well for real-time PCR. Before initiating 
hypoxic conditions, the cells were cultured overnight (16 hours) in serum-free medium to 
induce a quiescent state.  
 
Hypoxia conditions 
Cell preparations were exposed for 6h, 8h and 10h to hypoxic conditions in a Heraeus series 
6000 incubator (Thermo Electron Corporation, Asheville, NC, USA), with 3%O2, 5%CO2 and 
92% N2. Fibroblast used as controls, were prepared in the same way, and were kept under 
normoxic conditions. 
 
Fluorescence immunohistochemistry 
Immunohistochemistry was used to determine the expression of HIF-1α in synovial tissue 
explants. Cells were fixed with 3.7% paraformaldehyde for 15 minutes and subsequently 
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quenched with 100mM glycine to reduce background fluorescence. Permeabilization was 
performed for the detection of HIF-1α using 0.25% Triton X-100 for 15 minutes. Cells were 
washed with PBS (Gibco, Burlington, Ontario, Canada) and blocked with blocking buffer 
containing 5% goat serum (Dako Cytomation, Glostrup, Denmark), 1% fish skin gelatine 
(45% from Sigma, Steinheim, Germany), 0.05% Tween-20 (Sigma, Steinheim, Germany) in 
PBS. After blocking, monoclonal mouse (IgG1) anti-human HIF-1α (BD Pharmingen, San 
Diego, CA, USA) (dilution 1/50 in PBS) or monoclonal mouse (IgG1) was applied for 2h at 
room temperature. Cells were washed with PBS and subsequently incubated with the Alexa 
Fluor-488 labeled goat anti-mouse IgG1 antibody from Molecular Probes (Eugene, OR, USA) 
(dilution 1/500). Nuclear staining was performed using DAPI (Sigma, Steinheim, Germany) 
at a concentration of 100ng/ml. IgG1 isotyope controls were included as negative controls. 
 
VEGF protein expression determined by enzyme-linked immunosorbent assay 
(ELISA) 
Hypoxia induced secretion of VEGF by synovial fibroblast was investigated by ELISA by 
R&D systems Inc. (Minneapolis, MN, USA). Culture supernatants of FLS derived from 6 RA, 
6 SpA and 5 OA patients were collected after exposure to 8h of hypoxia (or normoxia). Each 
FLS line was derived from an individual patient and each sample was analyzed in triplicate. 
Data is displayed as the mean (pg/ml) for each group of patients and because of the small 
sample size, the standard error of the mean (SEM) was calculated to calculate the standard 
deviation of the sampling distribution.   
 
Real-time PCR 
RNA was isolated from 300.000 cells obtained from synovial fibroblast using samples of OA 
(n=5), RA (n=6) and SpA (n=6) patients using TRIzol (Life Technologies, Paisley, U.K.). The 
total RNA was extracted using the RNeasy Mini Kit (QIAGEN, Valencia, CA) according to 
the manufacturer’s instructions. Before reverse transcription, digestion of DNA was 
performed using the RNase-Free DNase Set (QIAGEN). cDNA was synthesized using 
oligo(dT) priming the Superscript II kit (Life Technologies). cDNA was quantified using the 
Quant-iT Oligreen ssDNA Assay kit (Molecular Probes Inc., Eugene, OR, USA) and 5ng 
cDNA was used to quantify the gene expression.  
Primers for the housekeeping enzyme HPRT were designed using the Primer Express 
software (Applied Biosystems, Foster City, CA). For HPRT, primers were TCA GGC AGT 
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ATA ATC CAA AGA TGG T (sense) and AGT CTG GCT TAT ATC CAA CAC TTC G 
(antisense) and CAA GCT TGC TGG TGA AAA GGA CCC C (probe). Assays on Demand 
(Applied Biosystems, Foster City, CA) were used for the amplification of Ceruloplasmin 
(Hs00236810) and VEGF (Hs00173626). Amplification and on-line detection of PCR 
products were carried out with optical 96-well plates (Applied Biosystems, Foster City, CA) 
in the ABI PRISM 7000 Sequence Detection System (Applied Biosystems, Foster City, CA). 
mRNA expression levels were calculated according to the delta delta Ct method.   
 
RESULTS 
 
Hypoxia induced expression of HIF-1α  in  synovial fibroblasts 
The expression of HIF-1α was examined in FLS derived from biopsy samples obtained from 
3 RA, 3 SpA and 3OA patients. Nuclear HIF-1α localisation could be detected after 6h of 
hypoxia (fig. 1). Strong perinuclear or nuclear expression of HIF-1α was observed in FLS 
obtained from RA patients (figures 1A and B). Also in FLS of SpA patients, patchy nuclear 
distribution was observed (fig. 1C). These expression patterns were observed in the majority 
of the FLS on each micropscopic slide. The perinuclear expression of HIf-1α, observed like a 
halo around the nucleus, is probably a high density of HIF-1α molecules queueing in order to 
enter the nucleus through its nuclear pores. We observed this phenomenon only in synovial 
fibroblasts from 2 RA patients.  
HIF-1α expression in OA synovium explants was weak and cytoplasmic (fig. 1D).  
No nuclear localization of HIF-1a was observed in normoxia. It is known that under aerobic 
conditions, HIF-1α is degraded by rapid ubiquination followed by proteasomal degradation 
[31]. This was in agreement with our HIF-1α stainings under normoxic conditions, where 
only a weak cytoplasmic distribution of HIF-1α could be observed in RA, SpA and OA FLS 
cultures.  
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Figure 1: Merged images captured using confocal immunofluorescence microscopy (using sections of 0.8µm, 
magnification x 1000). FLS explants were incubated in a hypoxic environment (3% O2) for 6h. FLS from 3 RA, 
3 SpA and 3 OA were examined.    
Strong nuclear (A) or perinuclear (B) staining of HIF-1α in FLS obtained from RA patients. Patchy nuclear 
expression in FLS derived from SpA. In OA synovium explants the expression of HIF-1α was very weak and its 
localization cytoplasmic (D). The cytoplasmic distribution of HIF-1α under normoxic conditions is displayed for 
FLS explants of RA (F), SpA (G) and OA (H). Isotype controls were included as negative controls (E).  
HIF-1α was detected using alexa fluor-488 and is represented in green. The nucleus was visualized using DAPI 
stain represented in blue.  
 
 
 
Hypoxia induced gene expression of VEGF and Cp in synovial fibroblasts 
Synovial cells were harvested and RNA was extracted as described in the section ‘Material 
and Methods’. The effect of hypoxia on VEGF and Cp mRNA expression was analyzed by 
real-time PCR. In order to analyze the stability of gene expression of household gene HPRT 
in hypoxic and normoxic conditions, FLS were incubated at 6h, 8h and 10h of normoxia and 
hypoxia. The results showed that the average gene expression of HPRT was relatively stable 
in both normoxic and hypoxic conditions and HPRT was further used to normalize gene 
expression (fig. 2).  
VEGF and Cp gene expression were calculated according to the delta delta Ct method where 
each delta delta Ct value represented the delta Ct value of the experimental gene observed 
under hypoxia compared to the delta Ct value in the normoxic environment. The data 
  
 - - 117 - - 
 
displayed in figure 3 are represented as the ratio of gene expression in hypoxia in comparison 
to normoxia.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: HPRT gene expression in RA, OA and SpA fibroblast-like synovial cells under normoxic and hypoxic 
conditions.  FLS obtained from 3 RA, 3 OA and 3 SpA were incubated at 6h, 8h or 10h of normoxia or hypoxia 
to verify the stability of the gene expression of HPRT. 
Individual Ct values are represented by (°) in normoxic and by ( ) in hypoxic conditions; (-) represents the Ct 
average in the group. Average Ct values (NORM av; HYP av) and standard deviation of Ct values (NORM SD; 
HYP SD) are given in table format under the figure.  
 
 
We observed no difference in VEGF gene expression in RA, OA or SpA FLS after hypoxic 
incubations (fig. 3, VEGF).  
There was a trend in hypoxia induced gene expression of Cp in FLS cultures of SpA and OA 
patients (fig.3, Cp), although additional samples need to be analyzed, before these findings 
can reach statistical significance. These values were on average markedly higher after hypoxic 
incubation. In addition, Cp gene expression under hypoxic conditions was higher in SpA and 
OA than in RA.  
 
 
28,00
29,00
30,00
31,00
32,00
33,00
34,00
35,00
RA OA SpA
Ct
value 
NORM av 31.53           30.07 30.46
HYP av 31.18 30.31                                     30.70
NORM SD                                1.49 0.51 0.95
HYP SD 1.43 1.29 0.98
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Figure 3: Gene expression of VEGF and Cp in FLS obtained from 6 RA, 6 OA and 6 SpA patients incubated in a 
hypoxic environment during 8h. Gene expression in hypoxic and normoxic conditions was normalized against 
HPRT. The mean of the individual ratios of gene expression in hypoxia compared to normoxia are displayed; 
error bars represent the SEM.  
 
 
Hypoxia induced protein secretion of VEGF in synovial fibroblasts 
The amount of secreted VEGF by synovial fibroblasts was detected using ELISA (fig. 4). 
VEGF production was increased in the supernatants of FLS cultures derived from synovial 
tissue of RA, SpA and OA patients after 8h hypoxia in comparison to normoxic conditions. 
The average secreted protein levels in RA, SpA and OA were 1.4, 1.8 and 1.7 times higher, 
respectively (fig. 4). These data also show that the level of VEGF produced by SpA FLS is 
higher than by RA FLS. There was a statistical difference between the amount of VEGF 
produced by the FLS in normoxic conditions between RA and SpA (p<0.05), showing that the 
basal secretion of VEGF is different in RA and SpA. Although no statistical significant 
difference between the secretion of VEGF in RA and SpA FLS incubated under hypoxic 
conditions in the currently analyzed was found, a similar trend was observed. Therefore, 
additional experiments to augment the sample size are underway.  
 
 
RA
OA
SpA 
R
at
io
 o
f n
or
m
al
iz
ed
 m
R
N
A
 e
xp
re
ss
io
n
VEGF                                                            Cp
0.00
1.00
2.00
3.00
4.00
5.00
R
at
io
 o
f n
or
m
al
iz
ed
 m
R
N
A
 e
xp
re
ss
io
n
  
 - - 119 - - 
 
 
Figure 4: Hypoxia-induced production of VEGF by cultured FLS from 6 OA, 6 RA and 6 SpA patients. Synovial 
fibroblasts were cultured for 8h under hypoxic (3% O2) or normoxic conditions. VEGF values are detected by 
ELISA. *= p=0.1, £=p<0.05 using Student’s T-test for hypoxic versus normoxia. Error bars represent the SEM. 
 
 
 
DISCUSSION 
Inflammatory arthritides, like RA and SpA, are accompanied by chronic synovitis. Persistent 
inflammation of the synovial tissue leads to hyperplasia of the synovial lining, resulting in a 
hypoxic environment in the joint. The molecular mechanisms in cellular adaptive response to 
hypoxia have been elicited and one principal regulator of this adaptive response is HIF-1α 
[9]. Nuclear staining of HIF-1α could be observed in RA and SpA FLS explants after 6h of 
hypoxia. These data are in agreement with Hitchon C. et al. which showed a strong nuclear 
staining of HIF-1α in synovial fibroblasts after 4-6h of hypoxia [32]. 
The synovial proliferation puts higher energy demands on the environment and this is often 
accommodated by the development of new blood vessels. A major cofactor in 
neovascularization is copper, of which the majority is bound to Cp.  
Cp is also a major ferroxidase by catalyzing the oxidation from toxic ferrous iron (Fe2+) to the 
safer ferric iron (Fe3+) [33] in order to promote the incorporation of iron in to transferrin. 
Patients with aceruloplasminemia, a hereditary deficiency of ceruloplasmin, have severe 
intracellular iron accumulation in a number of organs [34]. Ferrous iron can generate highly 
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reactive superoxide and hydroxyl radicals, hereby promoting oxidative stress [35]. Iron 
deposits have been described in the synovium of patients with RA [36] and these deposits can 
perpetuate inflammation by aiding in the production of free oxygen radicals.  
As Cp is implicated in angiogenesis and is regulated by HIF-1α in hypoxic conditions, the 
effect of hypoxia on the gene expression of Cp was investigated. Although we were unable to 
show a significant difference between gene expression in normoxia and hypoxia, there was on 
average a higher hypoxia induced gene expression of Cp in SpA and OA FLS than in RA FLS 
(fig. 3). However, these data need further confirmation in a large sample group.  
Although the patient cohorts examined in this study were small and even though we observed 
patient variability, there is a tendency towards a difference in Cp gene expression between 
synovial tissue explants of RA and SpA cultured in hypoxic conditions. This difference in Cp 
gene expression between the inflammatory arthritides may, in part, explain the difference 
observed in synovial vascularity between RA and SpA [26]. Cp also plays a role in 
angiogenesis by transporting copper, a major cofactor for different angiogenic factors [16, 
17].  Induction of Cp in synovial tissue of SpA could aid the formation of blood vessels, 
leading to the higher synovial vascularity observed in SpA [26]. In addition, Cp has been 
described as being differentially expressed in soluble protein extracts of synovial tissue in 
SpA in comparison to OA [37] (Chapter I). This difference could be explained by the active 
diffusion of Cp from the synovial fluid into the joint tissue. However, our real-time PCR data 
also show that local expression of Cp by synovial fibroblasts can play an important role in the 
inflammation of the synovial tissue by regulating iron oxidation and hereby protecting the 
cells form oxidative stress. 
Another important key player in angiogenesis is VEGF. VEGF is also regulated by HIF-1 in 
hypoxic conditions [12]. Hypoxia induced mRNA expression of VEGF was investigated by 
real-time PCR. We could, however, not observe any up regulation of VEGF gene expression 
in RA or SpA FLS upon 8h of hypoxia. There was no difference in the geometric average 
mRNA expression of VEGF in normoxic conditions in comparison to hypoxic conditions. 
However, when protein production of VEGF was analyzed in the supernatants of the cultured 
fibroblasts, significant higher levels of VEGF could be detected after 8h of hypoxia. It is 
likely that the induction of VEGF transcription appears earlier as described by Hitchon C. et 
al. who observed markedly enhanced expression of VEGF mRNA after 6h of hypoxia [32]. 
Additionally, VEGF protein production and secretion was higher in SpA FLS than in RA 
FLS. This distinction could be the result of molecular differences between RA and SpA FLS 
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and their ability to react to certain stimuli. Our data suggests that SpA fibroblasts can produce 
and secrete higher levels of VEGF than RA fibroblasts when cultured in a hypoxic 
environment. This could indicate a difference in ability to produce new blood vessels and may 
contribute to the higher vascularity observed in SpA synovium [26].  
 
As angiogenesis contributes to the chronic inflammation and proliferation of the joint tissue, 
especially in the formation and maintenance of the pannus tissue, the possibility of targeting 
the formation of new blood vessels by using anti-angiogenesis agents has gained interest over 
the past few years [38]. Especially in cancer, where angiogenesis is essential for the growth of 
most primary tumors and their subsequent metastasis, have VEGF receptor blockade (by 
monoclonal antibodies [39]) or VEGF Trap (a fully humanized soluble VEGF receptor fusion 
protein [40]), been successful in preventing tumor growth.  
As described earlier, angiogenic factors are copper-containing or copper-binding proteins 
[16]. The majority of circulating copper is bound to Cp and serum Cp is a good surrogate 
marker of copper status, because the liver secretes the protein into the blood at a rate 
dependent on copper availability [24]. It has been shown that a decrease in copper levels 
attenuates angiogenesis and tumor growth in animal tumor models [24]. Tetrathiomolybdate 
(TM), which forms a stable tripartite complex with copper and protein has been successfully 
applied in the treatment of Wilson’s disease [23]. Recently, it has been indicated that this 
copper-lowering agent could also be effective in arthritis as TM delayed the onset and 
suppressed the severity of clinical arthritis in adjuvant-induced arthritis in the rat [25]. 
Histological examination of the joint tissue of the treated animals clearly showed a significant 
reduction in synovial hyperplasia and inflammatory cell invasion in the joint tissue.  
 
In conclusion, we show that Cp, a copper binding protein, is locally produced by RA and SpA 
synovial fibroblasts. We have indications that upon hypoxic incubation, the mRNA 
expression of Cp is higher in SpA in comparison to RA synoviocytes. However, additional 
experiments are required to confirm the observed trends in gene expression.  
VEGF protein production and secretion is higher in SpA FLS, than in RA FLS cultured in 8h 
hypoxia.  
As both Cp and VEGF play a role in the formation of new blood vessels, it could be that the 
differences in gene and protein expression observed in this study are related to the differences 
in synovial vascularity between RA and SpA [26].  
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Since angiogenesis is triggered by hypoxia, these results could also indicate that there could 
be a discrepancy in molecular response upon the hypoxic microenvironment in the SpA in 
comparison to the RA joint. Finally, these differences could be responsible for the histological 
and clinical differences observed between the two inflammatory arthritides.   
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ABSTRACT 
We aimed to investigate potential synovial autoantigens in rheumatoid arthritis (RA) that 
could trigger the induction of B cell autoantibodies.  
Total protein extract of synovial tissue obtained from 7 RA patients was pooled and separated 
by 1-DE and 2-DE. The corresponding blots were probed with sera from RA (n=30) and 
disease control samples (n=30). Protein spots showing a sensitivity of >15% were identified 
by mass spectrometry.  
1-D immunoblots revealed one protein band with specificity in RA of 100%, a sensitivity of 
43%, which was identified as fibrinogen β chain. The 2-D analysis revealed the subunits of 
fibrinogen, especially the β and γ chain as the most prominent synovial autoantigens. We also 
identified vimentin, the Sa-antigen and carbonic anhydrase I as a potentially new synovial 
autoantigen. The protein patterns of these immunoreactive spots were observed as trains. The 
spots showing the highest autoimmune reactivity occurred at the acidic side of these trains 
and were recognized by ACPA-positive RA sera. Anti-modified citrulline (AMC) staining of 
these patterns confirmed protein citrullination.  
Therefore, post-translational modifications, such as citrullination due to alterations of PAD 
activity or generation of RA-specific epitopes, should be considered as trigger in tolerance 
break. 
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INTRODUCTION 
The inflammatory, chronic joint disease rheumatoid arthritis (RA) is characterized by 
inflammation of the synovial membrane which can ultimately lead to the formation of an 
invasive tissue, the pannus.  This pannus is capable of eroding adjacent cartilage and bone, 
primarily resulting in deformations of the joints of hands and feet. Synovial inflammation 
together with extra-articular manifestations, can lead to a severe decline in the quality of life. 
The presence of several autoantibodies with ranging sensitivities and specificities is one of the 
major arguments for an autoimmune nature of the disease. The first and most well known 
autoantibody is the rheumatoid factor. The family of anti-citrullinated protein/peptide 
antibodies (ACPA) recently described, are the most sensitive and specific markers for RA and 
occur before disease onset [1, 2]. These autoantibodies are directed against various proteins 
having one trait in common: all the proteins are modified post-translational. Indeed, some of 
their arginines have been converted to citrulline by the enzyme peptidylarginine deiminase 
(PAD) [3, 4].  
The primary site of disease manifestations is the RA synovium. In RA, the synovium consists 
of a variety of cell types, including synovial macrophages, synovial fibroblasts and infiltrating 
B and T cell populations. The organisation of lymphoid aggregates in follicular structures and 
the presence of clonally related Ig heavy chain and kappa light chain sequences suggest that 
the synovial tissue may act as a secondary lymphoid organ where affinity maturation of the B 
cell response, based on antigen specificity in situ takes place [5,6]. This strongly suggests the 
presence of autoantigens in the synovium. The observation that ACPA are produced by local 
plasma cells in the pannus supports this hypothesis [7]. Therefore, the in vivo characterization 
of potential autoantigens present in the synovium can lead to a better understanding of the 
disease process.  
Two-dimensional (2-D) gel analysis of synovial extracts gives an accurate image of the 
proteins expressed in the synovial membrane. Through comparison of protein patterns in 
different diseases, proteins related to a disease, or proteins implicated in the pathogenesis can 
be classified [8]. Potential autoantigens can be identified by probing the blots of these 2-D 
gels with sera from RA patients and controls [9]. This is in contrast with synovial protein 
microarrays in which only a limited protein repertory is offered to investigate specific 
antibody responses [10]. To this date, immunodetections are mainly performed on 1-D blots, 
with the obvious disadvantage of incomplete separation of a complex protein mixture such as 
synovial extracts [11]. A second disadvantage is that no protein charge isoforms (which are 
mostly due to posttranslational modification) can be observed although it is hypothesized that 
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breaking tolerance to self proteins could be induced by secondary modifications. One example 
is the oxidation and glycosylation of IgG, which may result in products targeted by 
rheumatoid factors [12, 13]. The usage of patient sera for immunodetection implies that only 
B cell reactivities are considered.  
The aim of the present study was to list the spectrum of synovial autoantigens that induce an 
autoimmune humoral response. Therefore, 2-D immunoblotting with RA and control patients’ 
sera to an RA synovial protein extract was performed, followed by identification by mass 
spectrometry.   
 
PATIENTS AND METHODS 
Patients 
Synovial biopsy samples were obtained from 7 RA patients, fulfilling the American College 
of Rheumatology (ACR) classification criteria for RA [13], undergoing needle arthroscopy of 
the knee as described earlier [14]. The biopsy samples were immediately snap frozen in liquid 
nitrogen and stored in liquid nitrogen until further analysis. A total of 46 synovial biopsy 
samples were collected from 7 RA patients of which 6 patients showed active synovitis. 
Detailed information on clinical characteristics is shown in table 1.  
Serum samples from 60 patients were collected comprising 30 patients diagnosed with RA 
fulfilling the ACR criteria [13], and 30 disease control patients. This control group consisted 
of 16 SpA patients fulfilling the European Spondyloarthropathy Study Group criteria [15], 10 
OA patients fulfilling the ACR criteria [16], 2 patients diagnosed with gout, 1 patient with 
villonodulaire synovitis, and 1 patient diagnosed with sarcoidosis. The clinical characteristics 
of these patients are indicated in table 1. Within the SpA group, the precise clinical entities 
are indicated as well. 
Table 1 also indicates which samples were used in the various experiments described in the 
manuscript.  
The study was conducted after approval by the local ethics committee. Written informed 
consent was obtained from all participating patients. 
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Table 1: Clinical data of patients of whom synovial tissue or serum samples were included 
 
D
ia
gn
os
is 
A
ge
 (y
ea
rs
) 
Se
x 
N
SA
ID
’s
 
D
M
A
R
D
’s
 
Bi
ol
og
ic
al
s 
SJ
C
 
C
R
P 
(m
g/
dl
) 
E
SR
 
(m
m
/h
ou
r)
 
A
nt
i-C
C
P 
(U
/m
l) 
D
is
ea
se
 
du
ra
tio
n 
Synovium           
RA 57 F + - - 8 10.5 72 4 0.2 
RA 53 F + - - 0 0.6 35 168 0.5 
RA 65 F + +(a) - 9 5.1 39 4 33 
RA 55 F + +(a) - 3 ND 29 556 2 
RA 50 F + +(a) - 9 7.5 77 1515 1.3 
RA 57 F + +(b) - 7 3.4 15 317 10 
RA 50 F + +(a) - 15 3.8 48 1515 1.5 
Sera           
RA * 28 F + - - 8 3.3 45 1600 1.5 
RA * 72 M + - - 7 9.3 45 2 0.1 
RA * f 75 F - - - 3 1 21 779 1 
RA * 63 M + +(b) - 4 6.5 55 2 12 
RA * 52 F + - - 2 0.7 6 140 0.2 
RA * 55 F + - - 8 10.5 72 4 0.2 
RA * 60 M + +(c) - 14 4 60 206 10 
RA * 36 F - - - 2 2.4 46 710 2 
RA * 45 F + - - 4 0.5 10 98 1.5 
RA * 52 M + +(a) - 11 16.4 71 1775 3 
RA * 57 F + - +(e) 13 12.2 55 146 9 
RA * f 50 M + +(a) +(e) 0 2.5 19 796 8 
RA * 50 F + - - 9 16.4 111 5 10 
RA * 49 M + - - 5 2.2 38 286 15 
RA * 51 F + - - 0 0.6 35 168 0.5 
RA * 49 M + - - 22 29 94 1600 2 
RA * 63 F + +(a) +(e) 0 1 26 497 7 
RA * f 75 F + +(b) - 3 0.8 26 265 30 
RA * 57 M + +(a) - 3 0.8 16 2 1 
RA * 79 F + +(c) - 3 0.1 4 2 6 
RA 49 M + +(a) - 3 1.6 44 153 10 
RA 68 M + +(a)(c) - 1 4.9 39 1600 15 
RA 63 F + +(a) - 9 5.1 39 4 33 
RA 53 F + +(a) - 3 111 29 556 2 
RA 48 F + +(a) - 9 7.5 77 1515 1.3 
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RA 55 F + +(b) - 7 3.4 15 317 10 
RA ° 55 F + +(b) - 0 9.2 45 1 1 
RA ° 49 F + +(a) - 1 0.4 20 2933 6 
RA ° 50 F + +(a) - 13 3 39 2362 22.5 
RA ° 73 M + +(b) - 9 0.2 1 1 0.8 
AS * 56 F + +(b) - 1 3.5 60 2 16 
USPA + SLE * 38 F + +(b) - 1 1.2 27 4 1 
USPA * 47 M + +(b) - 1 2.6 42 1 22 
USPA * 30 M + - - 4 0.4 5 13 0.5 
AS * 58 M + - - 2 4 30 4 25 
USPA * 47 M + +(d) - 1 1.7 8 1 2 
PsA *  29 M + - - 2 0.7 9 9 5 
AS * 57 F + +(b) - 2 0.3 7 1 9 
PsA * 33 M + - - 1 6.8 39 4 10 
USPA * 49 F + +(b) - 6 0.9 13 2 4 
PsA * 26 F + - - 1 0 1 2 0.9 
USPA * 26 F + +(a) - 6 21.1 115 2 2 
USPA * 58 M + - - 1 0.1 3 2 12 
PsA * 29 F + - - 1 0.8 24 2 10 
PsA * 34 M + +(b) - 1 1.1 17 2 4 
SPA * 29 M + - - 2 14.3 70 5 0.1 
OA and osteoporosis * 72 F - - - 1 0.5 13 2 8 
OA * 59 M + - - 0 0.2 3 111 35 
OA * 64 F + - - 1 0.1 1 4 999 
OA * 56 F + - - 5 0.1 5 4 0.5 
OA 58  + - - 1 0.2 29 4 7 
OA 46 M - - - 1 0.3 2 3 15 
OA and 
chondrocalcinosis 
72 F + - - 4 0.3 5 6 1 
OA 89 M - - - 2 0.3 14 1 12 
OA  60 F + - - 0 0.7 11 3 20 
Villonodular synovitis 32 M + - - 1 0.6 4 1 2 
Gout ° 47 M + - - 0 7 36 2 6 
OA ° 82 F + - - 1 1.2 34 5 2 
Gout ° 36 M - - - 2 4. 26 2 15 
Sarcoidosis ° 76 F - - - 1 4.8 77 1 22 
Except where mentioned otherwise: M = male; F = female; (+) = receiving; (-) = not receiving; NSAID’s = 
nonsteroidal antiinflammatory drugs; DMARD’s = disease-modifying antirheumatic drugs where (a)= 
methotrexate and (b)= sulfasalazine,  (c)= leflunomide, (d)= Immuran; Biologicals = biological modifiers where 
(e)= Infliximab. Treatment characteristics were determined at the time of tissue sampling; RA = rheumatoid 
arthritis, OA = osteoarthritis, USPA = undifferentiated spondyloarthropathy, PsA = psoriatic arthritis, AS = 
ankylosing spondylitis, SLE = systemic lupus erythematosus; ND = no data available; SJC = swollen joint count; 
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CRP = C-reactive protein; ESR = erythrocyte sedimentation rate; anti-CCP = antibody against cyclic 
citrullinated peptides determined by ELISA (Immunoscan RA, mark 2, Euro-diagnostica AB (Arnhem, The 
Netherlands) according to the manufacturer’s instructions using a cut-off value of 25U/ml; the disease duration 
displayed was determined at the time of tissue sampling. Patients used for 2-D immunoblotting (pH 3-10 and pH 
4-7) are indicated with ‘*’. Serum samples of patients used for 2-D immunoblotting with 4-12% Bis-Tris peptide 
gels are indicated with ‘°’. Serum samples used for 2-D immunoblotting of deiminated fibrinogen in vitro are 
indicated with ‘f’ 
 
 
Protein extraction biopsy material 
Prior to protein extraction, synovial biopsy samples were washed with DPBS (Gibco, 
Invitrogen Inc. Carlsbad, California, USA) to eliminate blood contamination. Protein 
extraction was performed using the PlusOne grinding kit (Amersham Biosciences, Uppsala, 
Sweden). Briefly, a maximum of 4 biopsy samples were transferred to an eppendorf tube and 
grinded for 4 minutes. 250µl extraction buffer (9.5M urea; 5% ampholine pH 3.5-10; 2% w/v 
CHAPS, 10mM DTT) containing a cocktail of protease inhibitors (Complete mini cocktail, 
Roche Applied Sciences, Indianapolis, USA) was added to the samples and incubated 
overnight at room temperature while gently shaking. Proteins were extracted by centrifugation 
for 10 minutes at 15000 x g at room temperature. Supernatant of 46 biopsy tissue samples was 
pooled and protein quantification was performed using PlusOne 2-D Quant kit from 
Amersham Biosciences (Uppsala, Sweden).  
 
In vitro deimination of fibrinogen  
Fibrinogen purified from human plasma (Plasminogen depleted fibrinogen, Calbiochem, 
Merck, Darmstadt, Germany) was dissolved at 1mg/ml in PBS pH 7.4 (37°). In vitro 
deimination was performed by incubation with rabbit skeletal PAD2 (Sigma-aldrich, St. 
Louis, MO, USA) (7 units/mg fibrinogen) overnight at 37° C in 100 mM Tris-HCl, pH 7.4, 
10mM CaCl2 with 5mM DTT. Reaction was stopped by adding EDTA to a final 
concentration of 50 mM. 
 
Gel electrophoresis 
1-Dimensional gel electrophoresis 
For SDS-PAGE, 10 µg/cm of total protein extract was loaded on a precast gel containing one 
slot (8x8 cmxcm, 4-12% Bis-Tris zoomgel, 1.0mm; IPG well (7cm); Invitrogen Inc. Carlsbad, 
California, USA). The sample was run under reducing conditions in MOPS SDS running 
buffer according to the manufacturer’s instructions.  
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 2-Dimensional gel electrophoresis 
Two-dimensional gel electrophoresis (2-DE) was performed according to Görg et al. [17] 
with minor adjustments. Briefly, 50µg of protein extract was dissolved in 100 µl rehydration 
buffer solution containing 9.5M urea, 2% v/w CHAPS, 10mM DTT and 5% Carrier 
Ampholyte solution (Amersham Biosciences, Uppsala, Sweden). The sample was centrifuged 
for 5 minutes at 13000rpm and subsequently incorporated in an immobilized pH gradient strip 
(IPG) of 7cm (Amersham biosciences, Uppsala, Sweden) containing a linear pH gradient of 3-
10 or pH 4-7. The IPG strips were rehydrated overnight.  After in-gel rehydration [18], the 
IPG strips were iso-electrically focused on the Multiphor II (Amersham Biosciences, Uppsala, 
Sweden) for a maximum of 7474Vh at 20°C using a three step program: 200V (10 min.-
33Vh) – 200V (1h30 – 2775Vh) – 3500V (1h20 – 4666Vh). After iso-electric focusing, the 
strips were equilibrated in two steps by gently shaking for 15 minutes in a solution containing 
Tris-HCl buffer (50mM, pH 8.8), 6M urea, 30% v/w glycerol, 2% SDS containing 2% DTT. 
Subsequently, equilibration in the same buffer was performed for 15 minutes in the presence 
of 4.8% iodoacetamide. After equilibration, the IPG strips were placed on a 12.5% Laemmli, 
4-12% Bis-Tris or 12% Bis-Tris peptide SDS-PAGE as specifically indicated further. The 
gels were run at 10°C applying 30V for 10 minutes followed by 150V until the 
bromophenolblue front reached the end of the gel (usually after 1h20).  
Gels were further used for Western Blotting or were stained with Coomassie G-250 [19] or 
silver [20]. 
For the separation of fibrinogen, 10μg of the protein was dissolved in 180 μl rehydration 
buffer containing 7M ureum, 2M thioureum, 4% CHAPS, 20mM DTT and 0.2% Carrier 
Ampholyte Solution (Amersham Bioscience, Uppsala, Sweden) and incorporated in a linear 
IPG strip pH 3-10 or pH 4-7  (Biorad, Hercules, CA, USA) by overnight rehydration. The 
strips were iso-electrically focused on the Protean IEF cell (Biorad, Hercules, CA, USA) 
using the following program: 100V (30 min) – 250V (30 min) – 8000V (2h) – 8000V 
(25000Vh). The strips were equilibrated in two steps prior to SDS-PAGE by gently shaking in 
50mM Tris-HCl buffer (pH 8.8) containing 6M urea, 20% glycerol, and 2% SDS. In the first 
step, 1.5% DTT was added followed by 4% iodoacetamide in the second step. The strips were 
subsequently placed on a 4-20% linear gradient Tris-HCl SDS-PAGE (Biorad, Hercules, CA, 
USA). The gels were run at 200V for 1h30 in the Criterion Cell (Biorad, Hercules, CA, USA) 
and stained with Sypro Ruby Protein Gel Stain (Biorad, Hercules, CA, USA).  
 
  
 - - 135 - - 
 
Western blotting 
Protein transfer to nitrocellulose Hybond C membranes (0.45µm) was performed by semi-dry 
Western blotting using the Multiphor II NovaBlot transfer unit (Amersham biosciences, 
Uppsala, Sweden) at 1,5mA/cm2 for 1 hour. Transfer of fibrinogen and in vitro deiminated 
fibrinogen was done by tank blotting using the Trans-blot cell (Biorad, Hercules, CA, USA). 
In all Western blot experiments, Ponceau S visualization of the membranes was done first. 
This reversible low sensitive staining was used to check the blotting efficiency, and to verify 
the 2-D pattern.  Prior to overnight incubation with human serum (1:100 v:v in PBS/0.3% 
Tween-20), blocking of the nitrocellulose membrane was done using PBS/0.3% Tween-20 for 
1 hour. The membranes were subsequently incubated for 1 hour with goat anti-human IgG 
labeled with alkaline phosphatase (Sigma, Steinheim, Germany) (1:1000 v:v in PBS/0.3% 
Tween-20) and immunoreactivity was visualized using NBT/BCIP. 
For the detection of citrullinated proteins, blots were chemically modified prior to 
immunostaining with a chemiluminescent substrate (Pierce, Rockford, IL, USA) as previously 
described [21] using the anti-modified citrulline (AMC) detection kit, (Upstate, 
Charlottesville, VA, USA).  
To reveal the total protein pattern, the membranes were stained with AuroDye (Amersham 
Biosciences, Uppsala, Sweden) according to manufacturer’s guidelines. This colloidal gold 
stain is highly sensitive and reveals all proteins transferred to the nitrocellulose membrane.  
This protocol was used for all gel electrophoresis experiments, apart from little modifications 
specific for certain experiments described hereafter. For 1-D SDS-PAGE (4-12% Bis-Tris), 
nitrocellulose membranes were cut into small bands of 0.3cm and each membrane strip was 
probed with a different serum sample.  
For Western blotting of 2-D peptide gels (12% Bis-Tris), PVDF membranes were used in 
stead of nitrocellulose membranes, because smaller molecules are better retained on PVDF 
membranes.   
For each Western Blotting experiment, negative controls were included where the blot was 
only incubated with the specific secondary antibody.  
The different visualizations of the blots were scanned and digitized with the ProXpress 
Imager from Perkin Elmer (Wellesly, MA, USA). At first, the Ponceau S-stained pattern was 
scanned, followed by the autoantigen detection and the AuroDye visualization. Digitized 
images were analyzed semi-manually using HT analyser Software (Perkin Elmer, Wellesly, 
MA, USA).  
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Pattern analysis 
After Ponceau S visualization, marks were added onto the membranes, which served as 
landmarks for matching. The location of the major spots was highlighted by piercing the 
membrane. Matching of the immunoreactive spots to the total protein pattern visualized by 
Ponceau S and AuroDye was done semi-manually using the HT-Software. Finally, the total 
protein pattern revealed by AuroDye (Amersham biosciences, Uppsala, Sweden) was 
compared to the pattern in the 2-D gel pattern visualized by silver staining [20] and 
Coomassie G-250 [19], in order to correlate the immunodetected spots with the corresponding 
spots visualized in the gel.   
 
Protein identification 
Spots of interest were excised from semi-preparative 2-D gels, digested with modified 
sequence grade trypsin (Porcine) (Promega, Madison WI, USA) using the Montage In-gel 
Digest kit from Millipore (Billerica, MA, USA) and analyzed by nano-LC/MSMS on a Q-
TOF I (Water, Milford, USA) equipped with an orthogonal Z-spray. Fragmentation spectra 
resulting from tandem mass spectrometry were searched against the mascot search engine 
(http://www.matrixscience.com) [22]. The mascot score is reported as 10*log10 (P), where P 
is the absolute probability that the observed match is a random event.  
 
 
RESULTS 
Protein extraction of synovial biopsy tissue 
Extraction of 46 pooled synovial tisuue biopsy samples obtained from the 7 RA patients 
yielded a total amount of 8.8mg protein at a concentration of 1.88mg/ml.  Preliminary studies 
on different protein extraction protocols revealed that the protein yield from experiments with 
the PlusOne Grinding kit (Amersham biosciences, Uppsala, Sweden) was far superior to 
cutting the biopsy samples into little pieces or using a Wheaton Douncer. Also, overnight 
incubation of the biopsy samples in extraction buffer revealed higher protein yields compared 
to the recommended <2h extraction time.  
 Immunoblotting of total synovial extract 
1-dimensional gel immunoblotting  
A pre-screening was performed on 1-D blot strips with 30 RA and 30 control sera (table 1) to 
rapidly visualize immunoreactivity against synovial proteins. Probing the strips revealed two 
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major immunoreactive bands (fig.1). However, the 55kDa band was observed on all strips, 
including the negative control strip incubated only with the secondary antibody and 
represented the heavy chain of IgG. The second abundant immunoreactive band appeared just 
above the IgG heavy chain at 58.8kDa. This protein band was completely absent from 
immunostrips probed with non-RA sera (specificity 100%) and was detected in 13/30 
immunostrips probed with RA sera (sensitivity 43%). The band was identified by mass 
spectrometry as the fibrinogen β chain (mascot score= 196). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: 1-D screening of immunoreactivity of RA sera (strip 1-30) against synovial tissue proteins in 
comparison with immunoreactivity of non-RA sera (strip 31-46) (4-12% Bis-Tris SDS-PAGE).  
The 55kDa protein band is visual on all membrane strips including the negative control strip incubated only with 
the secondary anti-human IgG antibody (strip BL). This protein band corresponds to the IgG heavy chain.  
A second abundant immunoreactive band is visible at 58.8 kDa band with 100% specificity and 43% sensitivity 
in RA patients. This band was identified as fibrinogen β chain. 
The enlarged view shows the negative control (1), a strip probed with RA serum (2) and non-RA serum (3). 
 
 
2-dimensional gel immunoblotting  
A total amount of 50µg of synovial tissue proteins was subjected to 2-DE using IPG strips 
with pH 3-10 (fig. 2A) and pH 4-7 (fig. 2B). The gels were used for Western blotting, in 
which the nitrocellulose Hybond C membranes were probed with sera from 20 patients 
diagnosed with RA (see table 1, patients indicated with ‘*’). Sera from patients with other 
rheumatic diseases were used as control group (n=20). 2-D blots incubated with only the 
secondary antibody were completely negative.  
 
  RA Non- RA BL 
MW  
(kDa) 
200 
 
116 
97 
 
66 
 
 
45 
 
31 
21 
14 
   55kDa 
58.8kDa 
1 
1 
2 3 
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Figure 2: Total 2-D protein pattern of synovial tissue separated on 12.5% Laemmli resolving gel using IPG 3-10 
(A) and IPG pH 4-7 (B) revealed by silver staining. 
Immunoreactive spots with a sensitivity ≥15% were identified and are indicated on the gel. Some of the 
immunoreactive spots were not visible on the silver stained gel.  
 
Immunoreactive spots with a sensitivity in RA of at least 15% were identified by mass 
spectrometry. The summary of these identifications is shown in table 2. If multiple proteins 
were identified in one spot, only the protein with the highest mascot score was listed. 
Identification of proteins such as keratin was not considered as the presence of this protein is 
most likely due to contamination during sample handling [23]. 
pH gradient 3-10 
We first analyzed the synovial tissue proteome by 2-DE using IPG pH 3-10 (fig. 2A). A total 
of 101 spots showed immunoreactivity with RA sera. Protein spots with a sensitivity of at 
 
3
MW
(kDa)
100 -
70 -
45 -
25 -
10 -
10pI (pH)
B008
B052
B053
B093
B058
B063
B009B003-5
B026
B027
(A)
B201   B202
B214 B215
B208
B209
B210 B211
B212
B216
B218
B219
B220
B203 B204
B205
B206
B223
B224
B228
MW
(kDa)
100 -
70 -
45 -
25 -
10 -
4 7pI (pH)
(B)
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least 15% were further analyzed (n=12). The specificity of these spots ranged from 65% to 
100%. These spots were selected for identification by mass spectrometry (table 2). Most of 
immune reactive synovial proteins were identified as the subunits of fibrinogen (α, β and γ 
chain). Although spots B063 and B093 were almost invisible on the gel, sensitive mass 
spectrometric analysis revealed their identity being carbonic anhydrase I and vimentin, 
respectively.  
In order to enlarge the resolution of the protein separation and since no reactivity was visible 
at the very basic site of the immunoblots; the analysis was repeated using IPG strips pH 4-7.  
   pH gradient 4-7 
2-D immunoblots using IPG pH 4-7 revealed 73 spots showing autoimmune reactivity with 
RA sera. Spots that showed a sensitivity of at least 15 % (fig. 2B) were identified (n= 20) as 
fibrinogen β or γ chain. The specificity of these immunoreactive spots ranged from 70% to 
100% (table 2).  
Similarities between immunoblots IPG pH 3-10 and pH 4-7  
By performing the immunoblot experiments with both the above mentioned pH gradients, all 
analyses were performed in duplex. Several immunoreactive spots could be matched between 
the gels of different pH gradients e.g. B008, B009 and B052, B053 on IPG 3-10 are identical 
to B202, B203 and B208, B209 on IPG 4-7, respectively. In addition, the identification of 
these spots confirmed these similarities. The separation resolution of the 2-DE with IPG 4-7 
was improved dramatically. Although we could find some extra autoantigen spots, they did 
not represent new additional autoimmune proteins.  
The 2-D protein patterns of immunoreactive spots were observed as trains consisting of 
adjacent spots of the same protein, but with a different isoelectric point (pI). Remarkably, 
immunoreactive spots with the highest specificity occurred at the acidic side of the spot train. 
For example, spot B201 and B202 (figure 2B), which were located on the acidic side of the 
train, showed a specificity of 100%. Spot B203, B204, B205 and B206 appearing at the basic 
side of the train, displayed a specificity in RA of 80%, 75%, 70% and 60%, respectively. Re-
incubation with RA serum of membranes previously probed with a control serum confirmed 
these results and revealed additional spots on the acidic side of the spot train (fig. 3).  
 
 
 
 
  
Table 2: Autoantigens present in synovial tissue visualized by 2-D immunoblotting on IPG pH 3-10 and pH 4-7 
and identified by mass spectrometry 
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Relation of immunoreactive spots with ACPA titers 
In this table spots B008, B053, B052 and B009, were the only spots that were citrullinated, as 
described in the next section. These spots were only recognized by CCP positive sera. 
Fibrinogen α chain was also detected by 4 CCP negative sera. In addition, carbonic anhydrase 
I (B063) was recognized by 2 CCP negative RA sera. Both proteins did not show any 
citrullination on AMC staining as is indicated in the next section.  
 
 
 
Figure 3: Re-incubation with RA serum (B) of membranes previously probed with control serum (A) (IPG 4-7; 
4-12% Bis-Tris SDS-PAGE). 
New immunoreactive spots appear at the acidic side of the spot train. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) 
(B) 
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Table 3: Relation of immunoreactive spots with ACPA titers 
Identification  FIBB VIME ND CAH1 FIBG FIBG FIBB FIBA FIBA FIBA
Spotnr. B008 B093 B058 B063 B053 B052 B009 B004 B005 B003 
Spec. (%) 100 100 100 95 95 90 85 85 85 85 
Sens. (%) 35 15 15 30 20 20 50 45 45 25 
Serum Anti-
CCP 
          
10 1175     x x x    
1 1600 x    x x x    
16 1600 x  x x   x x x x 
3 779 x      x x x x 
12 796 x      x    
8 710 x      x x x x 
17 497    x       
14 286  x x x   x x x x 
18 265 x x     x    
7 206 x   x x x x x x x 
15 168  x         
11 146     x x x    
5 140           
9 98   x        
2 2        x x  
4 2    x    x x  
6 4           
13 5    x    x x  
19 2        x x  
20 2           
 
Autoimmunoreactivity against a certain spot is indicated by ‘x’. The identification of the protein spots is given as 
the first part of the Swiss-prot entry name where FIBB= fibrinogen β chain; FIBG = fibrinogen γ chain; FIBA= 
fibrinogen α chain, VIME= vimentin; CAH1= carbonic anhydrase I and ND= no data. The spots that were 
citrullinated by AMC staining are underlined. The sensitivity (sens.) as well as the specificity (spec.) of the 
immunoreactivity is given in percentage. The amount of antibody against CCP determined by ELISA 
(Immunoscan RA, mark 2, Euro-diagnostica AB (Arnhem, The Netherlands) is presented by (anti-CCP).  
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Detection of citrullinated proteins 
A possible explanation of the increasing specificity of the immunoreactive spots at the acidic 
side of the spot trains is that the antibodies in RA patients are directed against proteins with a 
specific post-translational modification that gradually lowers the pI of the protein. One such 
modification is deimination of arginine to citrulline. The replacement of 1 arginine with 1 
alanine in β chain of fibrinogen theoretically lowers the pI with 0.32 units 
(http://us.expasy.org/tools/#proteome).  This would result in a shift of 0.375cm on an IPG pH 
4-7 strip of 8cm, which is exactly the distance between the individual spots in the spot trains 
observed on these 2-D gels (IPG 4-7, 12.5% Laemmli) (fig. 2B). Moreover, the relationship 
between the highly specific autoimmune spots with the ACPA titers (table 3) also supports 
this hypothesis. 
 
 
Figure 4: Anti-modified citrullline detection.  
Synovial extract was separated on an IPG pH 4-7, 12.5 % Tris-HCl gel and blotted on a nitrocellulose membrane 
prior to chemical modification of the citrulline residues. Citrullinated protein spots B201-B206 were identified as 
fibrinogen β chain, spots B208-211 are identified as fibrinogen γ chain. 
 
 
To explore this possibility further, 2-D blots of synovial extracts separated on IPG pH 4-7, 
12.5% Laemmli resolving gels were probed with the anti-modified citrulline antibody (fig 4). 
This reactive pattern confirmed that citrullinated proteins are present in the human synovial 
membrane as demonstrated by synovial histology data and 1-D analysis performed by several 
groups [24], [25]. Fibrinogen β chain and fibrinogen γ chain were found to be citrullinated in 
B206B205
B204B203B202
B201
B211
B209
B208
MW
(kDa)
pI(pH)4 7
100 -
70 -
10 -
45 -
25 -
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synovial protein extracts. These results were confirmed when AMC staining was performed 
on 2-D blots using IPG 3-10 (12.5%SDS-PAGE) (results not shown) where no other protein 
spots were citrullinated apart from fibrinogen β chain and fibrinogen γ chain.  
 In addition, all protein spots in a spot train seemed to be citrullinated, not only the spots 
appearing at the most acidic side. In order to address this phenomenon, we analyzed the 
behaviour of citrullination of fibrinogen on 2-DE. 
 
 Two-dimensional analysis of in vitro deiminated fibrinogen 
Analysis of fibrinogen purified from plasma (Calbiochem, Merck, Darmstadt, Germany) on 
IPG pH 4-7 (4-20% lineair gradient gel) revealed the three subunits of fibrinogen. The 
individual spots of the α and the β chain were not well resolved (fig. 5A). They appeared 
compressed together at the end of the pH gradient. This is not surprising since the calculated 
pI of the non-deiminated chains of fibrinogen is 8.08 for the α chain, 7.15 for the β chain and 
5.24 for the γ chain. Therefore, the non-deiminated fibrinogen was reanalyzed on IPG pH 3-
10 (fig. 5B) and the different fibrinogen chains were observed clearly as different protein 
trains with well resolved individual spots.  
In vitro citrullination of fibrinogen resulted not only in the appearance of more spots at the 
acidic side of the spot train, but also in a complete shift of the spot train towards a lower pI 
(fig. 5C). It was clear that the α and β chain had shifted to a lower pI, relative to the γ chain. 
Also, the most acidic spots in the α spot train shifted to a higher molecular weight, which is a 
known characteristic of citrullination [26]. In addition, citrullination was checked by AMC 
detection on the blotted membrane and revealed even more spots than on the corresponding 2-
D gel (data not shown), visualized by Sypro Ruby total protein stain, because of the 
differences in sensitivity between the detection methods. 
Immune reactivity against all three fibrinogen side chains was observed when in vitro 
citrullinated fibrinogen was probed with human RA serum (5D). Three RA sera (indicated in 
table 1 by ‘f’) were used for immunoblotting against in vitro citrullinated fibrinogen and all 3 
patients showed immune reactivity against the α, β and γ chains of in vitro deiminated 
fibrinogen. Moreover, the strongest immunoreactivity was observed against in vitro 
deiminated α chain.  
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Figure 5: in vitro citrullination of fibrinogen. 
2-DE of non-deiminated fibrinogen revealed distinct spot trains comprising of the three side chains of the protein 
(IPG pH 4-7 (A), IPG pH 3-10 (B); 4-20% linear gradient Tris-HCl gel; Sypro Ruby staining). Deimination of 
fibrinogen overnight with PAD2 revealed a shift towards the lower pI (IPG pH 4-7; 4-20% linear gradient Tris-
HCl gel, Sypro Ruby staining) (C) and immune reactivity against in vitro deiminated fibrinogen was observed 
(IPG pH 4-7; 4-20% linear gradient Tris-HCl gel, serum detection) (D). 
 
 
 Immunoblotting of total synovial extract on peptide gels 
The protein spots showing immunoreactivity with RA sera were located in the high MW 
region (>40kDa) of the gels. In order to investigate also potential immunoreaction in the low 
MW range, 4-12% Bis-Tris peptide gels were run. Four RA and 4 disease control serum 
samples (table 1, patients indicated with ‘°’) were used for immunoblotting. Despite the 
presence of numerous protein spots in the range of 2-30kDa as revealed by AuroDye staining, 
no immunoreactivity was detectable in the low MW region (data not shown). 
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DISCUSSION 
RA is an autoimmune disease which is characterized by the production of autoantibodies. 
Several autoantibody systems have been described like anti-RA33 (hnRNP-A2) antibodies or 
anti-collagen type II antibodies, but some of these autoantibodies are also present in a variety 
of other diseases [28, 29]. Other antibody systems, like antibodies against BiP (heavy chain 
binding protein) have been reported to be RA specific [30]. However, ACPA are the most 
specific and sensitive autoantibodies detected in 60%-70% of the RA patients [31]. As the 
synovium is the primary site of manifestation of the disease, we aimed to investigate potential 
autoantigens present in this tissue that could trigger the induction of autoantibodies. To 
achieve a representative image of the total proteome of the inflamed RA synovium, biological 
material of 7 RA patients was pooled. The 1-D screening with 30 RA sera and 30 control sera 
was performed to enable a more specific choice of second dimension gel in the 2-DE 
approach. The 100% specific autoreactive protein band revealed in the 1-D analysis contained 
the fibrinogen β chain.  
In the current 2-D immunoblotting, most of the autoreactive spots with a high specificity were 
identified as the components of fibrinogen. Other identified proteins were carbonic anhydrase 
isoform I and vimentin. Also, additional autoreactive proteins were present in the synovium, 
but they were not retained for further identification analysis because of their too low 
specificity for RA.  
Citrullinated vimentin has been reported as a potential autoantigen in RA as it has been 
identified as the Sa antigen which is highly specific for RA [32]. Although autoimmunity 
against carbonic anhydrase I has not been reported in RA to date, antibodies to carbonic 
anhydrase have been considered pathogenic factors in the development of autoimmune 
pancreatitis [33] and are present in sera from patients with Sjögren’s syndrome [34]. Early 
reports also describe autoimmunoreactivity against carbonic anhydrase I in systemic lupus 
erythematosis [35, 36]. This zinc enzyme assists rapid inter-conversion of carbon dioxide and 
water into carbonic acid, protons and bicarbonate ions and therefore plays an important role in 
tissue rehydration and secretory activities.  
The presence of antibodies against fibrinogen have been described in RA [11]. This 340 kDa 
protein, is encoded on chromosome 4 and synthesized by hepatocytes. It is composed of two 
identical subunits, each containing three polypeptide chains, the α chain with fibrinopeptide 
A, the β chain with fibrinopeptide B and the γ chain which are linked by disulfide bonds. 
Thrombin cleaves fibrinopeptides A and B from fibrinogen, resulting in the formation of 
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strands of insoluble fibrin monomers and polymers. These polymers can be cross-linked by 
transglutaminase to form a relatively stable and insoluble meshwork. Interstitial amorphous 
fibrin deposits are frequently seen in the synovial tissue as a consequence of the inflammatory 
process [37].  
Taking a closer look at the 2-D immune protein pattern, we observed that immunoreactive 
spots occurred in spot trains comprised of the same protein. It was also noticed that the 
immunoreactive spots with the highest specificity arose at the acidic site of these spot trains. 
Re-incubation with RA serum of membranes probed with disease control serum, revealed the 
appearance of additional spots at the acidic side of the spot train. Furthermore, these most 
specific spots are only recognized by ACPA positive RA sera. Combination of the protein 
spots that showed a specificity of 100% in RA augmented the sensitivity in RA up to 50%.  
Although, reactivity against fibrinogen α was also observed in CCP negative RA sera, 
combining of antigen substrates which leads to a higher sensitivity in RA could have 
implications in the design for new diagnostic tests for inflammatory arthritis. Fibrinogen β 
and γ, were only recognized by ACPA positive sera and these protein spots were found to be 
citrullinated in the synovium.  
Autoimmune reactivity of ACPA positive sera against the most acidic proteins in the 
autoimmunoreactive protein trains, suggests the presence of citrulline in these proteins, as 
citrullination is a posttranslational modification that lowers the pI of proteins. This was also 
illustrated by the in vitro deimination of purified human fibrinogen. The spots containing the 
α and β fibrinogen shifted to a lower pI and a higher apparent MW relative to the γ chain. 
AMC staining on the synovial extracts confirmed the presence of citrullinated proteins in the 
synovial membrane. Autoreactive spots with high sensitivity and specificity that contained 
citrulline were identified as the β and γ chain of fibrinogen. There were some citrullinated 
protein spots visible which were not identified because their sensitivity was too low. 
So far, fibrinogen is the only protein that is shown to contain citrulline residues in vivo in the 
synovial membrane. The deiminated forms of the α and β chain of fibrinogen in interstitial 
amorphous deposits are autoantigenic targets for ACPA [11]. In the present study, deiminated 
forms of the β and γ chain of fibrinogen were identified, but we could not detect any 
citrullinated forms of vimentin or carbonic anhydrase I. Moreover, there was some weak 
reaction in the MW and pI region of fibrinogen α chain on the nitrocellulose membrane on 
which AMC staining was performed, however, there was only a clear positive signal for 
fibrinogen β and a minor signal was observed for the γ chain. This could possibly be due to 
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the low amount of citrullinated α fibrinogen in the synovial protein extract used by our group, 
as the only autoimmune spot that was identified as fibrinogen α (B003) was not visible on the 
2-D gel visualized by a sensitive silver stain [21]. We started our experiments with a total 
protein extract of synovial tissue without prior sequential extraction steps in comparison with 
previous reports which used an enriched protein extract in fibrin [11]. This could in part 
explain the differences between our results and the results of the group of  Serre G. et al [11] 
which report on fibrinogen α and β, being the most prominent synovial antigens.  
On the contrary, if we incubated in vitro deiminated fibrinogen with sera, the most prominent 
autoantigen was the α chain of fibrinogen, which is in agreement with what has been reported 
in the literature. These findings illustrate the potential discrepancy that may arise between 
autoimmune studies based on in vitro deiminated potential autoantigens and autoimmune 
experiments based on in vivo autoantigens present in inflamed tissue.  
It is now known, that deiminated fibrinogen is not RA specific, and that it is a phenomenon 
nonspecifically associated with synovitis. It is not necessarily associated with the production 
of ACPA [25]. However, the RA specific immunoreactivity of the most acidic spots in a 
protein spot train, emphasizes the importance of considering posttranslational modifications 
as a trigger in tolerance break. It is possible that these RA-specific epitopes are generated by 
citrullination of arginine in a different amino acid context than usual due to altered PAD 
enzyme reactivity which is dependent on the amino acids flanking the arginine [27], [38].  
A known genetic factor that may influence the induction of ACPA is the presence of the 
HLA-DR shared epitope (SE) [39]. SE is significantly associated with ACPA levels as these 
were increased in SE positive versus SE negative RA patients [40].  
In summary, the present study describes a comprehensive inventory of a large array of 
synovial tissue B cell autoantigens by 2-D immunoblotting. The most abundantly and 
specifically recognized proteins were the β and γ chains of fibrinogen. By using 2-D 
immunoblotting, we were able to observe the in vivo synovial autoantigens as spot trains of 
which the most acidic protein spots were more specifically recognized by RA autoantibodies. 
Therefore, post-translational modifications, like citrullination, should be considered as crucial 
intermediates for the generation of autoantibodies. Indeed, both β and γ fibrinogen chain were 
found to be citrullinated. In addition, we also identified vimentin, which has already been 
reported as being the Sa antigen [32] and carbonic anhydrase I, which could be a potential 
new synovial autoantigen in RA.  
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Rheumatoid arthritis (RA) and spondyloarthropathy (SpA) are two frequent forms of 
inflammatory arthritis with an important morbidity and socio-economic impact on our society.  
Although similar joints can be affected in both diseases, their clinical presentation is different. 
Nevertheless, both pathologies are characterized by synovitis, the chronic inflammation of the 
synovial tissue. The synovial tissue lines the joint cavity and is responsible for the 
homeostasis in the joint. This delicate serous membrane is subject to acute inflammatory 
reactions upon stress and injury or to chronic inflammation upon unknown triggers which is 
the case in RA or SpA synovitis. In both RA and SpA, the synovial membrane of the affected 
joint undergoes several profound changes in synovial architecture. Infiltration of 
inflammatory lymphocytes initiates inflammatory processes, resulting in thickening of the 
synovial lining layer. This hyperplasia, due to infiltration of macrophages and monocytes, 
along with the local proliferation of synoviocytes, results in a hypoxic microenvironment 
associated with neovascularisation. Despite intensive investigations into the nature of chronic 
synovitis, the molecular differences between RA and SpA synovial inflammation are poorly 
understood.  
This project was intended to examine synovitis from a different point of view. The majority of 
reports on inflammatory arthritis has a histological or immunological character and has indeed 
resolved important issues concerning the chronic inflammation of the synovial tissue. The use 
of a molecular biochemical approach could shed a different light upon synovial inflammation 
and may reveal unknown differences between RA and SpA synovitis. Additionally, they 
could explain reported variation in synovial histology and could be fundamental to the 
distinctive clinical outcome observed between the inflammatory arthritides.  
 
We initiated our study by a differential screening of the synovial protein expression of 
cytosolic proteins derived from knee biopsy samples of patients diagnosed with RA, SpA and 
OA (chapter 1). The method of choice was a classic proteome analysis, which gave us the 
possibility to study protein expression profiles of several hundred proteins at the same time. 
The results of this study showed that the synovial cytosolic proteome of SpA as opposed to 
RA patients consisted of a unique set of proteins with a defined expression pattern for each 
form of chronic arthritis.  Proteins unique to either RA or SpA inflammation in the synovial 
tissue were identified. Proteins which had been implicated in inflammatory arthritis were 
detected.  
Our attention was drawn to a rather explicit feature on our 2-D gels. Analyzing the cytosolic 
proteome revealed a specific cluster of spots consisting of vimentin isoforms. This pattern 
  
 - - 160 - - 
 
was further analyzed in chapter 2 and appeared to be the result of protein processing. 
Vimentin is known to be processed by caspases [1] and our mass spectrometry data confirmed 
this. Imitating this processing in vitro showed the lack of post-translational modifications that 
would shift the cleaved fragments of the protein towards the acidic side of the 2-D gel.  
Since citrullination, a modification that changes an arginine to citrulline, is known to shift 
proteins towards the acidic pI [2], and because citrullinated vimentin is a known autoantigen 
in RA, the possible presence of this modification was examined. Indeed, fragments of 
processed vimentin were citrullinated in cytosolic protein extracts of RA, contrary to SpA, 
where there is little occurrence of citrullinated vimentin. This is in contrast with the 
occurrence of citrullinated fibrinogen, another well known citrullinated synovial protein, 
which is observed both in RA and SpA synovial tissue [3].  
Citrullination is a protein modification that has been implicated in many pathological 
processes [4] and it occurs in extreme conditions, since the enzyme responsible for the 
conversion is only activated in environments where calcium concentrations are high [5]. 
Therefore, on could attribute these finding to apoptosis as deimination of proteins has been 
associated with apoptosis of certain cell types [6, 7], although the exact sequence of events is 
unknown. 
The question remains however, as to why citrullinated vimentin is present in RA synovitis 
and not (or limited) in SpA synovitis. It is tempting to speculate that this is related to a 
difference in apoptosis or a better clearing of citrullinated residues in SpA in comparison to 
RA. The residence of citrullinated vimentin in RA synovium probably contributes to the 
development of autoantibodies and the reported high specificity of the ACPA family of 
antibodies in RA [8, 9]. Indeed, in chapter 2 we additionally show evidence that the presence 
of autoantibodies against processed citrullinated isoforms of vimentin was highly disease 
specific in RA. These findings indicated a novel concept in the development of autoantibodies 
in RA by which humoral autoimmunity is targeted against caspase cleaved and citrullinated 
fragments of an intermediate filament in synovial tissue, in a highly disease specific manner.  
 
Not only apoptosis, but also hypoxia can increase the amount of citrullination in tissue [10]. 
This was previously reported in astrocytes exposed to varying durations of hypoxia (2%O2) 
and showed upregulation of PAD and citrullinated glial fibrillary acidic protein (GFAP) [10].  
It is known that the affected joints of RA patients are hypoxic [11-13]. Due to the hyperplasia 
of the synovial lining, the distance between the cells and the nearest blood vessels increases, 
depriving the cells of oxygen, hereby creating a hypoxic microenvironment [14]. When 
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oxygen levels drop below 5%, HIF-1 start to take control over the transcription of over 70 
genes [15].  
In our intial proteomics study we indentified proteins, related to SpA inflammation, to be 
regulated by HIF-1. Alpha-enolase, aldolase A, triose phosphate isomerase and 
ceruloplasmin, were found to be up regulated in SpA versus OA (chapter 1). All of them have 
been described to be regulated by HIF-1 in hypoxic conditions [16, 17]. As the SpA joint is 
also subject to synovitis, we can assume the environment to be hypoxic. However, no present 
data have examined this.  
On the other hand, it is known that the SpA synovial tissue is highly vasculated and 
neovascularisation is indeed a reaction upon hypoxia. There is a difference in synovial 
vasculature between RA and SpA, where the amount of vascularity is reported to be 
significantly higher in SpA compared to RA [18]. We hypothesized that the tissue response to 
hypoxia was distinct in SpA versus RA. To address this, we investigated the ability of RA and 
SpA synovial fibroblasts (FLS) to produce VEGF and Cp, two proteins involved in 
angiogenesis, in hypoxic conditions (chapter 3). VEGF has been described as the key factor 
in angiogenesis [19, 20] and Cp binds and transports the majority of the circulating copper, a 
major co-factor for angiogenic factors [21]. Both elevated levels of VEGF, copper and Cp 
have been reported in serum and synovial fluid of patients diagnosed with inflammatory 
arthritis [22-25]. 
Results obtained from these experiments showed that elevated gene expression of Cp and 
higher protein production of VEGF in SpA FLS in comparison to RA FLS both cultured in 
hypoxia. Although additional confirming experiments are underway, these data suggest that 
the observed differences in synovial vascularity between RA and SpA [18, 26] could be at 
least partly attributed to this distinct response to hypoxia.  
 
In the final chapter, chapter 4, we describe a study searching for new synovial autoantigens. 
RA is an autoimmune disease characterized by the production of autoantibodies. Since the 
primary site of inflammation is the synovium and because of the characteristics of a proteome 
analyses, this allowed us to list the spectrum of synovial autoantigens that induce an 
autoimmune humoral response. By screening the presence of autoantibodies in 30 RA and 30 
non-RA serum samples against synovial tissue proteins, we confirmed that the most 
autoantibody reactivity in the synovial tissue was directed to subunits of fibrinogen 
(especially fibrinogen β and γ), confirming the data of Serre’s group [27].  
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However, we also identified vimentin, better known as the Sa-antigen and carbonic anhydrase 
I as potential new synovial autoantigens. The novelty in this report related to the use of a total 
protein extract in order to find new synovial autoantigens and the use of 2-D blots. Moreover, 
because of the characteristics of 2-DE, we were able to show that these autoimmune targets 
consisted of trains of adjacent spots, containing the same protein. Remarkably, the protein 
spots present at the more acidic side of the train, showed the highest specificity for RA. A 
modification, like citrullination could be crucial in the tolerance break and the development of 
autoantibodies and we could indicate these spots, representing fibrinogen β and γ, were 
citrullinated.  
Another novel aspect of the current study relates to the use of synovial tissue extracts from 
RA patients to search for new autoantigens in RA. In contrast to previous studies searching 
for citrullinated autoantigens where in vitro deiminated protein extracts were used. Therefore, 
the currently identified autoantigens represent the in situ situation in inflamed synovial tissue 
and may therefore lead to a better understanding of the autoimmune character of RA.  
 
Altogether, by using proteomics, we encountered different aspects of synovitis, pointing 
towards distinct molecular differences between RA and SpA synovitis. Expression patterns of 
proteins, modification of proteins and secretion of proteins appeared specific for each form of 
synovitis. We showed that proteomics is a fascinating tool to tackle the biology of synovitis 
and underline the role for 2-DE, the ‘old work horse’ of the classic proteomics approach, 
which allows protein modifications to be elucidated.  
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Rheumatoide artritis (RA) and spondyloartropathie (SpA) zijn twee frequent voorkomende 
vormen van inflammatoire artritis met een belangrijke morbiditeit en socio-economische 
impact op de samenleving. Alhoewel dezelfde gewrichten aangetast kunnen worden in beide 
aandoeningen, zijn de klinische verschijnselen verschillend. RA wordt als een aggressieve en 
destructieve gewrichtsaandoening beschouwd, integenstelling tot SpA dat veel minder erosief 
blijkt en waar bovendien pogingen tot herstel waargenomen worden. Desondanks worden 
zowel RA als SpA gekenmerkt door synovitis, de chronische ontsteking van het synoviaal 
membraan.  
Het synoviaal membraan bekleedt het gewrichtskapsel en is verantwoordelijk voor de 
homeostase van het gewricht. De ontsteking van dit delicate vlies kan accuut zijn door 
belasting en/of blessure, of er kan een chronische onstekingsreactie ontstaan waarvan, zoals in 
het geval van RA en SpA synovitis, de oorzaak ongekend is. Bij zowel RA als SpA ondergaat 
de synoviale architectuur van het aangetaste gewricht een aantal ingrijpende veranderingen. 
De inflammatoire initiatie gebeurt door de infiltratie van inflammatore cellen. Deze leiden tot 
een verdikking van het synoviaal weefsel, ten dele door de inflammatoire infiltratie, maar ook 
door de locale proliferatie van de synoviocyten. Deze hyperplasie resulteert in een hypoxische 
micro-omgeving geassocieerd met neovascularisatie. Ondanks diepgaand onderzoek naar de 
chronische natuur van synovitis, blijft de kennis omtrent het moleculair verschil tussen RA en 
SpA synoviale inflammatie gebrekkig.  
 
Dit project had de intentie om synovitis vanuit een ander perspectief te bekijken. Het 
overgrote deel van studies naar inflammatoire artritis hebben een histologisch of 
immunologisch karakter. Alhoewel deze analyses heel wat aspecten betreffende chronische 
ontsteking van het synoviaal membraan hebben opgehelderd, kan een meer moleculair, 
biochemische benadering een ander licht werpen op mogelijke verschillen tussen de RA en 
SpA synovitis aantonen. Daarnaast, kunnen dergelijke studies de beschreven verschillen in 
synoviale histologie verklaren en mogelijks een bijdrage leveren aan de zoektocht naar de 
oorzaak van de uiteenlopende klinische verschijnselen tussen de twee vormen van 
inflammatoire artritis.  
 
Dit project startte met een differentiële screening van de expressie van de synoviaal 
cytosolische eiwittten afkomstig van knie biopsie stalen verkregen bij RA, SpA en OA 
patiënten (hoofdstuk 1). De verkozen methode was een klassieke proteome analyse en dit 
gaf ons de mogelijkheid om het expressie patroon van honderden eiwitten terzelfdertijd te 
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bestuderen. De resultaten van deze studie toonden aan dat het synoviaal cytosolisch proteome 
van SpA in vergelijking met RA uit eiwitten bestond met een uniek expressie profiel voor 
elke vorm van artritis. Eiwitten uniek voor RA of SpA synovitis werden vervolgens 
geïdentificeerd en proteïnen gerelateerd aan inflammatoire artritis werden aangetroffen.  
Gedurende deze analyse werd onze aandacht gevestigd op een groep van eiwit spots die in een 
uitgesproken vorm gegroepeerd lagen op de twee-dimensionele (2-D) gels. Deze groep van 
spots werd geïdentificeerd als het eiwit vimentine. Het verdere onderzoek naar de afkomst 
van deze cluster van spots werd beschreven is hoofdstuk 2 en bleek het resultaat te zijn van 
eiwit processing.  
Het is gekend dat vimentine verknipt kan worden door caspasen en de massaspectrometrie 
data afkomstig van de verschillende eiwiten uit de groep bestigde dit. Wanneer we echter dit 
proces in vitro wensten na te bootsen, vertoonden de fragmenten van vimentine een ander 
patroon. De fragmenten waren niet opgeschoven naar de zure kant van de 2-D gel zoals op het 
in vivo beeld van het synoviaal cytosolisch proteome. 
 Een afwezigheid van een specifieke eiwit modificatie lag aan de basis van dit verschil. 
Citrullinatie, een modificatie waarbij een arginine omgezet wordt tot citrulline, veroorzaakt 
een shift op een 2-D beeld naar de zure kant en bovendien is gecitrullineerd vimentine een 
gekend autoantigen in RA. Om deze redenen werd de mogelijke aanwezigheid van deze 
modificatie onderzocht. Inderdaad, fragmenten van verknipt vimentine waren gecitrullineerd 
in cytosolische eiwit extracten van RA, in tegenstelling tot SpA, waar deze gemodificeerde 
fragmenten bijna volledig afwezig bleken te zijn. Deze resultaten zijn in strijd met het 
voorkomen van gecitrullineerd fibrinogeen, een ander gekend gecitrullineerd synoviaal eiwit, 
dat zowel in RA als SpA aangetoond is.  
Citrullinatie is een eiwit modificatie dat verwikkeld is in verschillende pathologieën en het 
komt voor in extreme omstandigheden aangezien het enzyme dat verantwoordelijk is voor de 
omzetting enkel geactiveerd wordt in hoge calcium concentraties. Men denkt dan 
onmiddellijk aan apoptose en inderdaad, er zijn rapporten die citrullinatie associëren met 
apoptose van bepaalde celtypes, echter de precieze volgorde van stappen in het proces is niet 
gekend.  
De vraag waarom gecitrullineerd vimentine zo prominent aanwezig is in het RA synovium en 
niet (of beperkt) in het SpA synovium blijft onbeantwoord. Een mogelijks verschil in 
apoptose of een betere opruiming van gecitrullineerde vimentine residues zou misschien aan 
de basis ervan kunnen liggen. Het verblijf van gecitrullineerd vimentine in het RA synovium 
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is ongetwijfeld geassocieerd met de ontwikkeling en de hoge specificiteit van antilichamen 
tegen gecitrullineerde proteïnen (ACPA) in RA.  
Inderdaad, bijkomend in hoofdstuk 2 toonden we aan dat de aanwezigheid van 
autoantilichamen tegen gecitrullineerde fragmenten van vimentine specifiek was voor RA. 
Deze bevindingen wezen op een nieuw concept in de ontwikkeling van autoantilichamen in 
RA waarbij humorale autoimmuniteit, gericht op caspase geknipt and gecitrullineerde 
fragmenten van een intermediair filament in het synoviaal membraan, ziekte-specifiek is.  
 
Niet enkel apoptose, maar ook hypoxie is geassocieerd met citrullinatie. Dit werd voorheen 
gerapporteerd in astrocyten die geïncubeerd werden in hypoxische omstandigheden (2% O2) 
van  verschillende duur waarbij er een verhoging van peptidyl arginine deiminase (PAD) en 
gecirullineerd gliaal fibrillair zuur eiwit (GFAP) aangetoond werd.  
Het is gekend dat de getroffen gewrichten van RA patiënten hypoxisch zijn. Wegens de 
hyperplasie van het synoviaal weefsel wordt de afstand tussen de cellen en het nabijgelegen 
bloedvat groter. Hierdoor verkleint de zuurstoftoevoer naar de cellen waardoor een hypoxisch 
microklimaat gecreërd wordt. Als het zuurstofgehalte onder de 5% valt, neem hypoxie 
geïnduceerde factor- 1 (HIF-1) de controle over de transcriptie van meer dan 70 genen.  
In onze initële proteome analyse werden eiwitten geïdentificeerd die in hypoxie onder invloed 
staan van HIF-1. De transcriptie van alfa-enolase, aldolase A, triose fosfaat isomerase en 
ceruloplasmine (Cp); eiwitten die verhoogde expressie vertoonden in SpA in vergelijking met 
OA (hoofdstuk 1), wordt geïnduceerd door HIF-1.  
Aangezien het SpA gewricht gekenmerkt wordt door synovitis, kunnen we aannemen dat ook 
hier de synoviale omgeving hypoxisch is. Er zijn echter geen studies die dit onderzocht 
hebben. Toch is het beschreven dat het SpA synoviaal membraan sterk gevasculeerd is en de 
vorming van nieuwe bloedvaten is een gekend effect van hypoxie. Bovendien blijkt er een 
verschil in synoviale vasculatuur te zijn tussen RA en SpA waar men bij SpA een verhoogde 
hoeveelheid aan bloedvaten waarneemt.  
Een mogelijkse hypothese was dat de weefsel respons op hypoxie verschillend is tussen RA 
en SpA. Hiervoor werd de mogelijkheid van RA en SpA synoviale fibroblasten (FLS) 
onderzocht om vasculair endotheliale groeifactor (VEGF) en Cp, twee eiwitten die een rol 
spelen in angiogenese, te produceren in hypoxische omstandigheden (hoofdstuk 3).  
VEGF  is beschreven als dé sleutelfactor in angiogenese en Cp bindt en vervoert koper; de 
belangrijkste cofactor voor factoren die instaan voor de vorming van nieuwe bloedvaten. 
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Zowel VEGF, koper als Cp zijn verhoogd in serum en synoviaal vocht van patiënten met 
inflammatoire artritis.  
De resultaten toonden een verhoogde genexpressie van Cp en een hogere produktie van 
VEGF aan in SpA FLS in vergelijking met RA FLS, beiden gegroeid in hypoxische 
omstandigheden. Alhoewel er extra confirmerende experimenten op de agenda staan, 
suggeren deze data dat het beschreven verschil in synoviale vasculariteit tussen RA en SpA 
gedeeltelijk  zou kunnen verklaard worden hierdoor.   
 
Finaal, in het laatste hoofdstuk (hoofdstuk 4) beschrijven we een zoektocht naar nieuwe 
synoviale autoantigenen specifiek in RA. RA is een autoimmuun ziekte gekarakteriseerd door 
de produktie van autoantilichamen. We hadden de mogelijkheid om de synoviale autoantigen 
te catalogeren door gebruik te maken van een grootschalige techniek zoals proteomics. 
Voor deze experimenten werden 30 RA en 30 non-RA serum stalen geïncubeerd ten opzichte 
van een synoviaal eiwit extract. De autoantilichamen aanwezig in het serum van RA patiënten 
waren gericht tegen dat de subunits van synoviaal fibrinogeen (vooral de β en γ subunit). De 
data confirmeerden de resultaten van de groep van Prof. Serre. Additioneel identificeerden we 
ook synoviaal vimentine, gekend as het Sa-antigen, en carbonic anhydrase I als potentiële 
nieuwe synoviale autoantigenen.  
Door het gebruik van 2-D gel electroforese (2-DE) en door de specifieke karakteristieken van 
deze techniek konden we aantonen dat deze autoimmune eiwitten uit treinen bestonden van 
aaneensluitende spots afkomstig van het zelfde eiwit. Merkwaardig genoeg, vertoonden spots 
die zich aan de zure kant van deze spot trein bevonden, de hoogste specificiteit voor RA. Een 
modificatie, zoals citrullinatie kan dus cruciaal zijn in de ontwikkeling van autoimmuniteit en 
we toonden ook aan dat zowel fibrinogeen β als γ gecitrullineerd waren.  
Er is een verschil tussen de beschreven studie in hoofdstuk 4 en wat reeds verschenen is in de 
literatuur omtrent synoviale autoantigenen. Door te vertrekken van een eiwit extract 
afkomstig van synoviaal weefsel afkomstig van RA patiënten benaderden de bekomen 
resultaten de in situ situatie in het inflammatoir gewricht, in tegenstelling tot het beschreven 
gebruik van in vitro gecitrullineerde cel extracten. 
 
Gedurende onze proteomics trip, zijn we met verschillende aspecten van synovitis in contact 
gekomen. Allen wezen ze in de richting van een moleculair verschil tussen RA en SpA 
synovitis. Expressie patronen van eiwitten, modificaties van eiwitten en de secretie ervan 
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bleken specifiek te zijn voor elke vorm van inflammatoire artritis. We toonden aan dat 
proteomics een fascinerend instrument is om de biologie van synovitis uit te spitten en 
onderlijnen dat er nog steeds nood is aan 2-DE, het ‘oude werkpaard’ van de klassieke 
proteomics, die als enige de post-translationele modificatie zo knap in beeld kan brengen.    
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Coming together is a beginning 
Keeping together is a progress 
Working together is success 
--Henry Ford 
 
  
 - - 172 - - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 - - 173 - - 
 
 
Alhoewel mijn naam op de voorpagina van deze thesis staat, kon dit werk niet verwezenlijkt 
worden door mij alleen en het is dan ook, traditiegewijs, in deze sectie dat anderen in de 
spotlight staan:  
 
Mijn promotoren Prof. Deforce en Prof. Elewaut:  
Dieter en Dirk, oftwel kortweg D&D genoemd door de docstudenten, jullie bijdrage aan dit 
werk is enorm geweest. Ik wil jullie bedanken voor de input aan financiële resources en 
wetenschappelijk visie. De discussie liepen soms hoog op, mede omdat ik ook altijd mijn 
zegje wou doen en zelden gemakkelijk overtuigbaar was. Toch denk ik, dat we mooi werk 
geleverd hebben en ik kijk er naar uit om ook na dit doctoraat met jullie verder te werken.  
 
Prof. De Keyser, ook u bent onmisbaar geweest in de creatie van resultaten beschreven in 
deze thesis. Uw expertise in het klinische maar ook uw interesse naar het moleculaire hebben 
een grote indruk op mij gemaakt.  
 
De groep van Ann Union by Innogenetics zou ik willen bedanken voor vlotte samenwerking 
en het mooie werk omtrent de synoviale antigenen.    
Ook Prof. De Sutter voor het gebruik van de hypoxie-incubator en Sylvie voor de leuke sfeer 
in het keldertje van de P3.  
 
Wetenschap kan enkel z’n vruchten afwerken wanneer men voldoende relativerend, 
ontspannend en ludiek de dingen kan benaderen.  
En op wie kon ik hiervoor beter rekenen dan mijn mede docstudentjes. Steek 6 jonge gasten in 
een lokaal van 4 op 10 en dat komt wel allemaal vanzelf: Ann-Sophie, Ben, Ivan, Stijnie, 
Alientje, Martin en nu ook Mado en Katleen, merci voor de koffie’tjes, de koekskes, de 
Duvels en vooral de sfeer, het begrip en jawel ook soms de stilte waardoor je alleen maar 
‘tokkel tokkel’ hoorde van 60 vingers op een toetsenbord. Daarnaast was er Filip die een 
bureau had van 4 op 10 voor hem alleen (ja, we waren jaloers, maar daar komt weldra 
verandering in ☺). Bedankt voor alle pc-stuff en de psychologische groepssessies (ya 
know.....) over de middag. 
De mensen van de routine, of ‘de DNA’ers’, nog zo’n bonte boel en zeker op feestjes en 
trouwfeesten. De foto’s, niet voor publicatie vatbaar, bewijzen dat. Wie moet er trouwens nog 
bevallen?!!! ☺  
Speciaal een thanks voor David, Nadine en Astrid die de administratie van ons labo in goede 
banen leiden. Merci voor de hulp bij crashende kopiemachines, verloren gaande faxen, te laat 
komende bestellingen, ingewikkelde SAP dossiers en zoveel meer! Ook merciekes aan 
Sabrina om ons labo’ke proper te houden en de leuke babbels over de bouwperikelen. Ik kom 
zeker eens langs! 
Een speciale vermelding geniet Sofie Vande Casteele, ookwel Sofie van de massa’s: wat 
zouden we zonder jou doen. Het gepruts aan de nanoLC met die mini mini 
schroevendraaiertjes en die naaldjes en pfff, ik was soms content dat ik geen stalen moest 
runnen als je in verlof was. Heel heel heel erg bedankt voor je inzet, expertise en 
enthousiasme waarmee je het mass spec werk deed en elke dag doet. Hopelijk lukt hetgeen we 
willen uittesten op dat nieuw machien! Spannend.... 
En dan zijn er nog de aanhangsels, ik noem ze graag de ‘aliens’; docstudenten van andere 
labo’s die bij ons wat praktisch werk komen doen: Céline, Heleen, Kristien, Kinjip (eigenlijk 
bijna een volwaardige FBT’er), Matthias, Phebe....Ook de reumaboys en girls (die de eerste 
jaren bij ons kampeerden tot het MRB af was): Pierre, Katrien, Tineke (merci voor het 
blotwerk en de AMC’s), Peggy, Ann, Sara, Ken, .....allen bedankt voor de wetenschappelijke 
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en klinische info (vooral thx hier aan Bert en Ilse), maar vooral ook voor de grappige 
momenten, de Duvels (alweer), de feestjes (om 17h ☺), de BBQ, de etentjes...... .  
Ook mijn vele thesisstudentjes: Erin, Liesbeth, JP, Laurence, Loreke, An-Sofie, Nele en 
Barbara, merci voor het werk en de leute.  
 
Ook de andere vrienden (ja, jullie daar, bende ongeregelden ☺): ik kan al een doctoraatsthesis 
op zich schrijven over alle docfeestjes, MC’s, Werchters, trouwfeestjes, tobbe-dansen, 
Sjakosj-stuiken, Salamandervoetballen, Abou-tequila-slammen, tequila-disco party’s (when 
Floor n° 10?, for all time sake!), Gentsche Fiesten, Pukkelpopjes, tuinfeestjes, oudejaartjes-
nieuwejaartjes, etc. die ik met jullie mee gemaakt heb. Jullie (en jullie kleintjes) waren dan 
ook de ideale uitlaatklep na een weekje labo-zwoegen. Ook mijn sportpartnerkes, ik noem ze 
graag mijn volleybabes....hihi...Luv you much!  
Een speciale vermelding voor mijnen ‘manager’ Wim: thx voor het over en weer gemail zo’n 
4,5 jaar geleden, het luisterende oortje en de ‘Dobbie-analyse’ van de vele situaties. Thx! 
En dan mijn drie musketiers: Saar en Cathy, mijn supergirls, die me zeer nauw aan het hart 
liggen samen met Steven, mijn rots in de branding.  
 
 
 
Tom, merci voor je nuchtere kijk op de dingen en de steun. Je weet wat je voor mij betekent! 
Ook mijn kleine Sofie: je bent een toffe meid en je was de ideale verstrooiing na een 
frustrerende werkdag.  
 
En dan een speciaal stukje om mijn ouders te bedanken. Ik ben tenslotte officieel “student” af. 
Ma en pa, merci! Pa, ik weet pa dat je me dikwijls gevraagd hebt wat ik daar eigenlijk zat te 
doen, ganse dagen in dat labo. Ehwel, ik weet niet of je na het bekijken van dit boekske daar 
veel wijzer uit zult geraken. Mijn job is eigenlijk geen ‘job’. Het is een interesse, een drang 
(een wat groot woord, maar kom...) naar kennis, denk ik. De frustratie en ontgoocheling kan 
soms zeer groot zijn. En je moet content zijn met weinig en het feit dat alles ultra traag 
vooruit gaat. Maar dan lukt het experiment toch en zijn de data goed en dat zorgt ervoor dat je 
toch blijft doorgaan. Ik weet niet of je het nu zult begrijpen. De resultaten van mijn werk zijn 
niet te meten in bakstenen, muren, vloeren of huizen. Ik kan niet zeggen, kijk daar eens: daar 
heb ik met mijn handen op zitten zwoegen. Je naam op een publicatie in een vooraanstaand 
tijdschrift is de top in mijnen job.  
Ik wil jullie vooral bedanken om mij te leren met m’n voeten op de grond te staan en om 
vooruit, en niet naast mij, te kijken. Merci!  
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It is amazing what can be 
accomplished when nobody 
cares about who gets 
the credit. 
--Robert Yates 
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